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Senescent cells have been implicated in the ageing process and in the development of various 
age-related disorders. A key characteristic of senescent cells is the presence of dysfunctional 
mitochondria, which are crucial for the development of the SASP (Correia-Melo et al., 2016). 
However, at this stage the underlying mechanisms by which mitochondria drive the SASP have 
not yet been completely elucidated.  
In this thesis, I have discovered that mitochondria in senescent fibroblasts have an increased 
abundance of mitochondrial DNA (mtDNA) in the cytosol compared to young proliferating 
fibroblasts.  Using super resolution microscopy, I discovered that a small subset of 
mitochondria in senescent cells display a recently identified phenomenon termed: limited 
mitochondrial outer membrane permeabilisation (miMOMP) (Ichim et al., 2015). This subset 
of mitochondria show activation of pro-apoptotic BAX and BAK which cause a limited release 
of cytochrome c and caspase-dependent DNA damage in the absence of cell-death in senescent 
cells. 
My data indicates that during senescence, miMOMP and the presence of BAX/BAK 
mitochondrial outer membrane pores allow the release of mtDNA to the cytosol. Consistent 
with a role for mitochondrial BAX/BAK and the release of mtDNA in cellular senescence, I 
found that both CRISPR/CAS9 deletion of BAX and BAK suppresses the SASP and the release 
of mtDNA during senescence, whilst maintaining the cell cycle arrest. Additionally, my data 
shows that cytosolic mtDNA binds to the DNA sensor cGAS, potentially activating the cGAS-
STING pathway which has been previously implicated in SASP regulation (Dou et al., 2017; 
Gluck et al., 2017; Yang et al., 2017). Moreover, genetic silencing of BAX/BAK in vivo 
prevents the upregulation of SASP related genes following the induction of senescence by 
irradiation. My data argue that the mitochondrial apoptotic pathway is a key SASP regulator. 
Finally, I have demonstrated that pharmacological inhibitors of either BAX or cGAS lead to a 
robust suppression of the SASP, without impairing the cell cycle arrest. These small molecule 
inhibitors may therefore pose as potential candidates for senostatic therapies in offsetting the 
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1. Chapter 1: Introduction 
 
1.1. Cellular Senescence 
Cellular senescence, which is generally characterized as an irreversible cell cycle arrest, has 
been defined as a classical hallmark of the ageing process. This phenomenon of persistent 
growth arrest was originally described by Hayflick and Moorhead in the 1960’s when they 
observed that human fibroblasts in culture had a defined replicative limit (Hayflick, 1965). 
Although these cells remain indefinitely unable to divide, they are metabolically active and 
undergo several dramatic phenotypic changes. In the decades that have followed this initial 
observation, senescent cells have been implicated in a variety of key biological processes. 
Primarily, senescent cells avert the replication of cells that have sustained genomic damage, 
therefore they have a role in tumour suppression (Serrano et al., 1997). Aside from tumour 
suppression, senescent cells function throughout the life course of an organism and have been 
demonstrated to engage in embryonic development and the wound healing process (Munoz-
Espin et al., 2013; Demaria et al., 2014). These roles are of clear benefit to an organism, 
however, the accumulation of senescent cells, which has been shown to occur with age, has a 
detrimental effect and has been implicated as a driver of the ageing process and associated 
pathologies (Baker et al., 2011; Xu et al., 2015a; Baker et al., 2016). 
 
1.2. Mechanisms Responsible for the Induction of Senescence 
Cellular senescence is a complex biological programme that occurs predominantly in response 
to cellular stresses and potentially functions as a mechanism to stop dysfunctional cells from 
proliferating. Its contribution to the ageing process has been postulated for a number of decades, 
therefore, extensive research has been undertaken to decipher the signalling pathways which 
promote and maintain the senescence response. Some of the main mechanisms involved in 
senescence are discussed in detail in this section.   
1.2.1. DNA Damage 
Throughout the life course of a cell it is constantly exposed to intra and extracellular stresses 
which can detrimentally affect the integrity of its genomic material (Menck and Munford, 
2014). Extensive genomic damage has the capacity to inflict mutations on important sequences 
of DNA which can become tumorigenic and lead to aberrant proliferation. Therefore, cells are 
equipped with the ability to transiently arrest the cell cycle and subsequently repair DNA 
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damage through a variety of mechanisms. However, where cells have sustained severe or 
irreparable DNA damage they implement the senescence programme to prevent replication on 
a damaged template, and thus, prevent tumorigenesis (Campisi and d'Adda di Fagagna, 2007). 
It has been well established that DNA damage is an effective inducer of senescence, in 
particular double stranded breaks. A key source of molecular damage in senescent cells is 
associated with the production of ROS (reactive oxygen species). ROS are elevated in a number 
of models of senescence (replicative, stress-induced and oncogene induced) and have been 
shown to damage DNA directly, in the form of both single and double stranded DNA breaks 
(DSB) (Chen et al., 1995b; Saretzki et al., 2003; Passos et al., 2010). Cells also can become 
senescent in response to hyperoxic conditions which promote intracellular damage via 
increased production of ROS (von Zglinicki et al., 1995; Roper et al., 2004). Interestingly, the 
role of ROS in senescence is multifaceted as they also play a role in maintaining a positive 
feedback loop whereby ROS induces short-lived DNA damage foci which maintain a constant 
stimulus. This continued initiation of damage engages the DNA damage response (DDR) and 
subsequently p21, which is a key senescence effector pathway for enforcing the cell cycle arrest 
and will be discussed later in this section (Passos et al., 2010). Alongside ROS-mediated 
damage, a number of exogenous sources of DNA damage have been identified which can 
induce senescence; ionising radiation, UVB irradiation and chemotherapeutic agents such as 
actinomycin D, etoposide and doxorubicin  (Di Leonardo et al., 1994; Robles and Adami, 1998; 
Zhang et al., 2002; Debacq-Chainiaux et al., 2005). Cellular senescence that occurs in response 
to DNA damage is often referred to as stress-induced premature senescence (SIPS). 
1.2.2. Telomere-dependent Senescence 
Telomeres are protective fragments of DNA that are located at the end of linear chromosomes. 
They consist of a series of tandem 5’-TTAGGG-3’ repeats which are stabilised by a protein 
complex collectively termed shelterin (de Lange, 2005). This complex consists of the proteins 
TRF1 and 2 (telomeric repeat binding factor 1 and 2) and POT1 (protection of telomeres 1), 
TIN2 (TERF1-interacting nuclear factor 2), tripeptidyl peptidase 1 and ras-related protein 1, 
together this complex forms a loop like structure termed the telomere loop (Griffith et al., 1999; 
de Lange, 2005). This loop acts to prevent the ends of the functional DNA strands being 
identified as a DSB and thus being fused together by DNA repair mechanisms (Blackburn, 
1991; Blackburn et al., 2015). During DNA replication, DNA is lost during each division due 
to DNA polymerase being unable to completely synthesise the lagging strand of the DNA. This 
is referred to as the end replication problem and is responsible for the loss of between 50 and 
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200 base pairs following each replication. Therefore chromosomes are equipped with telomeres 
to ensure that functional DNA is not lost but rather the non-functional coding DNA repeats 
telomeres consist of, this process is referred to as telomere shortening (Olovnikov, 1971; 
Watson, 1972). In the context of senescence, this is of particular interest as it has been 
demonstrated that extensive rounds of replication lead to the induction of senescence (Hayflick, 
1965). Since Hayflicks’ initial observation of senescence, it has been firmly established that the 
phenomenon he described can be explained by telomere shortening, and is referred to as 
replicative senescence (Harley et al., 1990). Mechanistically, extensive replication results in 
telomeres that become degraded to the point that their protective structure is impaired and they 
no longer perform their protective function, at this point, the DNA ends are recognised as a 
DSB and trigger a DDR which culminates in senescence (d'Adda di Fagagna et al., 2003). 
Furthermore, it has been demonstrated experimentally that the overexpression of telomerase, 
an enzyme which extends telomeres, leads to an extension in lifespan of cultured human 
fibroblasts, thus highlighting a causal role of telomeres in driving the induction of senescence 
(Bodnar et al., 1998).    
Telomere shortening does not occur exclusively as a consequence of replication, there is now a 
body of evidence pinpointing the role of oxidative stress as a driver of telomere shortening. In 
vitro, it has been demonstrated that oxidative stress induced by mild hyperoxia increases the 
rate at which telomeres are shortened by approximately 5 fold, and this subsequently induces 
premature senescence which resembles replicative senescence (von Zglinicki et al., 1995). To 
corroborate this, overexpression of antioxidants such as superoxide dismutase 3 reduces 
oxidative stress, slows the rate of telomere shortening and increases replicative lifespan in 
culture (Serra et al., 2003). Consistently, the rate of telomere shortening can be slowed in vitro 
by other mediators that reduce mitochondrial-derived ROS such as the antioxidant MitoQ, 
nicotinamide as well as mild mitochondrial uncoupling (Saretzki et al., 2003; Kang et al., 2006; 
Passos et al., 2007). Furthermore, dysfunctional mitochondria have been highlighted as 
contributing to telomere shortening (Liu et al., 2002). This occurs predominantly due to the 
production of ROS, as treatment in vitro using a mitochondrial targeted antioxidant reduces 
telomere shortening and also leads to an extension of their replicative limit (Saretzki et al., 
2003). Similarly, the replicative capacity of fibroblasts can be extended by reducing ROS 
production following mild mitochondrial uncoupling, which has been shown to be as a 
consequence of reduced telomere shortening (Passos et al., 2007). In addition to telomere 
shortening it has been highlighted that dysfunctional telomeres can be linked to the production 
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of inflammatory cytokines. Specifically it was discovered that exosomes containing noncoding 
telomere RNA transcripts [telomeric repeat-containing RNA (TERRA)] are secreted into the 
extracellular environment. These telomeric fragments can provoke the innate immune system 
to produce several cytokines which have been implicated in senescence (IL-6, TNF-α and IP-
10) (Wang et al., 2015). Therefore as both telomere dysfunction and the secretion of cytokines 
are features of senescence it is plausible that the two processes are interlinked, however, further 
study is required to confirm this.  
It was mostly thought that the contribution of telomeres to senescence was solely associated 
with telomere shortening, however, recent work has demonstrated that during stress-induced 
senescence damage to telomeric regions occurs regardless of telomerase activity (Hewitt et al., 
2012). Furthermore, in vivo it has been found that in the liver and gut of mice telomere damage 
increases with age, irrespective of telomere length (Hewitt et al., 2012; Jurk et al., 2014). 
Similarly, telomere specific damage that occurs independently of length has been observed to 
increase in the hippocampal neurons and liver of baboons with increasing age (Fumagalli et al., 
2012). It has also been demonstrated that in cardiomyocytes length-independent damage which 
occurs at telomeres leads to a persistent DDR and subsequent activation of p16 and p21 to 
induce senescence (Anderson et al., 2019). 
Various studies have shown that DNA damage which occurs at telomeres (referred to as TAF; 
telomere associated foci) is less efficiently repaired compared to non-telomeric damage and in 
some cases is irreparable (Kruk et al., 1995; Fumagalli et al., 2012; Hewitt et al., 2012). The 
lack of DNA damage repair is due to the TRF2/RAP1 mediated inhibition of DSB DNA repair, 
the purpose of this being to prevent telomere ends from being fused together. This occurs as 
TRF2/ ras-related protein 1 prevent non-homologous end joining of telomere ends by inhibiting 
the actions of DNA-Protein Kinase, furthermore this prevents the actions of ligase IV which 
also prevents end joining from occurring, together these mechanisms prevent the repair of 
double stranded telomeric damage (Bombarde et al., 2010).  
Furthermore, cells positive for TAF have been shown to accumulate with age in an assortment 
of organisms; mice, primates and humans (Herbig et al., 2006; Hewitt et al., 2012; Jurk et al., 
2014). Corroborating this, the presence of TAF positive cells has been noted to increase with 
age in an array of mouse tissues such as liver, intestine, lung, heart, muscle and bone (Hewitt 
et al., 2012; Birch et al., 2015; Farr et al., 2017; Anderson et al., 2019). With regards to 
senescence, it has been observed that the occurrence of TAF correlates with the presence of 
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other senescent markers in a number of diseases such as COPD, IPF and non-alcoholic liver 
disease (Birch et al., 2015; Ogrodnik et al., 2017; Schafer et al., 2017). Finally, studies whereby 
senescent cells have been cleared using either the INK-ATTAC mouse model or senolytic 
treatment have demonstrated a reduction in the presence of TAF in hepatocytes, 
cardiomyocytes, neurons and the medial layer of the aorta (Roos et al., 2016a; Ogrodnik et al., 
2017; Anderson et al., 2019; Ogrodnik et al., 2019). As such, the presence of TAF are 
considered a robust marker of senescent cells.  
1.2.3. Oncogene-induced senescence 
Oncogene-induced senescence was first described when it was observed that primary human 
and mouse cells could be permanently arrested in the G1 phase of the cell cycle following over 
expression of oncogenic ras (Serrano et al., 1997). It has since been established that 
approximately 50 oncogenes have the capacity to induce senescence (Gorgoulis and 
Halazonetis, 2010). Oncogene-induced senescence has been observed both in vitro and in vivo 
to act as a potent tumour suppressor mechanism. Generally, in oncogene-induced senescence 
the senescence response is induced by launching a powerful DDR signal which occurs as a 
consequence of aberrant DNA hyper-replication, DNA replication stress and DNA DSBs 
(Bartkova et al., 2006; Di Micco et al., 2006). In models of oncogene-induced senescence 
where the DDR has been impaired, such as inhibition of the DDR component ATM (ataxia 
telangiectasia mutated) the induction of senescence is bypassed (Bartkova et al., 2006). In vivo, 
this bypass is associated with an increased mean tumour size as well as exacerbated tumour 
invasiveness (Bartkova et al., 2006). Another feature of oncogene-induced senescence is the 
derepression of INK4A and ARF (collectively referred to as CDKN2A locus). The CDKN2A 
locus codes for two key tumour suppressors p16 and ARF which are frequently upregulated and 
play an important role in enforcing the cell cycle arrest through a p53/p21 mediated mechanism 
(Kim and Sharpless, 2006). Typically, at the early stages of life the expression of the CDKN2A 
locus is very low, however, with advancing age it has been observed that expression is increased 
in an array of organs (Krishnamurthy et al., 2004). Although at this stage, the cause of 
derepression is not well understood, current work has identified that the loss of the polycomb-
group gene bmi-1 leads to derepression and consequently can regulates senescence induction 
(Jacobs et al., 1999). More recently, it has been demonstrated during senescence that the 
polycomb group factor EZH2 (a histone H3 lysine-27 methyltransferase) is repressed (Ito et al., 
2018). This repression occurs from upstream WNT-MYC signalling and DNA damage 
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signalling through ATM. This is associated with a reduction in the presence of H3K27me3 
marks which induces the expression of CDK2NA (Ito et al., 2018).  
 
1.3. Molecular Pathways which Regulate Cellular Senescence  
During the induction of cellular senescence, cells typically respond to cellular stresses by 
mounting a DDR. The DDR subsequently feeds into activation of the p16-pRb and p53-p21 
pathways, these two signalling pathways are crucial for initiating and maintaining the cell cycle 
arrest. Both the p16-Rb and p53-p21 pathways can induce senescence independently, generally, 
whether one or both pathways are engaged depends on the stimulus and cell type.   
1.3.1. The DNA Damage Response 
The DDR is a key feature in replicative, telomere-induced, stress-induced and oncogene-
induced senescence (d'Adda di Fagagna et al., 2003; Campisi and d'Adda di Fagagna, 2007; 
Hewitt et al., 2012). Classically, the DDR responds to single stranded breaks (SSB) and DSBs 
of the DNA backbone, whereby it acts to halt cell cycle progression and recruit DNA repair 
machinery to allow repair of the DNA damage. If the damage is not severe then the DDR and 
subsequent cell cycle arrest is transient, however if the damage is severe or irreparable then a 
persistent DDR induces either senescence or apoptosis (d'Adda di Fagagna, 2008). It is clear 
that the nature and severity of the damage plays a role in dictating the decision between 
senescence and apoptosis, however, at this stage our understanding of the factors that determine 
cell fate are incompletely understood.  
Following the induction of DNA damage, there are two key complexes which recognise the 
damage depending on type of lesion. SSBs such as those induced following replication stress 
or UV are detected by a DNA repair complex which consists of RAD17 and the replication 
proteins A and C (2-5) (Weiss et al., 2002). Together, these proteins recruit a further complex 
to the site of damage, the 911 trimer complex which consists of RAD9, HUS1 and RAD1 
(Cortez et al., 2001; Weiss et al., 2002). This complex triggers the recruitment and activation 
of ATR (Ataxia telangiectasia and Rad3-related) (Cortez et al., 2001).  
The second complex which predominantly responds to DSBs is the PARP-MRN complex (Poly 
(ADP Ribose) polymerase - MRE11-RAD50-NBS1 proteins), this complex locates at the 
damaged site and recruits ATM (Falck et al., 2005). Recruitment of ATM triggers its auto 
phosphorylation, following activation ATM is also responsible for phosphorylating the histone 
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H2AX to γH2AX which also locates itself to the damaged site. γH2AX acts to further activate 
ATM and thus amplify its signal (Rogakou et al., 1999; Falck et al., 2005). 
The activation of ATM (to DSBs) and ATR (to SSBs) following the recognition of damage by 
the aforementioned complexes leads to a cascade activation of further DDR components 
(Marechal and Zou, 2013). The predominant function being to recruit appropriate proteins 
which transduce the damage signal to allow optimal repair of the damage. This is facilitated by 
a number of mediators such as mediator of DNA damage checkpoint protein-1, 53BP-1, breast 
cancer type-1 susceptibility 1 protein and claspin (Huyen et al., 2004). These proteins feed into 
and phosphorylate the proteins checkpoint-1 and 2 (CHK1, CHK2) following successive 
stimulation by either ATM or ATR. Following activation, CHK1 and CHK2 can then initiate 
the cell cycle arrest by acting on the effector proteins such as p53 and CDC25 (cell-division 
cycle 25) (d'Adda di Fagagna, 2008). CDC25A and CDC25C are phosphatases which regulate 
cell cycle progression through G1 to the S phase via activation of cyclin dependent kinases, 
however, when they are phosphorylated by CHK1 and CHK2 they become degraded and the 
cell cycle is halted (Mailand et al., 2000). Similarly, activation of p53 by CHK2 and ATM 
instigates transcription of the cell cycle regulator, p21, which subsequently blocks progression 
of the cell cycle (Di Leonardo et al., 1994; d'Adda di Fagagna, 2008).   
1.3.2. The p53-p21 Signalling Axis 
p53 is often referred to as the “guardian of the genome” due to its prominent role in tumour 
suppression. p53 is a transcription factor which responds to cellular stresses. Once active, it has 
the capacity to induce either a transient arrest, senescence or apoptosis depending on the nature 
of the stress (Murray-Zmijewski et al., 2008). In healthy proliferating cells, p53 is negatively 
regulated by the E3 ubiquitin protein ligase human double minute 2 (HDM2) which inhibits its 
activation as well as targeting it for degradation. As such p53 activity is constitutively low in 
the absence of stress (Zilfou and Lowe, 2009). However in states of cellular stress, a number of 
DDR components such as ATM, ATR, CHK1 and CHK2 can phosphorylate p53, this prevents 
HDM2 mediated p53 degradation and consequently leads to p53 activation (Banin et al., 1998; 
Tibbetts et al., 1999; Chehab et al., 2000). In the context of senescence, a key target gene of 
p53 is the cyclin-dependent kinase inhibitor (CDKI) p21. p21 prevents progression of the cell 
cycle by inhibiting cyclin dependent kinases and PCNA (proliferating cell nuclear antigen) and 
its upregulation is generally a key feature of senescent cells (Xiong et al., 1993; Waga et al., 
1994; Herbig et al., 2004; Passos et al., 2010).  It is important to note that p21 can be 
upregulated in non-senescent cells to transiently arrest progression of the cell cycle. For 
Chapter 1 - Introduction 
8 
 
example, it may be upregulated to allow for DNA repair to occur (Karimian et al., 2016). 
Mechanistically, it has been demonstrated that genetic removal of p21 in mouse embryonic 
fibroblasts and human fibroblasts prevents the senescence response (Brugarolas et al., 1995; 
Brown et al., 1997). Similarly, when the p53-p21 axis is impaired by knockout of CHK2 the 
replicative capacity of human fibroblasts is increased following the failure of CHK2 to activate 
p53 and subsequently p21 (Gire et al., 2004). Furthermore, in vivo when p21 is knocked out, 
senescence no longer occurs during the embryonic development process (Munoz-Espin et al., 
2013). Collectively, these studies implicate the importance of the p53-p21 axis in promoting 
the cell cycle arrest that is characteristic of cellular senescence. 
1.3.3. The p16-pRB Signalling Axis 
During the induction of senescence, the p53-p21 axis is generally the primary signalling 
pathway that is activated following a DDR. However, these stimuli can also engage the p16-
pRb pathway independently of p53. Like p21, p16 is a CDKI which is located in the perinuclear 
cytoplasm. Following the activation of p16 it translocates to the nucleus where it halts cell cycle 
progression by binding to CDK4/5 and 6 which in turn prevents phosphorylation of the tumour 
suppressor gene retinoblastoma (Rb). Consequently, Rb is maintained in a state of 
hypophosphorylation and therefore remains associated with the transcription factor E2F1 in the 
cytoplasm, this prevents transcription of E2F1 target genes which are responsible for promoting 
cell cycle progression (Rayess et al., 2012). Interestingly, the point at which the p16-pRB 
pathway is engaged varies between cell types. For example, in fibroblasts the activation of the 
p16-pRb pathway occurs secondary to the p53-p21 pathway, whereas epithelial cells have been 
demonstrated to become senescent through p16-pRb rather than p53-21 (Stein et al., 1999; 
Jacobs and de Lange, 2004). The importance of p16 is highlighted by a number of studies which 
have determined that p16 expression is enhanced in cells induced to senesce following a number 
of stimuli, such as oxidative damage, irradiation, telomere dysfunction and activation of 
oncogenic ras (Serrano et al., 1997; Meng et al., 2003; Chen et al., 2004a; Jacobs and de Lange, 
2004). Furthermore, it has been observed that p16 positive cells accumulate in an array of 
tissues with advancing age (Krishnamurthy et al., 2004; Waaijer et al., 2012). Following the 
induction of senescence, levels of p16 are relatively low, however with time expression 
increases, conversely p21 expression peaks immediately following the induction of senescence 
and subsequently decreases with time (Alcorta et al., 1996; Stein et al., 1999). Following these 
observations, it has been postulated that that the p16-pRB functions as a secondary barrier to 
prevent cell cycle progression in human fibroblasts. To support this idea it has been 
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demonstrated that cells which express low levels of p16 during senescence can resume 
proliferation when p53 is inactivated, whereas, those which express high levels of p16 however 
do not resume replication when p53 is inactivated (Beausejour et al., 2003).  
The underlying mechanisms which lead to p16 activation are not completely elucidated. 
However, the p38 mitogenic-activated protein kinase (MAPK) can respond to signals from the 
DDR, and has been shown to be able to stimulate both the p53-p21 and p16-pRb signalling 
pathways (Debacq-Chainiaux et al., 2010; Spallarossa et al., 2010). Furthermore, p38MAPK 
has multifaceted roles in senescence and has been described as an important regulator of the 
DDR by promoting ROS production which stabilises the DDR by inducing short-term DNA 
damage foci (Passos et al., 2010). P38MAPK has also been implicated as a regulator of the 
inflammatory profile exhibited by senescent cells (Freund et al., 2011).  
Interestingly, the role of tumour suppressors in the senescence inducing pathways varies 
between mice and human cells. It has been demonstrated in humans that activation of a DDR 
following telomere attrition or DNA damage leads to activation of the p53/p21 axis which 
inhibits CDK2-cycin E as well as CDK4/6-cyclinD which directly inhibits Rb to prevent cell 
cycle progression. In humans, Rb can also be inhibited by CDK4/6-cyclin D following the 
activation of p16. Thus the p53/21 and p16 pathways cooperate to provide two signalling 
networks which feed into Rb (Itahana et al., 2004). It has been demonstrated that knockout of 
p21 or p53 can result in senescence bypass (Brown et al., 1997; Wei and Sedivy, 1999), whereas 
p16 knockout alone cannot as Rb is still inhibited by p21 (Brookes et al., 2002). Dual knockout 
of both p16 and p21 leads to a bypass of replicative senescence in human fibroblasts (Wei et 
al., 2003b). As both pathways act downstream on Rb, studies have demonstrated that in human 
fibroblasts the senescence response can be bypassed by genetic knockout of Rb (Wei et al., 
2003a). In MEFs disruption of Rb genes is not sufficient to affect the senescence response (Sage 
et al., 2000). This is because in murine cells, the p53/p21 axis does not lead to inhibition of Rb, 
only the p16 pathway does via CDK4/6-cyclin D. Therefore p53/p21 and p16 promote the cell 
cycle arrest by independent mechanisms (Itahana et al., 2004). As such, in MEFs lacking p21 
there is no bypass of senescence as observed in human fibroblasts (Brown et al., 1997; Pantoja 
and Serrano, 1999). However, in MEFs it has been demonstrated that if one of the senescence 
modulating pathways is impaired (either the p53/p21 or the p16-Rb axis) then cells which have 
become senescent frequently become spontaneously immortalised following sustained culture 
(Dirac and Bernards, 2003; Odell et al., 2010). As such the activity of both pathways is 
important to maintain an irreversible cell cycle arrest in mouse cells. 




Figure 1.1 – Schematic overview of the DDR and signalling axis involved mediating 
senescence induction in human fibroblasts.  
DNA damage occurs in response to a number of stimuli such as telomere shortening, genotoxic 
stress and ROS, this damage triggers a DDR. Damage to the genome promotes both ATM and 
ATR to be phosphorylated and subsequently activated, this leads to recruitment and 
phosphorylation of γH2AX at the site of DNA damage. ATM also triggers induction of 
senescence by CHK2 mediated phosphorylation of p53, which in turn inhibits CDK-2 and 
subsequently blocks pRb activation which promotes the cell cycle arrest. pRb activation is also 
blocked by activation of p16 which inhibits CDK-4 and CDK-6. Activation of p16 occurs in 
response to ROS mediated activation of the MAPK/ p38MAPK. ATM also promotes 
mitochondrial biogenesis through MTORC1 and PGC1-β. This leads to an exacerbated 
production of ROS which in turn can maintain the DDR by inducing short-lived foci. 
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1.4. The Senescent Phenotype 
Senescent cells can be characterised phenotypically by a number of morphological changes. In 
addition to this they differ metabolically, as such, they display an array of fundamental changes 
with regards to gene expression, mitochondrial function and secretory profile. Collectively, 
these features are described as the senescent phenotype and will be discussed in depth in the 
forthcoming sections. 
1.4.1. Morphological Changes 
From a morphological perspective, senescent cells in culture can be clearly distinguished from 
their proliferating counterparts. Senescent cells undergo a vast increase in cellular volume, 
coupled with a flattening of both the nuclear region and cytoplasm, which is often observed to 
be vacuolised (Bayreuther et al., 1988). Frequently, this nuclear region may be multi-nucleated 
and tends to have an associated loss of the nuclear envelope (Mehta et al., 2007). Interestingly, 
in vivo, the morphology of senescent cells is generally not as distorted and reflects that of the 
tissue architecture.(Muñoz-Espín and Serrano, 2014). 
1.4.2. Growth Arrest 
The primary feature of senescence is the irreversible cell cycle arrest. Typically, analysis of 
senescent human fibroblasts and cells derived from mice reveals DNA content that is 
representative of the G1 phase of the cell cycle (Di Leonardo et al., 1994; Herbig et al., 2004). 
However, it is important to note that cells can undergo senescence at other stages of the cell 
cycle. For example, senescence that occurs in response to activation of oncogenes can arise in 
the G2 phase (Zhu et al., 1998). Recent work has revealed that senescence is not restricted to 
mitotic cells. It has been discovered that post-mitotic and terminally differentiated cells such as 
cardiomyocytes and neurons which do not progress through the cell cycle can become senescent 
(Jurk et al., 2012; Farr et al., 2016; Anderson et al., 2019). This abortion of cell cycle 
progression is facilitated by the upregulation of genes associated with the cell cycle arrest, 
crucially the CDKIs p16 and p21. The mechanisms responsible for the induction and 
maintenance of the growth arrest will be discussed in detail later. 
1.4.3. Alterations in Gene Expression 
In order for the senescent cells to sustain a stable cell cycle arrest it is critical that associated 
gene expression is altered to maintain this state. Therefore, analysis of genes that stimulate 
proliferation such as c-FOS, cyclin A, cyclin B and PCNA, are all repressed during the 
senescence programme (Seshadri and Campisi, 1990; Stein et al., 1991; Pang and Chen, 1994). 
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To complement the repression of these genes, the expression of genes responsible for regulating 
cell cycle inhibition are upregulated. It has been well determined that the CDKIs p21 and p16 
are responsible for the induction of the cell cycle arrest (Alcorta et al., 1996; Herbig et al., 
2004). Furthermore, senescent cells display a secretory phenotype that consists primarily of 
inflammatory mediators. This can in part be attributed to enhanced expression of genes 
responsible for encoding secreted proteins that are observed as part of this inflammation, 
namely; extracellular matrix degrading proteins, growth factors and a number of pro-
inflammatory cytokines (Shelton et al., 1999).  
1.4.4. Epigenetic Alterations 
Senescent cells display a heterogeneous phenotype which can include a number of dynamic 
alterations to chromatin structure and the epigenetic landscape. The transcription of genes can 
be regulated by these processes. For example, genes can be silenced when chromatin is coiled 
and compacted into a heterochromatin state or they can be activated when chromatin exists in 
a loosely coiled state (euchromatin) which allows access of the transcriptional machinery. 
Condensed regions of heterochromatin can be identified by markers such as methylation of 5-
methylcytosine in CpG dinucleotides and histone H3 on lysine 9 and 27 (H3K9me3 and 
H3K9me27), similarly, they can be identified by hypoacetylation of lysine on histones H3 and 
H4 (Grewal and Jia, 2007; Trojer and Reinberg, 2007). With regards to senescence, it has been 
observed that some senescent cell types display condensed regions of heterochromatin which 
are referred to as senescence-associated heterochromatin foci (SAHF) which can be recognised 
by punctate regions of DAPI staining (Narita et al., 2003). Moreover, SAHF were found to be 
associated with recruitment of RB which is responsible for repressing E2F genes which are 
known to promote cell cycle progression, it was subsequently demonstrated that inactivation of 
RB family proteins /silencing of p16 prevented SAHF formation (Narita et al., 2003). High 
mobility group A proteins have also been demonstrated to be integral in the development and 
structure of SAHF where they contribute to repression of cell cycle genes, in addition, HMGA 
proteins were shown to cooperate with p16 to stably repress E2F target genes in senescent cells, 
indeed silencing of HMGA2 led to a bypass of senescence (Narita et al., 2006). Further study 
of SAHF has revealed that they are enriched in the transcriptionally repressive histone 
macroH2A, it has also been found that the formation of macroH2A containing SAHF is 
dependent on a histone complex consisting of HIRA and ASF1a which are known to promote 
the formation of transcriptionally inactive heterochromatin (Zhang et al., 2005; Ye et al., 2007). 
The E3 ubiquitin ligase adaptor SPOP has been demonstrated to be upregulated during 
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senescence and can promote senescence, furthermore, it has been implicated as a potential 
upstream regulator of SAHF development (Zhu et al., 2015a). Recent work has unveiled that 
modifications in heterochromatin structure during senescence are underpinned by changes to 
the nuclear lamina which are associated with chromatin positioning and transcriptional 
regulation (Sadaie et al., 2013; Chandra et al., 2015). Specifically, it has been found that Lamin 
B1 a protein responsible for the structure underneath the inner nuclear membrane is 
downregulated in senescent cells as a consequence of autophagy mediated degradation (Freund 
et al., 2012; Ivanov et al., 2013; Sadaie et al., 2013; Dou et al., 2015). It has been shown that 
nuclear regions where Lamin B1 is depleted are associated with H3K9me3, corroborating this, 
the silencing of Lamin B1 promoted development of SAHF by instigating spatial relocalisation 
of perinuclear H3K9me3-positive heterochromatin (Sadaie et al., 2013).  
Collectively, these studies have highlighted that during senescence the formation of 
heterochromatin foci is a complex process which is associated with silencing of genes 
associated with the cell cycle which ultimately acts to reinforce a stable arrest of cellular 
proliferation.  
1.4.5. Resistance to Apoptosis 
Senescent cells have the ability to remain metabolically active despite no longer having the 
capacity to divide. Apoptosis is a process whereby cells are eliminated in a controlled manner. 
Senescence and apoptosis both occur in response to cellular stress, however, at this stage, it is 
not understood what dictates a cell to undergo senescence rather than apoptosis. However, there 
is some evidence suggesting that the level of stress plays a role in the designated response. For 
example, in cardiomyocytes derived from rats, a low level of the DNA intercalator doxorubicin 
culminates in senescence, contrastingly, a high dose results in apoptosis (Zhang et al., 2009). 
Consistently, in human fibroblasts it has been demonstrated that etoposide (a topoisomerase II 
inhibitor that induces double strand breaks) and hydrogen peroxide (an inducer of oxidative 
damage) leads to senescence at low doses and apoptosis at higher doses (Chen and Ames, 1994; 
Chen et al., 2000) (Probin et al., 2006). Similarly, exposure to a low level of UVB irradiation 
which causes DNA damage renders cultured skin fibroblasts senescent, but a high dose leads 
to apoptosis (Debacq-Chainiaux et al., 2005). However, aside from the level of stress, the type 
of cell seems to have a role in determining whether to undergo senescence or apoptosis in 
response to stress. In particular, fibroblasts and epithelial cells have a tendency to undergo 
senescence rather than apoptosis, for example, it has been demonstrated that the DNA damaging 
agent busulfan induces senescence in human fibroblasts, however, higher doses do not alter the 
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cell fate from senescence to apoptosis (Probin et al., 2006). The same effect has been 
demonstrated in melanoma cells whereby temozolomide induces senescence but not apoptosis 
(Mhaidat et al., 2007). Many cell types have the capacity to undergo both senescence and 
apoptosis, however, some cell types such as lymphocytes are more predisposed to undergo 
apoptosis rather than senescence (Campisi and d'Adda di Fagagna, 2007). Collectively, these 
data suggest that the nature and intensity of DNA damage in conjunction with the cell type play 
a crucial role in determining the cell fate. However at this stage, it is unclear whether differences 
associated with the intensity of damage are associated with the capacity for DNA repair to 
occur, or some inbuilt predisposition favouring senescence or apoptosis. 
Interestingly, many types of cells that have undergone the senescence programme are resistant 
to apoptotic stimuli. For example, it has been demonstrated that senescent human fibroblasts 
can resist apoptosis in response to high doses of hydrogen peroxide, UVB and the withdrawal 
of serum which induce apoptosis in their proliferating counterparts (Wang, 1995; Chen et al., 
2000; Yeo et al., 2000). This capacity to resist apoptosis has been attributed to the upregulation 
of anti-apoptotic BCL-2 proteins (B-cell lymphoma 2) (Wang, 1995; Chen et al., 2000; Sanders 
et al., 2013). Similarly, senescent keratinocytes have the capacity to resist UVB induced 
apoptosis (Chaturvedi et al., 1999). However, although many cell types are resistant to 
apoptotic stimuli, some become more sensitive; such as endothelial cells. For example, 
fibroblasts become more resistant to apoptosis as passage number increases, conversely, 
HUVECs (human umbilical vein endothelial cell) become more sensitive with age (Hoffmann 
et al., 2001). It has also been demonstrated that replicatively senescent porcine pulmonary 
artery endothelial cells undergo apoptosis more frequently than proliferating cells, this cell type 
has lower levels of anti-apoptotic BCL-2 proteins (Zhang et al., 2002).     
Alongside the BCL-2 proteins, there is evidence that p53 plays a role in determining whether a 
cell undergoes senescence or apoptosis. For example, in human fibroblasts treatment with 
hydrogen peroxide at a dose sufficient to induce apoptosis p53 expression was elevated 
compared to lower doses which lead to senescence (Chen et al., 2000). In addition to this, it has 
been demonstrated that the kinetics of p53 expression are also important in determining cell 
fate. For example, low levels of γ-irradiation induce a transient rise in p53 expression leading 
to cell cycle arrest, a reduction in p53 leads to rescue of the cell cycle. However, if the 
degradation of p53 is blocked, the cell cycle does not resume and cellular senescence ensues 
(Purvis et al., 2012). To support this notion, following mild oxidative stress induced DNA 
damage if p53 expression is stabilised by Nutlin-3a then the senescence programme is engaged 
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(Efeyan et al., 2007). Furthermore, there is evidence suggesting that the capacity to stabilise 
p53 is diminished with age in splenocytes, this data indicates that with age damaged cells may 
not be able to stabilise p53 sufficiently to engage the apoptosis process, however can still induce 
senescence, hence a possible explanation as to why senescent cells accumulate with age (Feng 
et al., 2007).  
1.4.6. Markers Characteristic of Senescent Cells 
First and foremost, it is important to note that there is no specific marker of senescence, 
therefore, it is essential to use several markers in conjunction to confidently identify senescent 
cells both in vitro and in vivo. The most prominent feature that distinguishes senescent cells 
from proliferating cells is the permanent cell cycle arrest. As such, prominent markers of 
senescence include proteins associated with enforcing this arrest, such as p16, ARF, p21, p15, 
p27 and p53 (Beausejour et al., 2003). Alongside the upregulation of these proteins, there is 
also a loss of proliferative markers such as Ki67 and the incorporation of BrdU (5-
bromodeoxyuridine) during progression through the cell cycle (Lawless et al., 2010).  
As senescence often occurs in response to cellular stress, a common feature of senescent cells 
is the evidence of DNA damage. Markers of DNA damage such as phosphorylated histone 
H2AX (γH2AX) and p53-binding protein-1 (53BP1) are frequently observed (Hewitt et al., 
2012). DNA damage which occurs specifically at telomeres referred to as TAF (telomere 
associated foci) has also been identified as an inducer of senescence and as such is a reliable 
marker of senescence (d'Adda di Fagagna et al., 2003; Hewitt et al., 2012). In addition, other 
markers of the DNA damage response such as phosphorylation of ATM (ataxia-telangiectasia 
mutated) and ATR (ataxia telangiectasia and Rad3-related) are often observed (d'Adda di 
Fagagna et al., 2003). Aside from genomic DNA damage, senescent cells often display changes 
to the structure of their chromatin as discussed earlier. This is evident by the formation of 
senescence associated heterochromatin foci, which can be detected by dense staining areas of 
DAPI (4’,6-diamidino-2-phenylindole). Also visible are areas enriched in histone 
modifications, such as methylation of Histone 3 Lysine 9. These modifications typically follow 
expression of p16 in cultured cells, however, they are not observed as frequently in vivo (Kosar 
et al., 2011). Further changes to the nuclear region are evident in the loss of the nuclear 
envelope, typically lamin B1 is no longer present in senescent cells (Freund et al., 2012). This 
loss has also been associated with the presence of nuclear fragments of DNA which are 
detectable in the cytoplasm of senescent cells (Ivanov et al., 2013; Dou et al., 2017; Gluck et 
al., 2017; Yang et al., 2017). 
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Perhaps the most widely used marker of senescence is the senescence associated β-
galactosidase (SA-β-Gal). Senescent cells display increased biogenesis of lysosomes and 
consequently the enzyme, lysosomal β-galactosidase. As such, at pH 6.0 β-Gal activity is 
detectable and can be used for the detection of senescent cells both in vitro and in vivo by 
histochemistry. SA-β-Gal has been demonstrated to be detectable in an array of senescent cell 
types and was first described in 1995, where SA-β-Gal positive cells were demonstrated to 
increase with age in samples of human skin (Dimri et al., 1995).   It is important to note that 
there are several limitations with regards to the identification of senescent cells using SA-β-
Gal, as it can be detected in confluent and starved cells as well as in immortalized cultures 
(Severino et al., 2000). 
1.4.7. The Senescence Associated Secretory Phenotype 
A key characteristic of senescent cells is the senescence-associated secretory phenotype 
(SASP). The SASP is a complex pro-inflammatory response which consists of cytokines 
(interleukins (IL) 6 and 8) and chemokines (monocyte chemoattractant proteins and 
macrophage inflammatory proteins), growth factors (transforming growth factor-β (TGF-β)) 
and various proteases for degrading the extracellular matrix (Campisi and d'Adda di Fagagna, 
2007).  
It has been hypothesised that the evolutionary purpose of this secretory profile is to signal the 
immune system to clear away senescent cells: a process known as immunosurveillance. Indeed, 
there is evidence to support this notion as the SASP has been demonstrated to result in 
phagocytosis and cytotoxic-mediated killing of senescent cells (Kang et al., 2011b). 
Furthermore, experimental work has revealed that the SASP limits the progression of liver 
fibrosis, as a consequence of removal of senescent hepatic stellate cells by natural killer cells 
both in vitro and in vivo (Krizhanovsky et al., 2008). The SASP also has powerful autocrine 
and paracrine effects, there is clear evidence that it strongly reinforces the senescence 
phenotype through the secretion of IL-8 to prevent the damaged cell in question re-entering the 
cell cycle (Acosta et al., 2008; Kuilman et al., 2008). Another chemokine which forms part of 
the SASP is IP-10, its production is induced by IFN-γ. Once secreted, it can act on its receptor 
CXCR3 to activate NF-κB which has a binding site in the promoter of IP-10. This allows IP-
10 to form a positive feedback loop to stimulate its own transcription which can re-inforce the 
SASP in a paracrine fashion (Perrott et al., 2017) 
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Furthermore, it has been demonstrated that senescent cells can exert damage to neighbouring 
cells. Similarly, the SASP has been shown to be capable of inducing senescence in surrounding 
cells through a TGF-β/ROS/DNA damage mediated mechanism in vitro, similarly in vivo, there 
is evidence that where senescent cells occur they are often found in clusters, which potentially 
occur as a consequence of paracrine effects (Nelson et al., 2012; Acosta et al., 2013). It was 
also demonstrated experimentally that transplanting very low numbers of senescent cells into 
the knee joint in vivo was accompanied by reduced survival, this was not observed when non-
senescent cells were transplanted (Xu et al., 2018). This study indicated the role of senescent 
cells in shortening health and lifespan, potentially by inducing senescence in surrounding 
tissues. This frailty that occurred following the transplant of senescent cells could be attenuated 
by senolytic drugs (Xu et al., 2018). 
Taken together, it seems clear that the primary function of the SASP is to promote clearance 
and prevent the proliferation of damaged cells, which could in turn, lead to tumorigenesis. The 
SASP has been demonstrated to have another beneficial effect and that is during the wound 
healing process. Following acute injury, senescent fibroblasts and endothelial cells form, which 
promote myofibroblasts differentiation through the SASP, specifically through secretion of 
PDGF-AA (platelet-derived growth factor AA). These myofibroblasts aid the healing process 
and therefore demonstrate that senescence is required for optimal wound healing (Demaria et 
al., 2014). Recent work has also established that the SASP plays an important role during 
embryonic development, through TGF-β/SMAD, the SASP promotes the induction of p21-
mediated developmentally programmed senescence which is essential in the development of 
organelles which comprise the structure of the inner ear; mesonephros and endolymphatic sac. 
In this process, the SASP also promotes clearance of senescent cells through a TGF-β mediated 
mechanism of macrophage recruitment (Munoz-Espin et al., 2013).  
Although the SASP can be beneficial, if senescent cells are not effectively cleared then chronic 
inflammation associated with the SASP can promote adverse effects. Interestingly, a recent 
study found that the SASP could had the capacity to promote regeneration through the induction 
of cell plasticity and stemness. This phenomenon was observed both in vitro and in vivo in 
keratinocytes, however, chronic exposure to the SASP diminished the regenerative response 
(Ritschka et al., 2017). Furthermore, a number of studies have revealed that if senescent cells 
are not cleared efficiently, then there are components of the SASP which can render fibroblasts 
and epithelial cells tumorigenic in vitro and in vivo (Krtolica et al., 2001; Kang et al., 2011b). 
Specifically in the liver of mice it has been shown that senescent hepatic stellate cells secrete a 
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SASP which drives hepatocellular carcinomas (Yoshimoto et al., 2013).  Interestingly, IL-8 
which is highly secreted during senescence is also highly expressed in cancer cells and has been 
comprehensively studied and is known to promote aberrant cellular proliferation which leads 
to tumorigenesis, as well as the maintenance and metastasis of tumours (Waugh and Wilson, 
2008). 
 
1.5. The Physiological Significance of Cellular Senescence  
Cellular senescence is an important biological process throughout the life course. At early 
stages, it is a key modulator of embryonic development, then as an organism progresses through 
life it is important in ensuring optimal wound healing and preventing the onset of tumours 
(Serrano et al., 1997; Munoz-Espin et al., 2013; Demaria et al., 2014). However, it has now 
been firmly established that with age senescent cells accumulate and this burden contributes 
towards the development of ageing and age-related pathologies (Baker et al., 2011; Xu et al., 
2015a; Baker et al., 2016). From an evolutionary context, senescence is a good example of 
antagonistic pleiotropy, whereby it is beneficial in early stages of life but is detrimental in the 
later stages (Williams, 1957). In this section, the significance of senescent cells to the 
development of age-related diseases and the emergence of senolytics will be discussed. 
1.5.1. Cellular Senescence and Ageing 
It has been firmly established that with advancing age there is an accumulation of senescent 
cells within a range of tissues. One of the earliest observations in vivo was the increased number 
of SA-β-gal positive cells in human skin samples taken from elderly people when compared to 
their younger counterparts (Dimri et al., 1995). Since then, it has been demonstrated that 
senescent cells accumulate in the tissues of a number of organisms, including; mice, primates, 
humans (Krishnamurthy et al., 2004; Herbig et al., 2006; Jeyapalan et al., 2007; Wang et al., 
2009; Hewitt et al., 2012; Waaijer et al., 2012). However, until recently it was not known 
whether these cells were drivers of ageing.  
To address this key question whether senescent cells are causal in the ageing process, mouse 
models were developed in which senescent cells could be selectively eliminated. Within the 
field, early work to assess the role of the tumour suppressor p16 as an effector of ageing was 
difficult as knockout transgenic animals have curtailed lifespans before the onset of age-related 
disorders due to the formation of tumours (Krimpenfort et al., 2001). Therefore one of the initial 
studies implicating senescent cells in the ageing process employed a model of premature ageing, 
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the BubR1 progeroid mouse. It was observed that in p16 deficient BubR1 mice there was a 
reduction in the accumulation of senescent cells with age, furthermore, these animals displayed 
a reduction in a number of progeroid features in tissues lacking p16 accumulation, such as 
cataract development and the increase in subcutaneous adipose tissue. However, a number of 
progeroid features such as dermal thinning and the thickening of the arterial wall remained 
unchanged (Baker et al., 2008). Following these findings, the same group set out to develop a 
model where p16 cells could be selectively killed. In order to do this they developed the INK-
ATTAC (INK-linked apoptosis through targeted activation of caspase), this system expresses 
a FK506-binding protein fused to caspase 8. Following treatment with the drug AP20187, the 
fusion protein dimerises and induces apoptosis specifically in p16INK4A positive cells. This 
system was employed in the BubR1 background and following the selective elimination of 
senescent cells intermittently it was found that there was a reduction in some progeroid features 
of these mice such as cataract development, sarcopenia and accumulation of subcutaneous 
adipose tissue (Baker et al., 2011).  
Later on it was shown in wild-type mice that bi-weekly clearance of senescent cells from 
midlife onwards culminated in an extension in median lifespan (but not maximum lifespan) in 
two genetically distinct backgrounds. Furthermore, from a health span perspective, it was 
observed that cataract development, the accumulation of subcutaneous adipose tissue, 
glomerulosclerosis, cardiomyocyte hypertrophy and the development of cancer were also 
decreased following selective clearance of p16 positive cells (Baker et al., 2016). Importantly 
these studies were the first to implicate senescence as potential drivers of the ageing process, 
not only that, they have provided a tool which can be used to address the role of senescent cells 
in various diseases.  Alongside the INK-ATTAC mouse model, a similar model referred to as 
the p16-3MR mouse has been developed, whereby p16 positive cells can be selectively 
eliminated following administration of the drug ganciclovir (Demaria et al., 2014). Together 
these two models have allowed the role of senescent cells in age-related diseases to be dissected 
(which will be discussed in detail in Section 1.5.3).  
1.5.2. The Emergence of Senolytics 
Following the INK-ATTAC model which established senescence as a causal player in the 
ageing process, naturally there have been a number of studies investigating pharmacological 
compounds which can selectively kill senescent cells (referred to as senolytics).  
Chapter 1 - Introduction 
20 
 
The first published senolytics were the combination therapy of the drugs dasatanib and 
quercetin (Zhu et al., 2015b). These two compounds were identified as having senolytic 
therapies after it was discovered that the survival of senescent adipocytes was dependent on the 
ephrins EFNB1, EFNB3, PI3Kδ (phosphatidyl 3-kinase-δ), BCL-XL, p21 and the serpin 
plasminogen-activated inhibitor-2 (PAI2). Genetic silencing and pharmacological targeting of 
these factors resulted in the induction of apoptosis in senescent cells but not proliferating cells. 
It was found that dasatanib which is a pan-tyrosine kinase inhibitor and effectively blocks the 
ephrin receptors in conjunction with the flavonoid quercetin which can inhibit the serpins, 
together displayed senolytic activity comparable to that of the BCL-2 inhibitors. Furthermore, 
it was demonstrated in vivo that senescent cells were eliminated and subsequently resulted in 
an improvement in health span (reduced osteoporosis, improved exercise capacity and a delay 
in the development of age-related pathologies) in a progeroid mouse model (Zhu et al., 2015b). 
Specifically addressing the implications of osteoporosis and age-associated bone loss in mice, 
it has been demonstrated that the combination of dasatanib and quercetin prevents the age-
related loss and indeed reduces frailty. These effects were also observed using INK-ATTAC 
mice and were attributed to the pro-inflammatory environment associated with the presence of 
senescent cells, consistently, inhibition of the JAK/STAT pathway prevented the SASP and 
also improved bone formation (Farr et al., 2017). Recently it was published that the onset of 
senescence can drive liver steatosis, the authors showed treatment with dasatanib and quercetin 
could reduce liver steatosis (Ogrodnik et al., 2017). It has also been demonstrated that following 
the onset of obesity there is an accumulation of senescent cells which drive anxiety-related 
behaviour, it was shown that clearance of these senescent cells using dasatanib and quercetin 
could alleviate these behaviours (Ogrodnik et al., 2019). Dasatanib and quercetin have also 
been shown to reduce fibrosis and hypertrophy in aged mice which was associated with a 
restoration of the regenerative capacity of the heart (Lewis-McDougall et al., 2019). Senescent 
cells have also been implicated in the development of idiopathic pulmonary fibrosis, here, it 
was demonstrated that treatment with dasatanib and quercetin improves exercise capacity and 
lung compliance in a mouse model of pulmonary fibrosis (Schafer et al., 2017). Following this, 
the first human clinical trial has been conducted to assess the safety of dasatanib and quercetin 
in idiopathic pulmonary fibrosis patients. In this study, the combination therapy was well 
tolerated and although there were no beneficial effects on pulmonary function there were 
improvements in physical function. Therefore warranting evaluation of dasatanib and quercetin 
in a larger cohort of patients for senescence associated diseases (Justice et al., 2019).   
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As discussed earlier a common feature of senescent cells is their resistance to apoptotic stimuli. 
It has been demonstrated that in a number of cell types this resistance is facilitated by 
upregulation of anti-apoptotic BCL-2 family proteins; BCL-2, BCL-XL and BCL-W. These 
proteins prevent apoptosis from occurring by binding to and preventing the activation of pro-
apoptotic BCL-2 family members. The senolytic compounds ABT737 and ABT263 
(navitoclax) promote selective apoptosis in senescent cells by inhibiting the anti-apoptotic 
actions of BCL-2, BCL-XL and BCL-W. This allows the pro-apoptotic BCL-2 proteins which 
are usually rendered inactive in senescent cells to activate BAX and BAK (BCL-2 homologous 
antagonist/killer), together these proteins form pores in the outer mitochondrial membrane 
which allow cytochrome C to be released and subsequently trigger a caspase cascade 
culminating in apoptosis (Tse et al., 2008; Song et al., 2011; Chang et al., 2016; Yosef et al., 
2016b).  Navitoclax, ABT737 have both been demonstrated to selectively kill senescent cells 
both in vitro and in vivo (Chang et al., 2016; Yosef et al., 2016a; Zhu et al., 2016). Additionally,  
it has been reported that fisetin (a flavone) and A1155463 and A1331852 can induce apoptosis 
in various senescent cells due to their action on BCL-XL (Zhu et al., 2017). Specifically, it has 
been demonstrated that navitoclax can reduce senescent cells following sub-lethal irradiation. 
Furthermore, it has been demonstrated in normal aged mice that navitoclax-mediated clearance 
of senescent cells offset premature-ageing of the haemopoetic system and promoted 
rejuvenation of haemopoetic and muscle stem cells (Chang et al., 2016; Zhu et al., 2016). 
Navitoclax has also been demonstrated to be beneficial in atherosclerosis. Here, senescent cells 
accumulate and drive pathology by increasing the expression of atherogenic and inflammatory 
factors (Childs et al., 2016). Using both navitoclax and the p16-3MR mouse model, the 
selective removal of senescent cells inhibits plaque growth and reduces the atherogenic 
environment (Childs et al., 2016). In addition, it has been published that navitoclax decreases 
cardiac fibrosis and hypertrophy that occurs in aged mice (Anderson et al., 2019). It has also 
been demonstrated that following a myocardial infarction navitoclax can improve functional 
outcomes and overall survival in mice (Walaszczyk et al., 2019). 
Another senolytic recently identified is UBX0101. UBX0101 inhibits the anti-apoptotic protein 
MDM2, thus preventing interaction and degradation of p53, and this leads to p53 
overexpression and subsequently apoptosis. UBX0101 has been demonstrated to effectively 
clear senescent chondrocytes such as those found in arthritic joints (Jeon et al., 2017). 
Furthermore, following clearance there was an increase in cartilage development, reduction in 
pain and an overall attenuation in the development of post-traumatic osteoarthritis. 
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Consistently, the same study reported the same beneficial effects following selective clearance 
of senescent cells in the p16-3MR mouse model (Jeon et al., 2017). This molecule is also being 
progressed to phase 1 clinical trials in osteoarthritis patients.     
Senescent cells can also undergo apoptosis when the interaction between p53 and FOXO4 
(forkhead box protein 04) is disrupted. During senescence it has been identified that FOXO4 is 
upregulated and binds to p53, effectively preventing p53-mediated apoptosis. Thus, it was 
observed that treatment of senescent cells with the peptide D-retro inverso FOXO4 promoted 
p53 activation, release of cytochrome C and subsequent apoptosis. Furthermore in aged mice, 
the inhibition of FOXO4 has been demonstrated to improve a number of aspects of health span 
such as fitness, renal function and hair growth (Baar et al., 2017). 
A group of proteins referred to as heat shock proteins (HSP) which have roles in protein folding 
and degradation, as well as cell development and growth have been implicated as a senolytic 
target. HSP90 acts on AKT and p-AKT which are key proteins as part of the anti-apoptotic 
PI3K/AKT pathway that is upregulated in senescence. Furthermore, it has been discovered that 
inhibitors of HSP90 (tanespimycin, geldanamycin and alvespimycin) can induce apoptosis in 
an array of senescent cell types of both human and mouse origin. In vivo, intermittent treatment 
with HSP90 inhibitors reduced the number of p16 positive cells as well as various age-related 
symptoms such as kyphosis, grip strength and overall body condition (Fuhrmann-Stroissnigg 
et al., 2017). Another molecule that has been identified as having senolytic activity is 
piperlongumine, although its mechanism is not fully understood, it is known to inhibit the 
phosphorylation of AKT (Makhov et al., 2014). It has been demonstrated to have the capacity 
to eliminate senescent cells in vitro (Chang et al., 2016).   
 




Figure 1.2 – Schematic demonstrating therapeutic strategies for alleviating the 
detrimental effects of senescent cells.  
It has been firmly established that exposure to stressful stimuli promote the induction of 
senescence. Generally senescent cells are removed by the immune system, but with age these 
cells accumulate. The presence of these senescent cells can promote neighbouring cells to 
become senescent through a paracrine mechanism. This in turn contributes to a chronic 
inflammatory environment which is believed to exacerbate tissue dysfunction and promote the 
ageing process. Therefore two strategies have emerged to prevent the deleterious effects of 
senescence. The first strategy is senostatic therapies, these aim to suppress the SASP without 
removing the beneficial cell cycle arrest. The second is that of senolytics, which selectively 
eliminate senescent cells without impacting healthy proliferating cells. Figure adapted from 
(Chapman et al., 2019) 
 
1.5.3. Cellular Senescence and Age-Related Diseases 
Senescent cells have been recognised as being present at the sites of disease for some time, 
however, it has been difficult to establish causality until recently. Collectively, the transgenic 
mouse models and the emergence of senolytics have provided excellent tools to dissect and 
understand the role of senescent cells in various age-related diseases. As such, a number of 
studies are currently underway and have been conducted to investigate these associations as 
summarised in Table 1.1. 
As previously discussed, during the onset of the age-related diseases; osteoporosis, 
osteoarthritis and atherosclerosis, senescent cells have been observed to accumulate at the sites 
of disease. Furthermore, the removal of these senescent cells using either senolytics or the 
transgenic mouse models has clear beneficial effects in each of these diseases (Childs et al., 
2016; Roos et al., 2016b; Farr et al., 2017; Jeon et al., 2017). Interestingly with age, there is 
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also a decrease in cardiac function, in the INK-ATTAC model it was observed that the clearance 
of senescent cells resulted in a decreased amount of cardiac hypertrophy as well as an increased 
resistance to cardiac stress (Baker et al., 2016). Further work has revealed that during ageing, 
cardiomyocytes, a key cell type found in the heart develop a senescent-like phenotype that can 
promote fibrosis and hypertrophy through the SASP. Interestingly, clearance of senescent cells 
either genetically (INK-ATTAC) or pharmacologically (navitoclax) reduced both hypertrophy 
and fibrosis, and in fact, promoted cardiomyocyte regeneration (Anderson et al., 2019). 
Similarly, it has recently been shown that senolytic treatment following acute myocardial 
infarction has beneficial effects by promoting tissue remodelling, improving cardiac function 
and improving overall survival (Walaszczyk et al., 2019). Therefore, these studies highlight the 
detrimental effect that senescent cells exert on cardiac function with age. 
Another tissue where function is impaired with advancing age is the lung. It loses elasticity and 
becomes more susceptible to pathogenic invasion. It has been previously highlighted that 
diseases of the lung such as chronic obstructive pulmonary disease and idiopathic pulmonary 
fibrosis display evidence of increased levels of senescent cells (Birch et al., 2015; Schafer et 
al., 2017). Interestingly, it has recently been demonstrated that the genetic clearance of p19ARF 
positive senescent cells improved the compliance and elasticity of lungs in aged mice, thereby 
partially restoring overall pulmonary function that deteriorates with age (Hashimoto et al., 
2016). Senescent cells have been demonstrated to be detrimental in idiopathic pulmonary 
fibrosis. Tissues from patients display exacerbated levels of senescent markers such as p21 and 
SA-β-gal (Yanai et al., 2015; Schafer et al., 2017). Furthermore, the negative effects of 
senescent cells were demonstrated when selective elimination of senescent cells using both 
transgenic mice and senolytics resulted in an improvement in overall pulmonary function, as 
well as a reduction in the SASP which has been demonstrated to be pro-fibrotic and thus 
aggravate the disease further (Schafer et al., 2017; Munoz-Espin et al., 2018).  
Another organ where its overall function can become reduced with age is the kidney. It has 
been noted that in individuals with glomerulosclerosis and atrophy of the nephrons, there is an 
exacerbated number of p16 and p53 positive cells in these regions (Melk et al., 2004). Clearance 
of senescent cells in the INK-ATTAC model resulted in an improvement of kidney function as 
well as a reduction in the hardening of the glomeruli of the kidney, i.e. a reduction in 
glomerulosclerosis (Baker et al., 2016). With age, the liver also becomes more susceptible to 
developing non-alcoholic fatty liver disease. This is another disease where the presence of 
senescent cells is observed. It was recently reported that senescent hepatocytes drive fat 
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accumulation in the liver which in turn contributes to liver steatosis and non-alcoholic fatty 
liver disease. Consistently, the clearance of senescent cells using either the INK-ATTAC model 
or dasatanib and quercetin lead to an overall reduction in hepatic steatosis (Ogrodnik et al., 
2017). These studies have highlighted the contribution of senescent cells to the age-associated 
reduction in renal function and the development of non-alcoholic fatty liver disease. 
An emerging area where senescent cells have been implicated is neurodegeneration, it has 
previously been highlighted that senescent markers are present in neurodegenerative diseases 
such as Alzheimer’s disease (Bhat et al., 2012; Musi et al., 2018). It has recently been published 
that genetic and pharmacological clearance of senescent cells in a mouse model of Alzheimer’s 
disease modulates accumulation of tau aggregates and in turn preserves cognitive function 
(Bussian et al., 2018). Similarly, another group recently published that senolytic treatment 
reduces neuroinflammation and improves cognitive function in an Alzheimers disease model 
(Zhang et al., 2019). Senescent cells have also been implicated in contributing to 
neuropsychiatric disorders. It was recently highlighted that obese mice harbour an increased 
burden of senescent cells. Specifically, high levels of senescent glial cells in proximity to the 
lateral ventricle (an important area for adult neurogenesis) were associated with an increase in 
anxiety-like behaviour(Ogrodnik et al., 2019). Both genetic and pharmacological clearance of 
these senescent cells alleviated anxiety-like behaviour (Ogrodnik et al., 2019).  
A number of other diseases and pathologies have been associated with senescence such as 
sarcopenia, type II diabetes and cachexia (Baker et al., 2011; Baker et al., 2016; Chang et al., 
2016; Berry et al., 2017; Xu et al., 2018; Palmer et al., 2019). However, it is important to 
consider that senescent cells have been demonstrated to be beneficial in some contexts. As 
previously mentioned, senescence is crucial for optimal wound healing and also is an important 
tumour suppressor mechanism to prevent the onset of cancer (Serrano et al., 1997; Demaria et 
al., 2014). Aside from these, senescent cells have also been demonstrated to be beneficial in 
diseases where they limit the progression of fibrosis. For example, during the development of 
liver cirrhosis senescent cells accumulate, the senescent cells are predominantly hepatic stellate 
cells, normally these cells proliferate and produce the fibrotic scar. However, the induction of 
senescence limits the formation of the fibrotic scar and these cells are subsequently cleared by 
natural killer cells which facilitates the resolution of the fibrosis (Krizhanovsky et al., 2008). 
Similarly, the onset of senescence has been shown to reduce oral submucous fibrosis and 
cardiac fibrosis (Pitiyage et al., 2011; Zhu et al., 2013). There is also some evidence that 
senescence is beneficial in protecting against pulmonary hypertension. It has been observed 
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experimentally that mice deficient for p53 display aggravated pulmonary hypertension in 
response to hypoxia, consistently, activation of p53 can reverse pulmonary hypertension 
(Mizuno et al., 2011; Mouraret et al., 2013). Interestingly, the senescence programme can 
protect against the development of arthrosclerosis.  Although at later stages of the disease 
clearance of senescent cells is beneficial, studies have observed that mice deficient for p21 or 
p53 are more susceptible to the development of artherosclerosis, thereby indicating that the 
senescence programme provides a protective function against the development of 
atherosclerotic plaques (Mercer et al., 2005; Khanna, 2009; Childs et al., 2016).  
Finally, at this stage it seems that the clearance of senescent cells either genetically or using 
senolytics have generally been well tolerated in vivo with minimal side effects (Baker et al., 
2011; Justice et al., 2019). However, it is important to note that previous clinical studies have 
implicated thrombocytopenia and neutropenia as a side effect of BCL-2 inhibitors (Kaefer et 
al., 2014). Therefore work is currently underway to identify senolytics with minimal side 
effects, as such, a new class of drug has been reported as exhibiting senolytic activity; cardiac 
glycosides. As yet, these findings are unpublished, however, blockade of their target the Na/K-
ATPase has been previously implicated as being able to mitigate cellular senescence (Sodhi et 
al., 2018). However, at this stage the evidence from published studies clarifies that chronic 
treatment is not required to effectively clear senescent cells using existing senolytics, thereby 
intermittent administration has the capacity to minimise side effects (Zhu et al., 2015b; Chang 
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Disease Genetic Clearance Senolytic Therapy 
Atherosclerosis Childs et al., 2016 
Roos et al., 2016 
Childs et al., 2016 
Alopecia N/A Yosef et al., 2016 
Cachexia 
Baker et al., 2016 
Berry et al., 2017 
Berry et al., 2017 
Xu et al., 2018 
Cataracts Baker et al., 2011 N/A 
Cardiac Ageing 
Baker et al., 2016 
Anderson et al., 2019 
Zhu et al., 2015 
Baker et al., 2016 
Anderson et al., 2019 
Diabetes Palmer et al., 2019 Palmer et al., 2019 
Fatty Liver Disease Ogrodnik et al., 2017 Ogrodnik et al., 2017 
Glomerulosclerosis Baker et al., 2016 N/A 
Idiopathic Pulmonary 
Fibrosis 
Schafer et al., 2016 
Yanai et al. 2015 
Schafer et al. 2016 
Muñoz‐Espín et al., 2018 
Lung Ageing Hashimoto et al., 2019 N/A 
Myocardial Infarction N/A Walaszczyk et al., 2019 
Neurodegeneration Bussian et al., 2018 
Bussian et al., 2018 
Musi et al., 2018 
Zhang et al., 2019 
Neuropsychiatric 
Disorders 
Ogrodnik et al., 2019 Ogrodnik et al., 2019 
Osteoarthritis Jeon et al., 2017 Jeon et al., 2017 
Osteoporosis Farr et al., 2017 Farr et al., 2017 
Sarcopenia Baker et al., 2011 
Chang et al., 2016 
Xu et al., 2018 
 
Table 1.1– Diseases that have been associated with cellular senescence. 
 It has been established using either genetic or pharmacological means of senescent cell 
clearance that senescent cells play a role in the development of a number of age-related diseases. 
This table summarises diseases where senescent cells have been implicated as having a causal 
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1.6. The Role of Mitochondria in Cellular Senescence 
Mitochondria are important organelles that regulate a myriad of cellular processes, for example 
they play a key role in the production of energy, orchestrating the apoptotic process as well as 
regulating various aspects of cellular metabolism (Nunnari and Suomalainen, 2012). 
Dysfunctional mitochondria are a prominent feature of cellular senescence, and both have been 
implicated as classical hallmarks of the ageing process (Lopez-Otin et al., 2013). In this section 
we review the relationship between the two. 
1.6.1. Mitochondrial Dynamics and ROS in Senescence 
Mitochondria in senescent cells undergo several fundamental changes. For example, 
mitochondrial morphology is dramatically altered in senescent cells. A normal mitochondrial 
network constantly undergoes fission and fusion events to promote reorganisation, facilitate 
mitochondrial replication as well as segregate dysfunctional entities, this continuous process 
ensures that the metabolic needs of the cell are met (Detmer and Chan, 2007). Interestingly, the 
mitochondria networks of senescent cells and old cells are composed of a vastly increased 
number of mitochondria which exist in a hyper fused state (Jendrach et al., 2005; Yoon et al., 
2006). This occurs in response to a dysregulation of fission and fusion machinery, whereby 
studies have revealed that senescent cells display a reduction in dynamin related protein 1 
(DRP1) and mitochondrial fission protein 1 (FIS1) which are key mediators of the fission 
process, this culminates in an overall reduction of fission and fusion events in senescent cells 
(Mai et al., 2010). Furthermore, in vitro it has been demonstrated that senescence can be 
induced when mitochondria are maintained in a fused state following the knock down of FIS1, 
if FIS1 is reintroduced then the senescence response is suppressed. In addition, if FIS1 is 
depleted in conjunction with the fusion regulator OPA1, then fragmented mitochondria results 
and no senescence response (Lee et al., 2007). Consistently, in a model where DRP1 is 
downregulated due to depletion of a mitochondrial E3 ubiquitin ligase senescence, the fusion 
regulator MFN1 (mitofusin-1) accumulates and promotes an elongated mitochondrial network, 
in response, cells become senescent (Park et al., 2010). Collectively, these data highlight that 
mitochondrial dynamics are a fundamental part of the senescence programme; however, it is 
not entirely clear how elongated mitochondria may drive the process. 
It is believed that one way in which elongated mitochondria can initiate senescence is through 
the exacerbated production of ROS (Yoon et al., 2006). In 1972, the “mitochondrial free radical 
theory of ageing” was proposed by Denham Harman, where he hypothesised that mitochondrial 
ROS could drive the ageing process as a consequence of the damage they inflict on DNA and 
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protein structures (Harman, 1972). The link between ROS and senescence was first observed 
when it was noted that cells cultured in low oxygen had reduced levels of oxidative damage and 
had an increased lifespan (Packer and Fuehr, 1977). The superoxide anion is the most damaging 
of the mitochondrial derived ROS and is produced as a consequence of electron leak along the 
electron transport chain. As cells reach the end of their replicative lifespan it has been observed 
that the production of ROS is exacerbated, this has been observed in a number of models of 
senescence such as replicative senescence, stress-induced and oncogene induced senescence 
(Saretzki et al., 2003; Passos et al., 2007; Moiseeva et al., 2009; Passos et al., 2010). 
Furthermore, it has been demonstrated by a number of groups that mitochondrial ROS is not 
just a feature of senescence it can in fact drive oxidative damage which can induce senescence 
in human fibroblasts through a ROS-mediated DDR (Chen et al., 1995a; Passos et al., 2007; 
Moiseeva et al., 2009; Passos et al., 2010). Oxidative stress which occurs in response to ROS 
has been demonstrated to accelerate telomere shortening and subsequently induce telomere-
dependent senescence (von Zglinicki, 2002). It has since been established that telomeric regions 
are explicitly sensitive to the damage induced by ROS and damage occurring here induces 
senescence (Petersen et al., 1998; Passos et al., 2007; Hewitt et al., 2012). Consistently, 
telomere dysfunction can be averted and replicative lifespan in vitro extended by mediators that 
reduce mitochondrial-derived ROS such as the antioxidant MitoQ, nicotinamide as well as mild 
mitochondrial uncoupling (Saretzki et al., 2003; Kang et al., 2006; Passos et al., 2007). 
Similarly, in vivo, the inhibition of the antioxidant enzymes catalase and manganese super oxide 
dismutase (MnSOD) has been associated with an increase in telomeric damage. Furthermore, 
telomeric damage induced by overexpression of the pro-oxidant monoamine oxidase can be 
reduced following treatment with N-acetyl-cysteine (NAC) (Anderson et al., 2019). There have 
been a vast number of studies demonstrating the increase in oxidative damage with age in 
various organisms (Oliver et al., 1987; Hamilton et al., 2001). However, there are a number of 
conflicting studies where manipulation of antioxidant defences and oxidant production do not 
support the hypothesised role of oxidative damage in ageing (Muller et al., 2007). For example, 
the overexpression of catalase in mice does not lead to an extension in maximal life span (Chen 
et al., 2004b). 
Interestingly, ROS have been implicated in maintaining the senescence response as well as 
inducing it. Promoting overexpression of the main senescence effectors in vitro such as p16, 
p21, p53 and oncogenic Ras all promote an increase in ROS production (Lee et al., 1999; Macip 
et al., 2002). Following these observations, it was recently discovered that mitochondrial ROS 
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are involved in a positive feedback loop during the induction of senescence. Following the 
induction of senescence, ROS are produced where they induce short-lived DNA damage foci 
to instigate a DDR. ROS are continuously produced to maintain DNA damage which leads to 
a persistent DDR. This persistent DDR culminates in senescence, mechanistically, it has been 
demonstrated that this feedback loop is active until the growth arrest is firmly established, then 
it is no longer required (Passos et al., 2010). 
1.6.2. Mitochondrial Quality Control in Senescence 
Dysfunctional mitochondria are traditionally cleared and recycled via a specialised form of 
autophagy termed mitophagy. This process enables the targeted degradation of mitochondria 
which have been tagged with polyubiquitin chains consisting of parkin and PINK1 (PTEN 
induced kinase 1). Recognition of these chains by the receptor proteins optineurin, NDP52 and 
TaxBP1 engages the autophagic machinery and these dysfunctional mitochondria are 
subsequently engulfed and recycled by autophagosomes (Zaffagnini and Martens, 2016). 
During the onset of senescence there is a clear accumulation of dysfunctional mitochondria, 
however, it is unclear whether mitophagy contributes to this process. 
For mitochondria to be recycled they need to be isolated, however, as discussed earlier 
mitochondria in senescent cells have a reduction in the fission/fusion machinery and exist in a 
predominantly hyperfused state (Yoon et al., 2006). Therefore it is unclear in senescence how 
effectively senescent cells can segregate dysfunctional mitochondria for mitophagy. 
Furthermore, PINK1 which is important for labelling mitochondria for degradation is 
downregulated in senescent cells. PINK1 also plays a role in promoting mitochondrial fission, 
therefore it may contribute to the hyperfused networks characteristic of senescence (Dalle Pezze 
et al., 2014). Recent work has highlighted that senescent cells produce hydrogen peroxide via 
the mitochondrial enzyme monoamine oxidase-A, this production of ROS was associated with 
accumulation of p53 which inhibited parkin. This lead to mitochondrial dysfunction and an 
impairment of the mitophagy process with a subsequent induction of senescence via a classical 
DDR. Furthermore, they demonstrated that restoration of mitophagy either by mTOR inhibition 
or overexpression of parkin prevented the onset of both mitochondrial dysfunction and 
senescence (Manzella et al., 2018). Similarly, during the induction of senescence it has been 
demonstrated that impaired mitophagy occurs following p53 accumulation which interacts with 
parkin preventing its translocation to damaged mitochondria. It was also demonstrated that 
restoring mitophagy decreased mitochondrial mass accumulation and delayed cellular 
senescence (Ahmad et al., 2015).  It has also been demonstrated that impairment of the 
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autophagy machinery by downregulation of key autophagic regulators such as ATG7, ATG12, 
and Lamp2 has been shown to induce premature senescence in primary human fibroblasts, 
furthermore, it was demonstrated that the onset of senescence could be delayed by antioxidants 
and inhibition of p53 (Kang et al., 2011a). Interestingly, the transcription factor GATA4 which 
is normally degraded by autophagy is stabilised in senescence, this stabilisation activates NF-
κB which instigates the SASP. The stabilisation of GATA4 is dependent on the DDR, but not 
on p53 or p16 (Kang et al., 2015). 
Although there is mounting evidence that supports the impairment of mitophagy and autophagy 
in senescence, there is also evidence that mitophagy and autophagy can promote the onset of 
senescence. For example, it is known that during autophagy there is formation of the TASCC 
(TOR-autophagy spatial coupling compartment), here mTOR and lysosomes accumulate during 
OIS. At the TASCC site there is a high number of amino acids which have been demonstrated 
to promote synthesis of the SASP factors IL-6 and IL-8 through mTOR (Narita et al., 2011). 
Furthermore, in OIS it has been found that autophagy-related genes are upregulated, the authors 
also demonstrated that knockdown or inhibition of autophagic regulators delayed the 
senescence phenotype and SASP (Young et al., 2009). Therefore at this stage, there is some 
conflicting evidence for the role of autophagy and mitophagy in senescence which requires 
further study to broaden our understanding of the relationship between the two. 
1.6.3. Mitochondria are necessary for Development of the Senescence Phenotype 
The relationship between mitochondria and senescence has been investigated for a number of 
years and has predominantly been associated with their role as ROS generators, however, 
previous studies have failed to concretely address whether mitochondria are required for the 
senescence process or the changes observed are merely a consequence of the senescence 
programme. Therefore our lab designed a proof of principle study to shed light on the role of 
mitochondria in senescent cells. A system was designed whereby fibroblasts overexpressing 
the ubiquitin ligase parkin found on mitochondria could be targeted to undergo mitophagy 
following the induction of mitochondrial depolarisation, this results in mitochondrial clearance 
(Tait et al., 2013; Correia-Melo et al., 2017). Viable fibroblasts could therefore be generated 
which are completely devoid of mitochondria and rely on glycolysis rather than mitochondrial-
mediated ATP production. This system allowed mitochondria to be cleared prior to and post 
development of senescence to dissect the role of mitochondria. It was discovered that the 
clearance of mitochondria at the point of senescence induction resulted in a reduced cell size, 
SA-β-Gal and ROS, as well as a reduction in the cell cycle inhibitors p16 and p21 compared to 
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mitochondria competent fibroblasts. However, although proliferating slowly following the 
induction of senescence, these cells did undergo a complete cell cycle arrest. Perhaps most 
interestingly is that these mitochondrial depleted fibroblasts had a severely diminished SASP, 
the key factors IL-6, IL-8, GRO and MCP-1 were all significantly reduced (Correia-Melo et al., 
2016). Fundamentally, this study was the first of its kind to demonstrate that mitochondria are 
crucial for regulating the pro-oxidant and pro-inflammatory features of senescence. 
Importantly this study also identified a novel pathway that is involved in the induction of 
senescence. It was demonstrated that the DDR activates ATM which directly phosphorylates 
Akt, this   leads to phosphorylation and activation of mTORC1 (mammalian target of rapamycin 
complex 1). This in turn triggers mitochondrial biogenesis via PGC1-β (peroxisome 
proliferator-activated receptor-gamma coactivator 1β). It was demonstrated that inhibition of 
either mTORC1 or ATM in vitro could alleviate mitochondrial biogenesis observed during 
senescence and subsequently markers of senescence and the SASP. Furthermore, mTORC1 
inhibition in vivo using rapamycin was associated with reduced mitochondrial content and 
markers of senescence (p21, SA-β-Gal and TAF) as well as reduced secretion of SASP factors 
(Correia-Melo et al., 2017).  Further work has revealed that the beneficial effects associated 
with alleviating the SASP via mTOR targeting with rapamycin can improve the health span of 
mice (Lesniewski et al., 2017; Houssaini et al., 2018; Correia-Melo et al., 2019). In addition to 
this, a number of studies have demonstrated elongated lifespan following treatment with 
rapamycin, although this cannot be directly attributed to the SASP suppressive effects 
associated with targeting mTOR (Harrison et al., 2009; Lesniewski et al., 2017).  
 
1.7. Mitochondrial Mechanisms Regulating the SASP 
Following the observation that mitochondria underpin the pro-inflammatory features of 
senescence this raises the natural question as to what the possible molecular mechanisms are 
which provide the link between mitochondria and the SASP.  
1.7.1. Mitochondrial Metabolites and Regulation of the SASP 
An emerging link between senescence and mitochondria is the role of mitochondrial 
metabolites. The most comprehensively studied metabolite is perhaps nicotinamide adenine 
dinucleotide (NAD). The prominent function of NAD+ is to act as a cofactor where it accepts 
and carries electrons in turn becoming reduced to NADH. This occurs along the electron 
transport chain as well as following oxidation of organic molecules during oxidative 
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phosphorylation (Genova and Lenaz, 2014). Generally the NAD+/NADH is tightly regulated to 
maintain optimum mitochondrial function. Interestingly, it has been reported that senescent 
cells exhibit a lower ratio of NAD+ to NADH. The increase in NADH has been attributed to 
decreased levels of the cytosolic enzyme malate dehydrogenase found in senescent cells, this 
enzyme functions to produce malate from oxaloacetate, in doing so it uses NADH (Lee et al., 
2012). Of further interest is a study which has implicated nicotinamide 
phosphoribosyltransferase (NAMPT) as being reduced in replicative senescent cells (Amano et 
al., 2019). NAMPT functions to salvage NAD+ from nicotinamide, as such its diminished 
activity is associated with exacerbating the low NAD+/NADH ratio. This study also discovered 
that overexpression of NAMPT lead to a decrease in age-related increases in p53, which in turn 
resulted in an increase in cellular lifespan (van der Veer et al., 2007). From an ageing 
perspective it has been noted that declining NAD+ levels are observed in a number of older 
organisms (Braidy et al., 2011; Gomes et al., 2013). It was also recently identified that low 
NAD+/NADH levels provoke a cell cycle arrest, but in addition also drive p53 activation 
through AMPK (5' adenosine monophosphate-activated protein kinase), this in turn was shown 
to initiate the IL-1 arm of the SASP (Wiley et al., 2016). Recent work has identified NAMPT 
as being a regulator of the SASP independently of the cell cycle arrest (Nacarelli et al., 2019). 
It was shown that NAD+ metabolism is a key regulator of determining the level of SASP 
secretion. In contrast to the Wiley et al study, they found that NAD+ suppresses AMPK, which 
decreases the p53-mediated inhibition of p38MAPK (P38 mitogen-activated protein kinases) 
which leads to an increase in NF-κB activity and subsequently an elevated SASP. It is proposed 
that this may explain why forms of senescence such as OIS which are associated with a higher 
NAD+/NADH ratio have a more intense SASP than forms of senescence such as replicative and 
stress induced senescence which have a lower NAD+/NADH ratio (Nacarelli et al., 2019).  
Emerging work has begun to demonstrate an intricate link between NAD+ levels and 
downstream effectors of the senescence programme. NAD+ may also impact on the senescence 
phenotype by its effect on the activity of mitochondrial enzymes, specifically the NAD+ 
dependent malic enzymes 1 and 2. These enzymes process the tricarboxylic acid cycle 
metabolite malate into pyruvate, interestingly, cells depleted of malic enzyme 1 and 2 undergo 
premature senescence via a p53-dependent mechanism (Jiang et al., 2013). NAD+ has also been 
implicated as having a regulatory role in DNA damage repair. PARP, is a key element of the 
DDR which requires NAD+ to effectively repair genomic damage. Consistently, it has been 
demonstrated that following irradiation PARP inhibition promotes an accelerated onset of 
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senescence due to unrepaired DNA damage (Efimova et al., 2010). A further group of proteins 
associated with DNA damage repair is the sirtuins. The sirtuins are deacetylases that are 
dependent on NAD+ in general, the sirtuins family are decreased in senescence and as such 
render cells more prone to oxidative stress and DNA damage, this is likely associated with the 
decreased levels of NAD+ (Grabowska et al., 2017; van de Ven et al., 2017). From an in vivo 
perspective, the age-related decline in NAD+ levels can be prevented by inhibiting NADase 
cluster of differentiation 38 (NADase CD38) which is responsible in part for degrading NAD+, 
this has been associated with reduced levels of the senescence marker TAF in the muscles and 
liver of mice (Tarrago et al., 2018). Similarly, supplementation of NAD+ using the precursor 
nicotinamide mononucleotide was demonstrated to alleviate telomere dysfunction in mice in 
part due an increase in function of sirtuin 1 which is responsible for DNA repair (Amano et al., 
2019). Interestingly, CD38 is not highly expressed in senescent cells, however, exposure of 
non-senescent cells to the SASP promotes an increase in CD38 mRNA and protein levels which 
was associated with an increase in NADase CD38 activity. Therefore it has been suggested that 
the SASP may be responsible for disrupting NAD+ homeostasis during the ageing process 
(Chini et al., 2019). 
Another two mitochondrial peptides which have been implicated in the regulation of the SASP 
are humanin and MOTS-c. These two peptides have been found to be increased in senescent 
cells. Interestingly, it has been demonstrated that following the treatment of senescent cells with 
these two peptides, there is an engagement of mitochondrial energetics which results in an 
overall increase the SASP (Kim et al., 2018). From a mechanistic perspective, it has been 
demonstrated that humanin is produced in response to stress and subsequently activates the 
JAK/STAT (janus kinase/signal transducers and activators of transcription) pathway. Previous 
work has implicated the JAK/STAT pathway as having a regulatory role in cytokine production, 
consistently, work in vitro has demonstrated that pharmacological inhibition of JAK/STAT can 
ameliorate the SASP and has beneficial effects such as reducing frailty in mice in vivo (Xu et 
al., 2015b).  The other peptide MOTS-c is a known activator of AMPK, which as discussed 
earlier can feed into mTOR/PGC1-β mediated mitochondrial biogenesis, as well as inducing a 
cell cycle arrest via p53 and p21 activation (Jiang et al., 2013; Correia-Melo et al., 2016; Kim 
et al., 2018). 
Interestingly, it has also been observed that AMPK can be engaged by increases in the AMP to 
ATP ratios (Mihaylova and Shaw, 2011). It is known that disruption to the electron transport 
chain can impact on the production of ATP, affecting this ratio. A number of studies have 
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reported that the AMP to ATP ratio is increased in senescent cells (Wang et al., 2003; 
Zwerschke et al., 2003). Furthermore, inhibition of ATP synthase to perturb the ratio also 
induces premature senescence in human fibroblasts (Stockl et al., 2006). Defects in the electron 
transport chain have also been implicated in senescence, for example, inhibition of complex I 
using rotenone, complex II by 2-thenoyltrifluoroacetone and complex III by antimycin A 
induces senescence (Yoon et al., 2003; Stockl et al., 2006; Moiseeva et al., 2009). In addition, 
it is known that for the electron transport chain to function effectively the mitochondrial 
membrane potential needs to be maintained, however, senescent cells display a depolarised 
membrane (Passos et al., 2007). It has also been demonstrated that depolarisation of human 
fibroblasts by partial uncoupling using carbonylcyanide p-trifluoromethoxyphenylhydrazone 
leads to premature senescence and an increase in ROS (Stockl et al., 2007). From an ageing 
perspective it has been demonstrated that genes associated with the electron transport chain 
become downregulated with age in a number of organisms such as flies, worms and monkeys 
(Kayo et al., 2001; McCarroll et al., 2004; Ferguson et al., 2005). At this stage it is not entirely 
clear how defects in the electron transport chain can drive senescence and is the subject of 
ongoing research, however, one hypothesised idea is that defects promote an increase in the 
production of ROS which are a known driver of senescence. 
Collectively, these studies are beginning to unveil the role of mitochondrial metabolites 
imbalances in provoking both senescence and the SASP. Therefore one strategy to offset the 
deleterious effects of senescence may be to restore the balance of these metabolites. 
1.7.2. Mitochondrial DAMPs as Candidates for the SASP 
An emerging and unexplored area in the context of senescence is that of damage associated 
molecular patterns (DAMPs). DAMPs can take the form of nuclear or cytosolic proteins which 
can engage the innate immune system to provoke a pro-inflammatory response. As previously 
discussed the molecular mechanism by which mitochondria trigger the SASP is not completely 
understood. One potential molecule which could trigger inflammation is mitochondrial DNA 
(mtDNA). Mitochondria have their own genome which is distinct from the nuclear genome, it 
is 16569bp and takes the form of a circular double helix located within the inner membrane. 
mtDNA is of prokaryotic origin and of striking similarity to that of bacterial DNA i.e. it is not 
methylated like nuclear DNA (Gustafsson et al., 2016). As such, free mtDNA has been 
established as a potent DAMP which can provoke a strong inflammatory response via the innate 
immune system (West et al., 2015). It has been demonstrated that in a variety of tissues mtDNA 
can provoke the secretion of various pro-inflammatory cytokines such as IL-1β, IL-6, IL-8 and 
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TNFα, all of which have been implicated in the SASP (Little et al., 2014). From an ageing 
perspective mtDNA is particularly interesting as it has been observed that circulating mtDNA 
free from mitochondria increases with age in humans. This increase also correlates with the 
expression of a number of pro-inflammatory cytokines (Pinti et al., 2014). Of further interest is 
that two studies investigating the relationship between mitochondria and the SASP have 
demonstrated that when Rho (0) fibroblasts which do not contain mtDNA are induced to 
become senescent they have a dramatically decreased secretion of SASP factors (Correia-Melo 
et al., 2016; Wiley et al., 2016). Mitochondrial DAMPs do not comprise solely of mtDNA, 
other DAMPs identified which can provoke a pro-inflammatory response include; transcription 
factor A (TFAM) which is bound to mtDNA, cytochrome C (a pro-apoptotic inner membrane 
protein), cardiolipin (an inner membrane lipid) and ATP (Wilkins et al., 2017). Finally, it has 
also been recognised that in senescent cells DNases such as TREX1 and DNase 2 which are 
responsible for degrading cytoplasmic DNA are downregulated, as such it is possible that if 
mtDNA is escaping from mitochondria during senescence it would not be rapidly removed and 
therefore be available to promote a pro-inflammatory response (Takahashi et al., 2018). Taken 
together these observations question whether mtDNA may be released by dysfunctional 
mitochondria during senescence and provoking the SASP through the innate immune system. 
It is known that the toll-like receptors (TLR) have evolved to recognise unmethlyated DNA 
whereby a rapid immune response can be mounted following the detection of bacterial 
infection. It has recently been demonstrated that TLR9 specifically can identify mtDNA and 
generate an inflammatory response through p38 MAPK and NF-κB (Bao et al., 2016). TLR9 is 
located on the endoplasmic reticulum prior to stimulation, its activation can also stimulate 
transcription of interferon (IFN) genes (Leifer et al., 2004; Uematsu and Akira, 2007). This is 
particularly interesting as both NF-κB and type 1 IFN genes have been implicated in prompting 
the secretion of SASP factors in response to cytoplasmic nuclear DNA (Dou et al., 2017; Gluck 
et al., 2017; Yang et al., 2017; De Cecco et al., 2019). In addition, TLR2 has recently been 
implicated in controlling the senescence associated secretory phenotype in OIS through their 
recognition of acute-phase serum amyloids A1 and A2 which act as DAMPs, however, in this 
study there was no observable increase in gene expression of TLR9 (Hari et al., 2018). 
Therefore, it is plausible that free mtDNA could be acting as a DAMP and triggering an 
inflammatory response through a TLR9 dependent mechanism.  
Intracellular free mtDNA can also be recognised by the NLRP3 inflammasome (nucleotide 
binding domain and leucine-rich repeat pyrin domain containing 3) (Nakahira et al., 2011; 
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Shimada et al., 2012). The NLRP3 inflammasome responds to DAMPs and PAMPs (pathogen-
associated molecular patterns), once activated it forms a complex with apoptosis-associated 
speck-like protein, this in turn recruits and promotes autocatalytic activation of caspase 1 into 
cleaved caspase 1. The role of cleaved caspase 1 is then to cleave pro-IL-1β to the mature form 
IL-1β, which promotes its secretion and that of IL-18 (Jo et al., 2016). It has been demonstrated 
that macrophages which have been depleted of mtDNA have a vastly reduced secretion of IL-
18 by the NLRP3 inflammasome (Shimada et al., 2012). In the context of senescence, the 
NLRP3 inflammasome has been found to be active and contribute to the SASP in OIS and 
senescent vascular endothelial cells (Acosta et al., 2013; Yin et al., 2017; Wiggins et al., 2019). 
The regulation of the NLRP3 inflammasome is not very clear, however there is evidence that 
AMPK plays an important role in its regulation (Cordero et al., 2018). It has also been 
demonstrated that NLRP3 mediated low grade inflammation contributes to ageing as genetic 
clearance of NLRP3 relieves a number of age-related pathologies such as bone loss and loss of 
glycemic control (Youm et al., 2013). Furthermore, anti-ageing drugs such as rapamycin, 
metformin and resveratrol which are known to inhibit the SASP in vitro have also been 
demonstrated to target and inhibit the NLRP3 inflammasome, therefore it is plausible that some 
of the SASP supressing effects may be due to action on the NLRP3 inflammasome (Li et al., 
2016; Ko et al., 2017).  
A third innate immune pathway which has been implicated in the recognition of mtDNA is the 
cGAS-STING (cyclic GMP-AMP synthase – stimulator of interferon genes) axis. cGAS is a 
cytosolic sensor which recognises double-stranded DNA and has recently been demonstrated 
to promote a response to mtDNA (West et al., 2015). Under normal circumstances, cGAS exists 
in an auto-inhibited state, however, following the recognition of DNA, the active site of cGAS 
undergoes a conformational change and cyclic GMP-AMP (cGAMP) is synthesised as a 
secondary messenger. cGAMP binds to STING which is located at the endoplasmic reticulum, 
this activates STING and promotes its translocation to the golgi apparatus. STING then 
activates TBK1, which phosphorylates and leads to dimerization of IRF3 (interferon regulatory 
factor 3), IRF3 then translocates to the nucleus where it promotes transcription of INF-β genes. 
STING can also phosphorylate IKK (inhibitor of nuclear factor kappa-B kinase) which targets 
it for degradation, following IKK degradation, NF-κB is activated which also translocates to 
the nucleus and promotes transcription of IFN-β genes. This leads to induction of the 
inflammatory cytokines tumour necrosis factor (TNF), IL-1β and IL-6 (Chen et al., 2016). The 
cGAS-STING axis has been widely implicated in senescence by a number of groups. It has 
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recently been demonstrated that during senescence Lamin B1, a protein which protects nuclear 
integrity is lost, in turn it has been observed that fragments of nuclear DNA bud off and form 
in the cytoplasmic region. These fragments of nuclear DNA have been termed cytosolic 
chromatin fragments (CCFs) and have been shown to promote the SASP following there 
recognition by cGAS and subsequent downstream activation of NF-κB (Ivanov et al., 2013; 
Dou et al., 2017; Gluck et al., 2017; Yang et al., 2017). These studies employed genetic ablation 
of cGAS and/or STING. It was found that the absence of cGAS in human fibroblasts impaired 
the SASP but did not avert the cell cycle arrest or DDR, however there was clear inactivation 
of NF-κB without cGAS. Furthermore, in vivo following irradiation in STING KO mice there 
was a depletion of SASP factors such as IL-1α and β, but no changes in markers of DNA 
damage such as γH2AX  (Dou et al., 2017). Interestingly in fibroblasts derived from mice, 
knockout of cGAS impaired both the SASP and the cell cycle arrest, furthermore, it was 
demonstrated that in vivo there was an overall reduction in senescent cells and the SASP in 
cGAS deficient mice following irradiation (Gluck et al., 2017). To date, all studies addressing 
the role of cGAS and STING in senescence have used genetic silencing methods to suppress 
them. Naturally, this is the gold standard method for implicating the role of a protein in a 
process, however, there have been no pharmacological means of silencing these pathways. 
Recently, it has been identified for the first time that a subset of anti-malarial drugs such as 
quinacrine dihydrochloride (QC) and 9-amino-6-chloro-2-methoxyacridine (ACMA), 
chloroquine and primaquine disrupt the binding of DNA to cGAS and can prevent downstream 
activation of type 1 IFNs (An et al., 2015). Furthermore, a small molecule inhibitor has been 
identified that inhibits the catalytic pocket of cGAS (but does not prevent binding to double 
stranded DNA), this inhibitor has been show to block type 1 interferon activity both in vitro 
and in vivo in an autoimmune disease model (Vincent et al., 2017). There has been intense 
interest from the autoimmune field to discover inhibitors of the cGAS-STING axis, however, 
the role of these drugs has not been addressed in the context of senescence. Therefore it is of 
extreme interest to determine the role of these drugs as potential senostatic therapies (drugs 
which remove the deleterious SASP but not the tumour suppressive effects of the cell cycle 
arrest).   
At this stage, there is evidence to suggest these innate immune pathways are active in 
senescence, but it is not determined whether mtDNA could be driving them.  
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1.8. Mitochondrial Outer Membrane Permeabilisation 
A key question to address is; what are the mechanisms that could enable the release of 
mitochondrial DAMPs into the cytosol? Here we review an emerging phenomenon in the field 
of apoptosis where it has been identified that mitochondria can become permeabilised in the 
absence of triggering cell death. As there is significant overlap between apoptosis and 
senescence it is considered that this could be a potential molecular mechanism that could 
facilitate release of mitochondrial DAMPs into the cytosol. 
1.8.1. Limited Mitochondrial Outer Membrane Permeabilisation 
Apoptosis is a tightly regulated process which ensures that damaged and defective cells are 
eliminated quickly and effectively. The purpose being to prevent damaged cells dividing and 
potentially becoming tumourigenic (Taylor et al., 2008). Apoptosis usually occurs in response 
to stressful intrinsic and extrinsic stimuli such as DNA damage and genotoxic stress. Following 
the induction of intrinsic damage, the pro apoptotic members of the BCL-2 family become 
activated. PUMA, BCL-2-associated agonist of cell death (BAD) and NOXA are pro-apoptotic 
members which supress the anti-apoptotic members BCL-XL and BCL-2 (Taylor et al., 2008). 
As discussed earlier, these anti-apoptotic members are upregulated in senescent cells and hence 
render there resistance to apoptosis, these members are also the targets of senolytics such as 
navitoclax (Chang et al., 2016). Once the anti-apoptotic members are inhibited, activation of 
BAX (BCL-2-associated x protein) and BAK (BCL-2 homologous antagonist killer) occurs. 
Bax and Bak are two nuclear-encoded proteins present in higher eukaryotes that function to 
permeabilise the mitochondrial outer membrane in a regulated manner to facilitate cell death 
via apoptosis. BAK is constitutively located at the outer membrane of the mitochondria where 
it is anchored via its hydrophobic C-terminal α9 helix, when inactive BAK exists as a monomer 
(Ferrer et al., 2012). BAX exists in a more dynamic state, in non-apoptotic cells BAX localises 
to the mitochondria, however, it is constantly retro-translocated to the cytosol by BCL-XL to 
prevent formation of active oligomers (Schellenberg et al., 2013). The activation of BAX and 
BAK can be triggered by intrinsic stimuli such as DNA damage or cytokine deprivation. 
Similarly, they can also be activated by external stimuli via the activation of the death receptor 
pathway which is initiated by TNF-α, Fas ligand and TNF-related apoptosis inducing ligand 
(Westphal et al., 2011).   
Following activation, both BAX and BAK undergo extensive conformational changes where 
there hydrophobic regions become buried within the outer membrane or surrounding protein 
interface, this process forms large oligomers which span the outer membrane to the cytosol. 
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Specifically for BAX, eversion of its α9 tail allows it to become integrated with the outer 
membrane, in doing so the 6A7 epitope is exposed which is a characteristic mark of its 
activation (Gavathiotis et al., 2010). The formation of pores via BAX and BAK is an area of 
immense study and as yet is particularly unclear due to its complexity. It has been proposed 
that BAX forms a “daisy chain” like oligomer, whereas BAK forms a more doughnut shaped 
octameric pore (Reed, 2006; Pang et al., 2012). At this stage, it is clear that BAX and BAK can 
form pores independently, however, it is unclear whether they co-interact during the formation 
of pores, although evidence does suggest there is an element of dependency for BAX during 
BAK pore formation (Mikhailov et al., 2003). Of further interest in the context of senescence 
is that mitochondrial dynamics have been associated with oligomerisation of BAX. 
Specifically, the loss of DRP1 (a mediator of mitochondrial fission which is downregulated 
during senescence) has been associated with inhibiting apoptotic scission of mitochondria but 
does not prevent the translocation and accumulation of BAX clusters (Karbowski et al., 2002; 
Montessuit et al., 2010). Following pore formation, the mitochondrial membrane integrity is 
lost and the membrane becomes depolarised. Proteins that are normally conserved within the 
inner membrane can escape through the BAX and BAK pores. The process of pore formation 
and subsequent release of inner membrane proteins is referred to as mitochondrial outer 
membrane permeabilisation (MOMP). Specifically in the context of apoptosis, cytochrome C 
is released, once located in the cytosol it forms a complex with apoptotic protease-activating 
factor 1 and pro-caspase 9 which is referred to as the apoptosome. The apoptosome then 
activates caspase 9 which promotes cleavage of caspase 3 and 7. These two executioner 
caspases promote fragmentation of the nuclear DNA and promote blebbing of the cell 
membrane via activation of ROCK 1. Cells then shrink and are phagocytosed by macrophages, 
concluding the apoptosis process (Tait and Green, 2010). 
Classically, MOMP has always been considered an all or nothing process, referring to that all 
previous work has demonstrated that the cell death process is either engaged or it is not. 
However, a recent study has revealed that in fact a small subset of mitochondria within a cell 
can become permeabilised without engaging the cell death machinery. Specifically, using super 
resolution microscopy it was observed that following mild stress there was an observable 
release of cytochrome C which was associated with sub-lethal activation and cleavage of 
caspase 3 and 7. However, it was demonstrated that limited mitochondrial outer membrane 
permeabilisation termed minority MOMP (miMOMP) does not meet the required threshold to 
induce cell death, however, the sub-lethal activation of caspase 3 and 7 results in DNA damage. 
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Specifically, the DNA damage induced by sub-lethal activation of caspase 3 and 7 occurs 
through the DNase CAD (caspase activated DNase). CAD is responsible for fragmenting DNA 
during apoptosis. During miMOMP, it was demonstrated both in vitro and in vivo that CAD 
induces double stranded DNA breaks and subsequently a DDR. Accordingly, it was 
demonstrated that CAD triggers cleavage of PARP1 and phosphorylation of JNK and H2AX in 
a caspase dependent manner (Ichim et al., 2015).  
 Furthermore, this DNA damage and miMOMP were demonstrated to be tumourigenic in vivo. 
This permeabilisation and subsequent DNA damage was dependent on the formation of BAX 
and BAK pores (Ichim et al., 2015). As DNA damage is a key feature of senescent cells and is 
essential in promoting the induction of senescence via the DDR, it is of significant interest to 
understand whether mitochondrial dysfunction that is characteristic of senescence is in part 
driven by this miMOMP process. Prior to the discovery of this miMOMP phenomenon, a 
separate group investigating the potential of BCL-2 inhibitors to induce apoptosis in cancer 
cells discovered that the same anti-apoptotic BCL-2 inhibitor (ABT737) was able to induce 
senescence in a cancer cell line. They discovered that this occurred in a p53 and p21 dependent 
manner due to DNA damage as a consequence of low grade caspase 3 activity which was 
insufficient to induce apoptosis (Song et al., 2011). Therefore one may speculate that this 
observation was driven by miMOMP. Furthermore, could this miMOMP be a potential 
mechanism for releasing mitochondrial DAMPs and mediating the SASP?  
Interestingly, this process of miMOMP can be induced by treatment using the BCL-2 inhibitor 
ABT737, which as mentioned earlier is a senolytic drug (Ichim et al., 2015; Chang et al., 2016). 
Therefore, it seems reasonable to question whether these inhibitors are in fact acting as a double 
edged sword. It has been established that they are effective in the abolition of senescent cells, 
however, it is yet to be addressed whether paradoxically these inhibitors may be inducing 
miMOMP in healthy proliferating cells leading to DNA damage and thus potentially promoting 
genomic instability and further senescence. This therefore raises a number of questions; firstly, 
will treatment with ABT737 be inducing damage in non-senescent cells? Secondly, is this 
process of miMOMP and subsequent DNA damage a form of mitochondrial dysfunction which 
could be a driver of senescence induction?  




Figure 1.3– Overview of the role of mitochondria and cellular senescence.  
During senescence there are dramatic changes to the morphology of the mitochondrial network, 
this is facilitated in part by increases in mitochondrial biogenesis, changes in the fission/fusion 
machinery as well as an impairment of mitophagy to clear dysfunctional mitochondria. 
Furthermore, there is disruption to the electron transport chain which has been associated with 
changes in metabolite levels such as that of AMP and NAD+. Senescent cells are characterised 
by an exacerbation in the production of ROS, this has been demonstrated to drive senescence 
through the induction of DNA damage, as well as damage neighbouring cells. Finally, we 
hypothesise that the recently discovered phenomenon of miMOMP may be promoting release 
of mtDNA which could be promoting the SASP through one of the innate immune system 
pathways such as cGAS-STING, the NLRP3 inflammasome or TLR-9. Figure adapted from 
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1.8.2. Mechanisms facilitating mtDNA Release 
Although a wide number of studies have identified cytosolic mtDNA and subsequent immune 
responses, it has not been known until recently how mtDNA can escape from the inner 
membrane of the mitochondria. Within the apoptotic field it was noted that cells undergoing 
caspase independent apoptosis produced a type 1 IFN response which was shown to occur as a 
consequence of mtDNA and subsequent cGAS activation (Rongvaux et al., 2014; White et al., 
2014). These studies implicated that mtDNA release was dependent on BAX and BAK pores, 
however, recent work has highlighted the underlying mechanism. Using a combination of 
sophisticated live-cell imaging and super-resolution microscopy techniques it has been 
demonstrated that BAX and BAK form oligomers which result in enlarged pores, termed 
macropores. These macropores gradually widen up to 1µm which allow the inner membrane to 
herniate through. It is not exactly clear how mtDNA escapes but it is speculated that the inner 
membrane ruptures  allowing the escape of mitochondria components including mtDNA to the 
cytosol (McArthur et al., 2018; Riley et al., 2018). Importantly, it was demonstrated that 
deletion of both BAX and BAK is required to prevent mtDNA release as single deletion of 
either BAX or BAK using CRISPR-CAS9 did not prevent its release. Therefore demonstrating 
that BAX or BAK can form macropores independent of each other (Riley et al., 2018).  
Of further interest is that these studies used the BCL-2 inhibitor ABT737 to provoke this 
process (McArthur et al., 2018; Riley et al., 2018). As discussed earlier, this drug is being 
considered as a senolytic (Zhu et al., 2015b). Therefore it is of interest to understand whether a 
side effect of senolytic therapy using this family of drugs may in fact promote inflammation 
through mtDNA release. Not only that, considering there are wide spread changes in both 
mitochondrial function and morphology during senescence, it is plausible that a similar 
phenomenon of mtDNA release may be occurring to provoke the SASP through cGAS-STING. 
1.8.3. The Relationship between Caspases and Senescence 
Both apoptosis and senescence are intricate processes designed to avert damaged cells from 
replicating, as such there is significant mechanistic overlaps between the two. The caspases are 
a family of proteases which have been largely restricted to their role in apoptosis, however, 
emerging research has revealed that they participate in many other cellular processes such as 
T-cell maintenance, tissue differentiation and regeneration, as well as neural development. The 
role of caspases in senescence remains a vastly understudied area. Caspases can be broadly 
subdivided into two functions; those that facilitate apoptosis and those that regulate 
inflammation.  In humans, caspases 2, 8, 9 and 10 have been implicated in initiating the 
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apoptotic process and caspase 3, 6 and 7 are recognised as executing the process. Caspase 1, 4, 
5 and 12 on the other hand are known to regulate inflammation (Shalini et al., 2015).  
The role of caspases in apoptosis has been well defined. Their role is to dismantle and degrade 
the cell without damaging neighbouring cells or promoting inflammation by release of 
intracellular components. Apoptosis occurs in response to excessive stress intrinsically or 
extrinsically. Extrinsic activation occurs following activation of the death receptor, which leads 
to recruitment and dimerization of caspase 8 (Kang et al., 2004). This dimerization promotes a 
caspase cascade which results in the cleavage and activation of the executor caspases 3, 6 and 
7. Caspase 3 and 7 have similar substrate specificity whereas the contribution of caspase 6 is 
less clear. Caspase 3 is the best characterised and is known to activate the endonuclease CAD. 
CAD functions to cleave and fragment the nuclear DNA which leads its degradation (Sakahira 
et al., 1998). In addition, caspase 3 acts on gelsolin which cleaves actin filaments. This process 
leads to reorganization and disintegration of the cell into apoptotic bodies which can then be 
targeted for non-inflammatory phagocytosis (Kothakota et al., 1997; Fadok et al., 2001). 
Caspase 8 also can promote cleavage of BID which can activate the intrinsic pathway to 
promote the caspase cascade. This is facilitated by the initiator caspase 9 which is regulated by 
the BCL-2 and BH-3 family of proteins. Release of cytochrome c binds and forms a complex 
termed the apoptosome with caspase 9 as described earlier, this leads to cleavage and activation 
of caspase 3 and subsequently apoptosis (Li et al., 1997).   
In the context of senescence, it has been recognised that both IL1α and IL-1β are primed by 
caspases. In OIS, caspase 1 levels are elevated, here, it functions as part of the NLRP3 
inflammasome where it cleaves IL-1β to promote cytokine production. Furthermore, inhibition 
of caspase 1 reduced the SASP, as well as partially preventing the induction of p21-mediated 
cell cycle arrest (Acosta et al., 2013). Interestingly, another subset of caspases have been 
identified in activating the IL-1α arm of senescence. IL-1α can provoke the SASP by a 
signalling cascade that activates NF-κB following activation of the IL-1 receptor. In humans 
this cleavage occurs via caspase 5 and in mice caspase 11, silencing of these lead to a reduction 
in the IL-1α arm of the SASP (IL-6, IL-8 and MCP-1). Furthermore, it was demonstrated that 
silencing of caspase 11 (the murine homologue of caspase 5 in humans) in vivo following 
senescence induction lead to a decrease in the infiltration of macrophages to the site of 
senescent cells, therefore indicating that caspase mediated activation of IL-1α is crucial in 
signalling to the immune system to clear senescent cells away (Wiggins et al., 2019).  
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Interestingly, caspase 3 has also been implicated in driving senescence by inducing levels of 
DNA damage that are insufficient to induce apoptosis. This has been demonstrated in response 
to the BH3-mimetic ABT737 and the ROS peroxynitrite which is a nitric oxide radical 
(Matarrese et al., 2005; Song et al., 2011). Outside of senescence it has been demonstrated that 
caspase 3 can impact on proliferation. Specifically, B cells lacking caspase 3 show increased 
hyperproliferation both in vitro and in vivo. This proliferation can be rescued by dual knockout 
of caspase 3 and p21 (a substrate of caspase 3), suggesting that caspase 3 plays a role in 
regulating the expression of p21 (Woo et al., 2003). Interestingly, a recent study has established 
that p21 plays a role in regulating the activation of caspase 3, as knockdown of p21 in senescent 
cells, leads to an enhancement of the DDR, ATM then triggers NF-κB/TNF-α signalling which 
leads to caspase 3 mediated cell death via JNK (Yosef et al., 2017). Taken together it seems 
likely that activity of caspase 3 may well be reinforcing the DDR, and naturally its activity must 
be subject to tight regulation to prevent the balance being tipped and apoptosis occurring. 
Therefore, it is of particular interest to address whether miMOMP could be promoting this low 










Figure 1.4– Hypothesised mechanism of mtDNA release and role of miMOMP as a driver 
of senescence.  
First, it is hypothesised that during senescence mtDNA may be escaping from dysfunctional 
mitochondria, it is plausible that this is being facilitated by the formation of BAX and BAK 
macropores where the inner mitochondrial membrane herniates and allows its release. Once in 
the cytosol it could promote the SASP through one of the innate immune pathways such as 
TLR9, cGAS-STING or NLRP3. Second, it has been demonstrated that a small number of 
mitochondria can be permeabilised in the absence of cell death, termed minority MOMP. It is 
of interest to understand whether this process is a feature of senescence, as it can promote a 
DDR through sub-lethal caspase 3 activity. In addition, it is feasible that miMOMP may 
facilitate mtDNA release. The process of miMOMP can be provoked pharmacologically using 
the BH3 mimetic ABT-737 which inhibits the anti-apoptotic BCL-2 and BCL-XL proteins 
which normally prevent mitochondria from permeabilising via BAX and BAK pores. Therefore 
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1.9. Research Aims 
At this stage, mitochondria have been implicated as having an essential role in driving the pro-
inflammatory features of senescence, although the underlying mechanisms responsible remain 
unknown. Furthermore, using genetic manipulation it has been demonstrated that the cGAS-
STING axis is involved in the regulation of the SASP, however, the effects of pharmacological 
inhibitors on this pathway have not been explored. Therefore, the overall aim of this study is to 
dissect the intricate relationship between mitochondria and cellular senescence. 
Specifically, the aims of this study were: 
1. Investigate the involvement of mtDNA in senescence and as a potential candidate to act as a 
DAMP for the induction of the SASP. 
2. Explore the role of sub-lethal stress as a driver of mitochondrial permeabilisation. Does this 
process play a role in driving senescence or the SASP? 
3. Determine whether pharmacological inhibitors of the cGAS/STING pathway have potential 
as a therapeutic strategy for suppressing the SASP.




2. Materials and Methods 
 
2.1. Cell Culture 
Cell culture work has been performed using human embryonic lung MRC5 fibroblasts acquired 
from ECACC, Salisbury, UK that were stored in aliquots of 1 million cells at -180°C. These 
cells have been cultured at 37°C, 5% CO2, 20% O2 in Dulbecco’s Modified Eagle’s Medium 
D5796 – High Glucose. 500ml media is supplemented with 10% FBS (foetal bovine serum), 
6ml of penicillin-streptomycin (100µg/ml) and 6ml of 2mM L-glutamine.  
HEK293T cells were used for lentiviral transduction and were maintained in DMEM as detailed 
above with further supplementation using 1% non-essential amino acids, G418 antibiotic 
(10µl/ml) and sodium pyruvate (5ml of 100mM stock solution). 
Parental and rho (0) osteosarcoma 143B cells were a gift from the Mitochondrial Research 
Group at Newcastle University. These cells were maintained in DMEM as detailed above with 
further supplementation using 5% non-essential amino acids and 25µg/ml of Uridine.  
U20S cells were a gift from Dr Stephen Tait at the Beatson Institute, Glasgow. These were 
maintained in DMEM media as listed above.  
2.2. Induction of Senescence 
For stress-induced senescence, MRC5 fibroblasts were subjected to 20Gy of X-ray irradiation 
using an X-Rad 225 irradiator (Precision X-Ray, N-Branford, CT USA). Stress-induced 
senescent cells were analysed 10 days post X-ray irradiation (whereby the day of irradiation is 
classed as day 0). The induction of senescence in vitro was confirmed at day 10 by 
characterising cells for the presence of SA-β-Gal, the induction of p16 and p21, as well as the 
absence of proliferative markers such as Ki67 and EdUincorporation. In addition, cells were 
assessed for morphological changes such as an increase in cell size, nuclear size and a more 
flattened appearance. Details of how these experiments were conducted is described later in this 
section.  
In order to attain a model of replicative senescence, cells were maintained in culture until they 
stopped dividing and developed the senescence phenotype. Replicatively senescent cells were 
confirmed by culturing until a growth plateaux was achieved, cells were then maintained for a 
further 4 weeks to confirm that there was less than 0.5 population doublings. The senescence 
phenotype was then confirmed using the parameters described above.  




2.3. Maintenance, Storage and Revival of Cells 
Cells were counted using a 0.2mm Fuchs-Rosenthal haemocytometer with 20µl of cell 
suspension. Cells were manually counted on a DMIL Leica Microscope. An average of four 
counts of 8 adjacent squares gives the number of cells x 104/ml, subsequently the population 
doubling was calculated using the following calculation: 
PD = Initial PD + (log(Total number of cells/Number of cells seeded)/log(2)) 
For long-term storage of cells, cells were trypsinised, counted, centrifuged at 800g and then 
suspended in of 95% FBS/5% DMSO and aliquoted at a density of 1x106 into a cryogenic vial. 
These were then placed in a Nalgene Cryo freezing container for 24 hours at -80°C prior to 
storage in liquid nitrogen.  
In order to return cells stored in liquid nitrogen to culture, the cryo-vials were placed at 37°C. 
Once defrosted these cells were seeded into a 75 cm2 flask, once attached the media was 
replaced with fresh media to remove any residual DMSO. 
2.4. Drugs and Inhibitors 
For each drug/inhibitor used a stock solution was prepared, this was then aliquoted and stored 
at the appropriate temperature to avoid repeat freezing and thawing. Drugs and inhibitors were 
diluted in media prior to being added to cells. 














Drug/Inhibitor Supplier and Catalogue Number 
ABT737 Abcam (ab141336) 
ACMA ThermoFisher Scientific (A1324) 
BAX Channel Blocker Adooq Biosciences (A15335) 
BAM7 Sigma (SML0641) 
BIPv5 Sigma (SML0641) 
Bongkrekic Acid Abcam (ab142111) 
Caspase 1 Inhibitor (Ac-YVAD-cmk) Sigma (SML0429) 
Caspase 2 Inhibitor (Ac-VDVAD-CHO_ Sigma (SCP0076) 
Caspase 3 Inhibitor (Ac-LDESD-CHO) Sigma (SCP0079) 
Caspase 4 Inhibitor (Ac-LEVD-CHO) Sigma (SCP0087) 
Cyclosporin A Sigma (SML1575) 
2’,3’-Dideoxycytidine (ddC) Abcam (ab142240) 
Olesoxime (TRO 19622) Sigma (T3077) 
RU.521 Glixx Laboratories (GLXC-10900) 
Quinacrine Dihydrochloride Sigma (Q3251) 
QVD Abcam (ab141421) 
Table 2.1 - List of drugs and inhibitors used in experiments as well as suppliers and 
catalogue numbers. 
 
2.5.  Generating stably expressing BAK/BAX and STING deficient cell lines 
Plasmid expansion and purification: 
Plasmid elution 
Plasmids (BAX, BAK, STING (three separate constructs #1, #2 and #3) and Empty Vector) 
were received precipitated on filter paper. The plasmid DNA was eluted by cutting out a small 
section of filter paper using sterile scissors, and placing it into a 1.5ml micro-centrifuge tube 




with 20μl of nuclease-free H2O. The filter paper was then mixed with the H2O using a sterile 
pipette tip, and left at room temperature for 2 minutes. 
Bacterial transformation 
2μl of eluted plasmid DNA was added to 10μl of NEB Stable Competent E. coli cells in an 
Eppendorf tube, and mixed by gently vortexing. Tubes were then placed on ice for 30 minutes, 
and the cells were subsequently heat-shocked at 42°C for 30 seconds, and placed on ice for a 
further 5 minutes. Then, 500μl of SOC outgrowth medium (Invitrogen, Cat. Number 15544-
034) was added to the cells and DNA, which was then placed on an orbital shaker at 190 RPM 
at 37°C for 60 minutes. Whilst incubating, agar selection plates with the appropriate antibiotic 
drug were placed at room temperature. Following the incubation period, cells were mixed 
thoroughly and 300μl of the cell suspension was streaked onto the agar selection plates. Cells 
were incubated for 24 hours at 37°C. 
Alternatively, if previously transformed NEB Stable Competent E. coli cells have been stored 
in glycerol at -80°C, then 300μl of cell stocks can be incubated in SOC medium and then 
cultured on to pre-warmed agar selection plates, and incubated for 24 hours at 37°C.  
Plasmid expansion 
A single NEB Stable Competent E. coli colony was picked using a sterile pipette tip, which was 
then placed in 5ml lysogeny broth (LB) medium (Table 2.1) and incubated with horizontal 
shaking at 30°C for 6 hours. The cell suspension was then transferred to a vented conical flask 
containing 100ml LB with antibiotics (50ng/ml Ampicillin), and incubated on an orbital shaker 
at 180RPM at 30°C for 24 hours.  
Bacterial glycerol stocks 
In order to make bacterial glycerol stocks, 2ml of cell suspension from the previous step was 
transferred to a 15ml centrifuge tube and centrifuged at 5000g for 10 minutes at room 
temperature. The supernatant was then aspirated and the cell pellet was re-suspended in 1ml of 
a solution containing 30% glycerol: 70% LB (v/v), and was then placed in a cryovial for long-
term storage at -80°C. 
Plasmid isolation 
Following expansion, plasmids were purified from NEB Stable Competent E. coli cells using 
the PureYieldTM Plasmid Midiprep System (Promega). Briefly, 100ml of LB and NEB Stable 




Competent E. coli cell suspension was transferred into two 50ml centrifuge tubes, and 
centrifuged at 5000g for 10 minutes at room temperature. The pellets were then re-suspended 
in 3ml of Cell Suspension Solution and combined together, followed by the addition of 3ml of 
Cell Lysis Solution, and then mixed by inverting 5 times. Following a 3 minute incubation, 5ml 
of Neutralisation Solution was added and mixed by inverting 10 times, and the lysates were 
centrifuged at 15,000g for 15 minutes. A PureYieldTM Clearing Column (blue) was placed on 
top of a PureYieldTM Binding Column (white) and assembled onto a vacuum pump. The liquid 
was poured into the column stack and a vacuum was applied until the solution was drawn 
through. 5ml of Endotoxin Removal Wash was added to the binding column, and again the 
solution was pulled through by applying a vacuum. 20ml of Column Wash was added, and a 
vacuum was applied to pull all the solution through. A vacuum was then applied to the dry 
binding column for 60 seconds, and was then removed and placed onto a paper towel to remove 
any excess ethanol. 
The DNA was eluted by placing the binding column into a clean 50ml centrifuge tube, followed 
by the addition of 600μl of nuclease-free H2O and incubating for 1 minute. Next, the binding 
column was centrifuged at 2,000g for 5 minutes in a swinging bucket rotor centrifuge, and the 
filtrate was collected into a clean 1.5ml Eppendorf tube.  
Assessing nucleic acid purity and quantification 
DNA quality and quantification was performed using Nanodrop® 1000 spectrophotometer 
(Thermo Scientific). For purity, a 260/280 ratio of around 1.8 was considered satisfactory. 
Plasmid solutions were stored at -20°C for future use.  
Plasmid expansion 
Individual colonies were selected and grown overnight at 37°C in 5ml LB medium (Table 2.1) 
with Ampicillin (50ng/ml). 
Plasmid isolation 
Following expansion, plasmids were purified from B100 E. coli cells using the PureYieldTM 
Plasmid Midiprep System (Promega), as described above. 
Plasmid analysis 
Following plasmid purification, the plasmid DNA was digested with the XhoI and XbaI 
restriction enzymes to confirm that the Gibson assemble yielded the correct plasmids.   




2.6. Transfection and transduction protocols 
Retroviral plasmid transfection and viral production were carried out following class II safety 
procedures.  
NEB Stable Competent E. Coli cells transformed with the packaging plasmid, d8.9, or the 
envelope protein, VSVG, were grown and expanded as previously described under “Plasmid 
expansion”. DNA was purified as described under “Plasmid isolation” using the PureYieldTM 
Plasmid Midiprep System (Promega).  
5x106 HEK293FT cells were seeded in a 10cm dish and incubated for 24 hours in DMEM 
(supplemented with 1:100 non-essential amino acids and 1:100 sodium pyruvate (10mM stock; 
Sigma Aldrich, S8636). Cells were approximately 80% confluent at the point of transfection 
using LipofectamineTM 3000 reagent (Invitrogen, L3000015) Transfection was done in 
accordance with the manufacturers’ protocol. 6hrs post transfection, medium was removed 
from HEK293FT cells, and 10ml of fresh medium without antibiotics was added (use medium 
designated for target cells). Culture medium containing viral particles was harvested 48 hours 
later, then filtered through a 0.45μm pore PVDF filter and mixed with polybrene (10μg/ml final 
concentration). The medium was then added to MRC5 Fibroblasts which were approximately 
70% confluent.  MRC5 fibroblasts were in 6 well plates, therefore different virus titres were 
added to each well (0, 0.5, 1, 2, 4 and the remaining viral media). After 24 hours, the virus 
containing media was removed and fresh culture medium was added. Cells were then left for 
1-3 days to allow them to recover from exposure to the viral media. Once recovered, cells were 
maintained under selection by treating MRC5 Fibroblasts with 50ng/ml Puromycin (for BAX, 
BAK and Empty Vector) or Blasticidin 50ng/ml (STING #1, #2 and #3) for 5 days. Following 
selection, only transduced cells should remain to repopulate the wells. It is estimated that 
approximately 10-30% of MRC5s are successfully transduced prior to selection using this 
protocol. Transduced cells were confirmed by western blot. 
2.7. Transient Transfections 
MRC5 cells were seeded on coverslips at a density of 50,000 per well of a 12 well plate and 
left overnight to achieve a confluency of approximately 70-90% at the point of transfection. In 
accordance with the LipofectamineTM 3000 Reagent protocol, the DNA-lipid mix was prepared 
using Opti-MEMTM Medium (120µl per well of a 12 well plate) the LipofectamineTM 3000 
reagent (1.875µl per well of a 12 well plate), P3000 reagent (2.5µl per well of a 12 well plate) 
and 1250ng DNA per well of a 12 well plate. Once prepared the mix was incubated for 15 




minutes and then 125µl was added to cells for 36 hours. For a 0 day time point, cells were fixed 
at this point. For those used for studying senescence, they were irradiated at this point and fixed 
at the relevant time point. The following plasmids were used for transient transfections; cGAS-
GFP, TFAM-GFP and STING-mCHERRY. Transfected cells can be identified under the 
microscope by the fluorescent tags. This same protocol was used for transfecting mtDNA into 
MRC5 fibroblasts. 
2.8. Enzyme Linked Immunosorbent Assay 
Prior to Enzyme Linked Immunosorbent Assay (ELISA) analysis, cells were maintained in 
serum free media for 24 hours. This media is then collected. A sandwich ELISA (R&D 
Systems; DY206/DY208) was used to measure the concentration of SASP factors IL-6, IL-8 
and IP-10. A capture antibody at a concentration of 240µg/ml in PBS was used to coat the wells 
of a 96-well plate, and left to incubate overnight on an orbital shaker. The next day, the wells 
were washed twice using 150µl of 0.05% PBS-Tween20 wash buffer. Once washed, plates were 
blocked for 90 minutes using 150µl of reagents diluents; 1% BSA in PBS for IL-6 and 0.1% 
BSA in PBS for IL-8. Following blocking, two washes were performed using the wash buffer. 
25µl of standards and samples were loaded per well, incubated for 90 minutes. Two washes 
performed. 25µl of detection antibody was diluted 1:100 in the reagent diluents, 25µl added to 
each well and incubated for 90 minutes. Two washes performed. 12.5µl of Streptavidin-HRP 
diluted 1:200 in reagent diluents. 25µl of added to each well and incubated for 20 minutes. Two 
washes performed. A substrate reagent was prepared from Colour Reagent A and B, 1:1 H2O2 
and tetramethylbenzidine. 50µl added to each well. Plates incubated until colour develops, 
approximately 10-20 minutes. Once developed, 25µl of 2NH2SO4 added to each well to stop 
the reaction. An absorbance reader was used to determine the optical density at a wavelength 
of 450nm.     
2.9. Cytokine Array 
Conditioned media was collected 10 days post 20Gy X-ray irradiation following 24 hours of 
serum-deprivation. 30µL of media was then aliquoted into 500µl centrifuge tubes for analysis 
by cytokine array. The array was performed by Eve Technologies and the samples were 
analysed by a Human Cytokine 42-Plex.   
2.10. Western Blotting 
Protein Extraction from Cells  




Prior to collection, cells were rinsed in ice cold PBS, cells were then lysed using ice cold RIPA 
buffer (25µl per well in a 6 well plate). Cells were then scraped from the well and transferred 
to a 1.5ml Eppendorf tube. Tubes are vortexed quickly and transferred immediately to -80°C 
storage. 
Protein Quantification 
Lysates collected were placed on ice to defrost. Once defrosted they were centrifuged at 
16100g, 4°C for 10 minutes. Following this the protein concentration was determined using a 
colorimetric Bio-Rad DC protein assay kit was used in accordance with the manufacturer’s 
instructions (Bio-Rad; Reagent A, B and C, Catalogue numbers 500-0113/4/5 respectively). 
Once developed, the absorbance of the 96 well plate was measured using a Fluostar Omega 
microplate reader (BMG labtech). Using the absorbance value generated, the protein 
concentration was determined and samples were made up to the same concentration using RIPA 
buffer. The same volume of Mercaptoethanol (Sigma; Cat. Number M6250) was then added to 
each sample. Samples were denatured at 100°C for 5 minutes, then placed on ice to cool prior 
to storage at -80°C. 
Electrophoresis 
An acrylamide running gels was prepared and placed into a cassette (Invitrogen; Cat. Number 
NC2015 or NC2010) as per the table. The gel prepared was dependent upon the size of the 
proteins of interest. Once the running gel had set a 5% stacking gel was made up and placed 
into the cassette. Depending on the number of samples to be analysed a loading comb was 
placed into the cassette to produce loading wells.  
Once the stacking gel had set, the cassette was placed into an Invitrogen XCell Sure LockTM 
Mini-Cell Electrophoresis System and covered with Tris-Glycine running buffer. The comb 
was then removed, a protein standard (Bio-Rad, Cat Number; 161-0374) was loaded followed 










Acylamide Gel Composition 5% 10% 12% 15% 
MQ H2O (mL) 6.8 5.1 4 3.3 
30% Acylamide (mL) 
(Severn Biotechnology; 20-2100-10) 
1.7 2.6 3.3 4 
1.5M Tris pH8.8 
(Sigma; T6066) 
2.5 2.5 2.5 2.5 
10% SDS (Sigma; L4390) 100 100 100 100 
10% Ammonium Persulphate (Sigma; 215589) 100 100 100 100 
TEMED (Sigma; T9281) 8 4 4 4 
 
Table 2.2 Composition of acrylamide gels prepared for western blotting 
 
Transfer of Proteins on to a Nitrocellulose Membrane 
Once the gel had finished running a Trans-Blot SD Semi-Dry Transfer Cell (BioRad) was used 
to transfer the proteins from the gel to a nitrocellulose membrane (Millipore; IPVH00010). The 
gel was placed on the membrane, between two transfer pads soaked in transfer buffer. Transfer 
was performed at 20V for 1 hour. Successful transfer of proteins was determined by a brief 
staining with Ponceaux solution. 
Blotting of Membranes with Primary Antibodies 
Following transfer, the membrane was rinsed three times with PBS. It was then blocked for 1 
hour at room temperature using 5% milk in 0.05% PBS-Tween. Once blocked, the membrane 
was incubated in primary antibody overnight at 4°C. The next day, the membrane was rinsed 
three times for 5 minutes in PBS followed by incubation with the secondary antibody for 1 hour 
at room temperature for one hour. The membrane was then rinsed with PBS three times for 5 
minutes, 0.05% PBS-Tween for 5 minutes followed by a further three 5 minute washes with 
PBS. 
Detection of Protein Bands using Chemiluminescence 
Once rinsed sufficiently, the membrane was coated in Clarity Western ECL substrate (Bio-Rad; 
Cat Number 170-5060) and placed inside a FujiFilm Intelligent Dark Box II. The images were 
then developed and acquired using the software Image Reader Las-1000. Analysis was 




performed using ImageJ, the background was subtracted and intensity of the band was 
measured, this was then normalised to the relevant loading control.  
Western Blotting Solutions 
RIPA Buffer 
• 150mM NaCl, 
• 1% NP40 
• 0.5% NaDoC, 
• 0.1% SDS 
• 50mM Tris pH 7.4 
• Phosphatase and protease inhibitor cocktail (Thermo Scientific; 78442) 
Ponceaux Staining Solution 
• 0.5% Ponceaux 
• 5% Acetic Acid 
• 94.5% H2O 
Western Blot Running Buffer 
• 250µM Tris 
• 1.92mM Glycine 
• 0.1% SDS 
Western Blot Transfer Buffer 
• 250µM Tris 










Primary Antibodies for Western Blotting 


















































12105 - Cell 
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Signalling 
Lamin B1 Human 
Rabbit 
Polyclonal 























Human Mouse  
Mouse 
Monoclonal 
Ab16123 - Abcam 





























3033S – Cell 
Signalling 




13647S - Cell 
Signalling 
TFAM (D5C8) Rabbit Rabbit 
Monoclonal 
1:200 8076S - Cell 
Signalling 




13674S - Cell 
Signalling 
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Table 2.3 - Summary of primary and secondary antibodies used for Western Blotting 
 
2.11. Mitochondrial Membrane Potential Assay using the JC-10 Kit 
To measure mitochondrial membrane potential, cells are first trypsinised, suspended in media 
and then spun down at 800RPM for 2minutes to pellet the cells. Once pelleted, the supernatant 
is removed and cells are re-suspended in serum free media at a density of 1000,000 cells per 
1ml.  100µl of the cell suspension is then seeded in duplicate into a clear bottom, black walled 
96 well plate to give 100,000 cells per well. 50µl of the JC-10 dye loading solution (Abcam JC-
10 Mitochondrial Membrane Potential Assay Kit, ab112134) is then added to each well. Cells 
are then incubated for 1 hour at 37°C and 5% CO2. Following incubation, 50µl of Assay Buffer 
B was added to each well. Immediately following this the fluorescent intensity of each well 
(excitation/emission - 490/525nm and 540/590nm) was read using a Fluostar Omega microplate 
reader (BMG labtech). Prior to each well of the plate being read, the machine was set up to give 
the plate a gentle 2 second shake. Following reading, the ratio of fluorescence intensity at 
520nm/590nm was performed to give an indication of the mitochondrial membrane potential. 
This ratio is then expressed as a percentage of the control. 
2.12. Electron Microscopy 
Cells were grown on transwell inserts (Sigma, Cat Number CLS3413) in 24 well plates and 
fixed using 2% glutaraldehyde (Sigma, Cat Number G5882) in 0.1M Phosphate Buffer (Sigma). 
Cells were maintained in this solution until processing. 




At the point of processing, cells were washed for 2 hours in Phosphate Buffer. Following 
washing, cells were further fixed using 1% Osmium Tetroxide (Sigma, Cat Number 05500) in 
0.1M Phosphate Buffer for 1 hour. Following incubation, cells were washed for a further hour 
in 0.1M Phosphate Buffer.  Cells were subsequently dehydrated using 70, 90 and 100% ethanol 
for 15 minutes each (twice at 100%). Cells were then incubated for 10 minutes in Propylene 
Oxide (Sigma, Cat Number 471968). The cells were then embedded for an hour in 50% epoxy 
resin in propylene oxide. Cells were stored overnight on a shaker in fresh epoxy resin (Agar 
Scientific, Cat Number R1031). The following day, fresh epoxy resin was added and cells were 
maintained for a further 8 hours. Cells were then placed in BEEM embedding capsules (Ted 
Pella, Cat Number 130-SPC) with fresh epoxy resin and incubated for 48 hours at 60°C. 
Sections were then cut and stained with uranyl acetate and lead citrate. Samples were then 
analysed using a transmission electron microscope. 
2.13. Immuno Electron Microscopy 
Cells were grown on transwell inserts and fixed in 2% PFA in PBS for 5 minutes. Cells were 
then rinsed three times in PBS for 5 minutes each. Permeabilisation and blocking was 
performed for 1 hour using 0.1% Saponin, 1% BSA and 3% NGS in PBS. Following incubation, 
samples were rinsed three times in PBS for 5 minutes each. Samples were incubated with the 
antibody of interest overnight at 4°C (See Table X for antibody details). The following day the 
inserts were rinsed three times in PBS for 5 minutes each. Samples were incubated with the 
gold labelled secondary antibody for 3 hours at room temperature. Once incubated, samples 
were rinsed three times for 5 minutes each in PBS. Samples were then fixed in 2% 
Glutaraldehyde in 0.1M Phosphate Buffer prior to processing for Electron Microscopy as 
detailed in Section 2.12. 
2.14. Mitochondrial Isolation 
Cells were grown in 10cm dishes, at the point of collection, cells were quickly rinsed in ice cold 
PBS. 5ml of ice-cold PBS was then added and cells were scraped from the well and collected 
in a Falcon tube. Once collected, they were centrifuged at 800g for 5 minutes at 4°C. Cells were 
then re-suspended in Mitochondrial Isolation Solution and transferred to a glass homogeniser. 
Cells were broken open using 60 strokes within the homogeniser. The solution was then 
centrifuged for 5 minutes at 800g, 4°C, to remove cell nucleus and membranes. The supernatant 
was transferred to a new tube and centrifugation was repeated to ensure all of the membranes 
have been removed. A small aliquot of the supernatant was taken for a whole cell extract, the 
remaining supernatant was centrifuged at 16100g for 10 minutes at 4°C. The supernatant was 




collected as this is the cytosolic fraction. The pellet is the mitochondrial fraction. 1ml of 
Mitochondrial Isolation Solution is added and centrifuged at 16100g for 10 minutes at 4°C to 
wash the pellet. This step is repeated. The pellet is then re-suspended in 100µl of solution. 
Protein quantification is performed as detailed in Section 2.10. All fractions stored at -80°C.  
Mitochondrial Isolation Solution 
• 20mM HEPES-KOH pH7 
• 220mM Mannitol (MW=182.17g/mol): 4g/100ml 
• 70mM Sucrose (MW342.3g/mol): 2.39g/100ml 
• 1mM EDTA (2ml of 0.05M stock in 100ml) 
• 0.5 mM PMSF (add on the day of use) 
• 2mM DTT (add on the day of use) 
2.15. Mitochondrial DNA Extraction 
Following mitochondrial isolation a Qiagen DNeasy Blood and Tissue extraction kit was used 
to extract mitochondrial DNA. The isolated mitochondria were centrifuged at 16100g for 10 
minutes to pellet the mitochondria. The pellet was reuspended in 200µl of PBS and 20µl of 
proteinase K was added, followed by 200µl of Buffer AL. Mitochondria thoroughly vortexed 
and incubated at 56°C for 10 minutes. 200µl of 100% ethanol was then added and thoroughly 
vortexed. The mixture was then transferred into the designated DNeasy Mini spin column and 
centrifuged at 6000g for 1 minute. The flow through collected in the collection tube was 
discarded. The spin column was placed into a new collection tube and 500µl of buffer AW1 
was added and centrifuged at 6000g for 1 minute. Again, the flow through and collection tube 
was discarded.  The spin column was placed into a new collection tube and 500µl of buffer 
AW2 was centrifuged for 3 minutes at 20000g. Flow through and collection tube discarded. 
The spin column was placed into a fresh collection tube and 200µl of buffer AE was added and 
incubated for 1 minute. The sample was then centrifuged for 1 minute at 6000g to elute the 
DNA. This final step was repeated to enhance the DNA yield. 
2.16. DNA Gel Electrophoresis 
To determine that the extracted mtDNA was exclusively DNA of mitochondrial origin a DNA 
gel was ran. First, an 0.8% agarose gel was prepared (0.8g of agarose with 100ml of TAE). 5µl 
of 1x SafeView Nucleic Acid Stain was added to the solution. The solution was then 
microwaved for approximately 1 minute until sufficiently dissolved. The gel was then cast and 
loading comb inserted. Once set satisfactorily, the gel was placed into the electrophoresis tank 




and TAE buffer was added until the gel was completely submerged. The comb was then 
removed. First, a GeneRulerTM 10kb plus DNA Ladder was added, and then 20µl of isolated 
mtDNA was added to the subsequent sample wells. Once loaded, the gel was ran for 1 hour, 
90V, 66mA and 6W. Once the gel had ran satisfactorily, it was analysed and imaged under a 
UV lamp.  
TAE Buffer (50X) 
• 242g Tris base 
• 57.1ml glacial acetic acid 
• 100ml of 500mM EDTA (pH 8.0) 
• 1L distilled H2O  
 
2.17. MitoSOX Staining for ROS Measurement using Flow Cytometry 
MitoSOX is a red dye that targets mitochondria and is specifically oxidised by superoxide ions, 
it therefore can be used to detect mitochondrial ROS. Cells grown in 6 well plates were rinsed 
with PBS and subsequently trypsinised, media was added and cells transferred to a falcon tube. 
Cells were centrifuged for 3 minutes at 1600RPM. Media was then aspirated. Cells were then 
re-suspended in 500µl of MitoSOX (MitoSOX diluted 1:1000 in serum free media, Invitrogen, 
M36008) and incubated for 10 minutes at 37°C. Following incubation, the media was aspirated 
and cells were re-suspended in 2ml of serum free media. Unstained control cells were not 
incubated with MitoSOX, they were just trypsinised and re-suspended in serum free media. 
MitoSOX fluorescence intensity was determined by flow cytometry (Partec) using the red 
fluorescence channel (FL3 channel). Each measurement was performed in triplicate.  
2.18. Measurement of Cellular Bioenergetics using Seahorse XF24 Analyser 
Analysis of ATP production via oxidative phosphorylation and glycolysis was assessed using 
a Seahorse XF24 analyser. Prior to analysis, cells were placed in unbuffered basic media for 
one hour (supplemented with 5mM glucose, 2mM l-glutamate and 3% FBS). Cellular 
bioenergetics were measured by oxygen consumption rate (OCR) and extracellular media 
acidification rate (ECAR). In order to determine the source of ATP a number of inhibitors are 
required to dissect cellular bioenergetics and assess mitochondrial function. An inhibitor of 
ATP synthase oligomycin (1µM) was used to inhibit ATP generation, in order to assess 
maximal ATP production the mitochondrial chain uncoupler carbonyl cyanide p‐
trifluoromethoxy‐phenylhydrazone was used. In addition, complex 1 inhibitor rotenone 




(0.5µM) and complex 3 inhibitor antimycin (2.5µM) were used together to energy production 
via the respiratory chain. The OCR indicates total ATP production. In order to calculate the 
amount derived from mitochondria the OCR with oligomycin is subtracted from the basal OCR, 
this is then multiplied by the phosphorus/oxygen ratio of 2.3 (Brand, 2005). In order to 
determine ATP derived from glycolysis, the ECAR is used. This is because during glycolysis 
there is a 1:1 ratio of ATP production with lactate production. ECAR occurs due to lactate and 
bicarbonate production. Therefore, when ECAR is calibrated to the proton production rate, the 
rate of glycolysis can be determined (Wu et al., 2007; Birket et al., 2011).  
2.19. Huygens Software for miMOMP 
Images for miMOMP analysis were acquired from cells labelled with Cytochrome C and 
TOM20 antibodies by 3D imaging using z-stacks on the Leica SP8 Confocal microscope. 
Approximately 30 z-stacks were acquired for each coverslip imaged. All images were acquired 
using the same parameters on the microscope. Following imaging, micrographs were processed 
for deconvolution using the Huygens Deconvoltion Software. Once optimised, identical 
parameters were used to deconvolve each image to remove any background or noise from the 
image. Deconvolution was used to improve the quality of the images and provide the optimum 
quality for analysing the colocalisation of two channels. Once all images were deconvolved the 
level of colocalisation was assessed using the colocalisation tool within the Huygens 
Deconvolution Software. This was performed by individually “cutting” each cell out in 3D from 
the z-stack. Once isolated, the software performed a statistical colocalisation analysis using the 
Pearson Correlation Coefficient, Spearman’s Coefficient and the overlap between channels. 
These were then recorded in an excel spreadsheet.  
2.20. Immunofluorescent Staining of Cells 
Cells for staining by immunofluorescence were grown on sterile coverslips in 12-well plates. 
Fixation was performed using 4% paraformaldehyde in PBS for 10 minutes (for staining of 
mitochondrial proteins, 0.2% glutaraldehyde was added to the fixation solution). Once fixed 
cells were stored in PBS at -80°C. For staining, coverslips were rinsed twice for 5 minutes in 
PBS, permeabilisation was then performed using 0.5% Triton-X in PBS for 15 minutes at room 
temperature. A further two 5 minute PBS washes were carried out. Blocking was then 
performed for one hour at room temperature using 5% NGS in PBS. Once blocked, cells were 
incubated overnight at 4°C with the primary antibody diluted in 5%NGS/PBS as detailed in 
Table 2.4.  Following overnight incubation, cells were rinsed briefly ten times using PBS. They 
were then incubated for 2 hours at room temperature in the secondary antibody as detailed in 




Table 2.4. They were then quickly rinsed ten times in PBS and mounted using ProLong Gold 
with DAPI. 
Primary Antibodies for Immunofluorescence  
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1:1000 ab15580 - Abcam 
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Secondary Antibodies for Immunofluorescence 
Wavelength Reactivity Host Dilution Reference 
647 Rabbit Goat 1:500 
40839 - Sigma 
Aldrich 
647 Rabbit Goat 1:1000 
1700082 - Life 
Technologies 
594 Rabbit Goat 1:1000 
1745478 - Life 
Technologies 
594 Mouse Goat 1:1000 
1310420 – Life 
Technologies 
555 Mouse Goat 1:1000 
A-21422 - 
Invitrogen 
488 Mouse Goat 1:1000 
1664729 - Life 
Technologies 
488 Rabbit Goat 1:1000 
1275894 – Life 
Technologies 
Anti Mouse 10nm 
Gold Conjugate 
Mouse Goat 1:50 
EM.GMHL10 - 
BBI Solutions 
Anti Rabbit 10nm 
Gold Conjugate 
Rabbit Goat 1:50 
EM.GAR10 - BBI 
Solutions 
 
Table 2.4 - Primary and secondary antibodies used for Immunofluorescent Staining 
 




2.21. Senescence-associated β-Galactosidase Staining of Cells 
Cells were grown on sterile coverslips in 12-well plates and fixed using 2% paraformaldehyde 
and 0.2% glutaraldehyde in PBS for 5 minutes. Once fixed, cells were rinsed three times in PBS 
for 5 minutes. Cells were than incubated in 1ml of SA-β-Gal staining solution at 37°C for 
approximately 24 hours. Once stained, cells were rinsed three times in PBS for 5 minutes and 
coverslips were mounted on to slides using ProLong Gold with DAPI. Imaging was performed 
on a Leica DM550 microscope using the LasX software. Approximately 10 random images 
were taken and quantified using the LasX software.    
SA-β-Gal Staining Solution 
• 1.5ml 1M sodium chloride 
• 20µl 1M magnesium chloride 
• 800µl 0.5M citric acid 
• 1.2ml 0.1M sodium phosphate 
• 5ml distilled water 
Staining solution pH adjusted to 6.0 using NaOH, volume then made up to 10ml using distilled 
water.  
• 8.8ml staining solution detailed above 
• 200µl X-Gal at 20mg/ml in dimethylformamide 
• 1ml potassium ferro-cyanide 
2.22. Imaging using Stimulated Emission Depletion Microscopy 
Imaging using Stimulated Emission Depletion Microscopy (STED) has been performed using 
a Lecia SP8 Confocal gSTED 3D Super Resolution microscope based in the BioImaging Unit 
at Newcastle University. 
For ImmunoFISH staining for STED analysis of telomeres, the same protocol was employed as 
detailed above with a few minor changes for optimised compatibility with STED. Notably, 5µl 
of Cy3 Telomere probe is used in the hybridisation mix and following the final PBS rinse an 
addition 5 minute PBS rinse is performed. Once complete, the samples are incubated in ToPro3 
(1:8000 in PBS) to stain the nucleus. A further three 5 minute rinses in PBS are performed. 
Samples are then mounted using ProLong Diamond without DAPI.   




2.23. Gene Expression Analysis on BAXfl/BAK-/- Livers 
Experiments performed using liver tissue from BAXfl/BAK-/- and BAK -/- mice were 
performed by Dr Stephen Tait, Dr Joel Riley and Dr Catherine Cloix from the Beatson Institute 
for Cancer Research at Glasgow, UK. 
In order to delete BAX specifically in the liver, 8 week old BAXfl/BAK-/- mice were injected 
with an Adeno-associated virus (AAV). Specifically, AAV mediated recombination was 
performed using a Virus carrying the Cre recombinase under the control of a hepatocyte-
specific thyroid-binding globulin (TBG) promoter. Briefly, viral particles (2×1011 genetic 
copies/mouse) of AAV8.TBG.PI.Cre.rBG (Addgene, Catalog number: 107787-AAV8) diluted 
in 100 μl PBS were injected via tail vein in 8 week old mice. Following the injection of the 
virus, the mice were left for 7 days, they were then subsequently irradiated with 4Gy. Livers 
were collected from BAXfl/BAK-/- and BAK -/- mice 7 days post-irradiation/sham irradiation 
for gene expression analysis. Within each of the 4 experimental groups, there were 5 mice (3 
males and 2 females).  
RNA extraction, cDNA synthesis and Real Time Polymerase Chain Reaction (RT-PCR) were 
performed at the Beatson Institute for Cancer Research. The following target genes were 
assessed: CXCL1, IFNα, IL-1α, IL-1β, IL-6, Inhibin A, MMP3, OAS1, p16 and p21. 18S was used 
as the reference gene and mRNA expression of target genes was normalised to 18S using the 
ΔΔC(t) method. 
The AAV.TBG.PI.Cre.rBG was a gift from James M. Wilson (Addgene viral prep #107787-AAV8; 
http://n2t.net/addgene:107787) 
2.24. Statistical Analysis 
GraphPad Prism 6.0 was used for statistical analysis, results are considered as statistically 
significant when p≤0.05. For normally distributed data, the differences between two groups was 
tested for statistical significance using an independent samples two-tailed t-test. For data which 
was normally distributed and there was more than one group a one-way ANOVA was used, a 
Tukey’s comparison post-hoc test was also performed. Where data was not normally distributed 
a Mann-Whitney U-test was used for determining statistical significance
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3. Chapter 3: Mitochondrial pores BAX and BAK release mtDNA during 
senescence and regulate the SASP 
Previous work in the senescence field has largely depicted the role of mitochondria as ROS 
producers which function to maintain the DDR and subsequently stabilise the cell cycle arrest 
(Passos et al., 2010). However, the role of mitochondria in senescence is multi-faceted, it has 
been established that mitochondria undergo a number of distinct changes in terms of dynamics 
and function (Jendrach et al., 2005; Yoon et al., 2006). Furthermore, it has recently been 
revealed that the characteristic pro-inflammatory response of senescent cells is in fact 
dependent on mitochondria (Correia-Melo et al., 2016). Naturally, this raises the question of 
how mitochondria are driving the SASP from a mechanistic perspective.  
mtDNA release into the cytosol has been shown to be a major factor driving pro-inflammatory 
phenotypes, mostly through its binding to cGAS and activation of STING pathway (West et al., 
2015; Bao et al., 2016). Interestingly, the cGAS STING pathway has also been shown to be a 
major regulator of the SASP, however, the role of mtDNA in this process has not been 
investigated (Dou et al., 2017; Gluck et al., 2017; Yang et al., 2017). 
In this chapter, I hypothesised that mitochondrial dysfunction characteristic of senescent cells 
is associated with an increased cytosolic release of mtDNA and that this process may explain 
the SASP. Additionally, I investigated the mechanisms by which mtDNA can be released to the 
cytosol during senescence. Finally, I investigated the impact of blocking mtDNA release on the 
senescent phenotype. 
Therefore, the first aim of this study was to characterise whether mitochondrial DNA was 
present outside of the mitochondria in senescent cells. Secondly, following the observation that 
mtDNA was present in the cytosol, work was undertaken to understand the mechanism which 
was facilitating its release. Finally, it was assessed what the impact of blocking mtDNA release 
has on the senescent phenotype. 
3.1. Mitochondria are dysfunctional during senescence 
The initial aim of this study was to characterise mitochondria in senescence. Previous work has 
described mitochondria in senescent cells as having a hyperfused morphology which consists 
of elongated, interconnected mitochondrial networks (Yoon et al., 2006). Similarly, it has been 
reported that mitochondrial mass increases following the onset of senescence (Passos et al., 
2007). Following the establishment of stress-induced senescence in MRC5 fibroblasts 
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mitochondrial networks were visualised using immunofluorescent labelling of the 
mitochondrial outer membrane protein TOM20 (outer membrane translocase domain 20) 
(Figure 3.1A). The size of the network was determined by manually drawing around the 
mitochondrial staining. It was found that the size of the mitochondrial network was significantly 
increased compared to proliferating cells (p<0.0001) (Figure 3.1B). Previous studies have 
highlighted that the increased mitochondrial networks observed during senescence occur in 
response to a DDR mediated activation of MTORC1 and the mitochondrial biogenesis mediator 
PGC-1β, in addition, this promotes increased production of ROS (Correia-Melo et al., 2016). 
First, I assessed VDAC which is a highly conserved mitochondrial outer membrane protein 
which serves as a reliable marker of overall mitochondrial content (Lemasters and 
Holmuhamedov, 2006). I found that senescent cells had a 1.5 fold increase in VDAC compared 
to proliferating cells (p=0.0474, Figures 3.1C and D). Consistently, I found that PGC-1β protein 
levels were significantly increased in senescent cells compared to proliferating cells (p=0.0258) 
(Figures 3.1C and E). In addition, measurements of MitoSOX fluorescence using flow 
cytometry revealed that superoxide anion production was increased approximately 15-fold in 
senescent cells compared to their proliferating counterparts (p=0.0063) (Figure 3.1F). Finally, 
I assessed mitochondrial membrane potential using the fluorescent dye JC-10, which indicated 
that both stress-induced and replicatively senescent cells display decreased mitochondrial 
membrane potential compared to proliferating cells (p<0.0001 and p=0.0038, Figure 3.1G).  
Collectively, these results highlight that mitochondria in senescent cells differ fundamentally 
in terms of morphology and functionality.  
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Figure 3.1 - Characterisation of mitochondria in senescent cells.  
MRC5 fibroblasts were induced to become senescent either by 20Gy irradiation (10 days post-
IR) or through replicative exhaustion. (A) Representative images of mitochondrial networks 
from proliferating and senescent cells labelled using TOM20 and the nuclear stain DAPI, cells 
were imaged on a 63x objective by confocal microscopy. (B) Bar graph illustrating the size of 
mitochondrial networks as measured by manually drawing around the TOM20 staining in 
proliferating (white bars) and senescent (red bars), n=4 independent experiments. (C) 
Representative western blot of PGC-1β, VDAC (voltage dependent anion channel) and actin. 
(D and E) Bars graph demonstrating quantification of VDAC (D) and PGC1-β (F) normalised 
to actin in proliferating (white bars) and senescent (red bars), n=3-6 independent experiments. 
(F) Bar graph showing the fold change of MitoSOX in proliferating (white bar) and senescent 
cells (red bar) as measured by flow cytometry, n=4 independent experiments. (G) Bar graph 
depicting measurement of mitochondrial membrane potential using the JC-10 dye in 
proliferating (white bar) and senescent (red bars) cells, n=5-8 independent experiments. Bar 
graph data is shown as mean + SEM, the box and whisker plot demonstrates second and third 
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quartiles with the median (box) and lower and upper quartiles depicted by horizontal lines either 
side of the box. Statistical significance was determined using a two-tailed unpaired t test. For 
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3.2. mtDNA is present in the cytosol of senescent cells 
Previous studies investigating the location of cytosolic mtDNA have utilised confocal 
microscopy with antibodies against mitochondria and double stranded DNA (West et al., 2015). 
Therefore, in order to investigate the sub-cellular localisation of mtDNA in proliferating and 
senescent cells, super-resolution and confocal microscopy were employed to visualise the 
mitochondrial networks by immunofluorescence using an antibody for TOM20 and an anti-
DNA antibody. In proliferating cells, the majority of DNA detected in the cytosol co-localised 
with the mitochondrial network. However, in both replicative and stress-induced senescent cells 
the mean number of nucleoids outside of the mitochondrial network and the percentage of cells 
displaying free mtDNA was significantly increased compared to proliferating cells (Figures 
3.2A, B and C). In addition to fluorescence microscopy I confirmed our data using Immuno-
Electron microscopy. I examined cytosolic DNA in proliferating and senescent mouse adult 
fibroblasts by labelling DNA using a gold-conjugated secondary antibody which can be 
visualised using transmission electron microscopy. In senescent cells, labelling of DNA outside 
of the mitochondria is visible (Figure 3.2D). Furthermore, the cytosolic fraction was separated 
from whole cell lysates acquired from proliferating, stress-induced and replicatively senescent 
cells and the presence of mtDNA was assessed using PCR. My results show that mtDNA was 
enriched approximately 7-fold in cytosolic fractions from senescent cells compared to 
proliferating cells (Figure 3.2E). Finally, by Western Blot I probed mitochondrial and cytosolic 
extracts taken from proliferating and senescent cells for the protein TFAM, a transcription 
factor responsible for packaging mtDNA nucleoids. It was found that there was a 3-fold 
increase in the level of TFAM observable in the cytosolic fraction of senescent cells compared 
to proliferating cells (p=0.0265, Figures 3.2F and G).    
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Figure 3.2– mtDNA is present in the cytosol of senescent cells. 
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(A) Representative images of proliferating and senescent cells labelled for DNA (green) and 
mitochondria (red) taken using super-resolution microscopy, white arrows in the enlarged 
images highlight mtDNA nucleoids located outside of the mitochondrial network. (B) Bar graph 
depicting quantification of the mean number of DNA nucleoids outside of the mitochondrial 
network in proliferating (white bar) and senescent (red bars) cells, n=4 independent 
experiments. (C) Bar graph depicting the percentage of cells displaying DNA outside of the 
mitochondrial network in proliferating (white bar) and senescent (red bars) cells, n=4 
independent experiments (D) Representative immune-electron microscopy images of 
proliferating and senescent cells labelled using an anti-DNA antibody with a gold-conjugated 
secondary antibody. Red arrows highlight labelled DNA outside of the mitochondrial network. 
(E) Bar graph depicts the fold-change of mtDNA specific DNA present in cytosolic fractions 
from proliferating and senescent cells as measured by PCR. (F) Representative Western Blot 
image where protein levels of UQCRC2, TFAM and β-Actin were measured in mitochondrial 
extracts and cytosolic fractions acquired from proliferating and senescent cells.  (G) Bar graph 
depicts the quantification of TFAM in the cytosolic fraction of proliferating and senescent cells 
normalised to the mitochondrial protein UQCRC2 and expressed as fold-change. Bar graph data 
is shown as mean, error bars represent the standard error of the mean, statistical significance 
was determined using either a one-way ANOVA or a two-tailed unpaired t test. (The 
representative immuno-electron microscopy image and PCR data was performed by Hanna 
Salmonowicz). 
 
When the presence of cytosolic DNA was assessed using immunofluorescence in Figure 3.2A 
and by immuno-electron microscopy in Figure 3.2D, the DNA was labelled using an anti-DNA 
antibody. Although this method of labelling mtDNA nucleoids is widely used in the 
mitochondrial field it is important to note that it binds all forms of double-stranded DNA, 
therefore it would also bind nuclear DNA if it was present in the cytoplasm (West et al., 2015; 
McArthur et al., 2018; Riley et al., 2018). To determine if DNA found in the cytosol was of 
mitochondrial origin we determined if it co-localised with TFAM by super-resolution 
microscopy (Figure 3.3A). Analysis of proliferating cells reveals that majority of mtDNA 
nucleoids are present within the mitochondrial networks where TFAM staining is also present. 
In senescent cells I observed that there is an increased number of cytosolic DNA nucleoids 
visible outside of the mitochondrial network (2.9 vs 0.2 in proliferating cells, p,0.001) (Figure 
3.2B). It was discovered that in senescent cells 53% of cytosolic DNA nucleoids were also co-
localised with positive staining for TFAM, whereas in proliferating cells only 5% of cytosolic 
DNA colocalised with TFAM (p<0.001, Figures 3.3B and C). These data suggests that a large 
% of cytosolic DNA in senescent cells is of mitochondrial origin.        
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Figure 3.3 – Cytosolic DNA in Senescent Cells colocalises with TFAM. 
(A) Representative immunofluorescence image of DAPI (blue), DNA (green), TFAM (cyan) 
and mitochondria (red labelled using BAC-MAM 2.0-RFP) in a proliferating and a stress-
induced senescent cell acquired on a 63x objective using super resolution airyscan microscopy. 
White arrows indicate colocalisation of cytosolic DNA and TFAM. (B) Bar graph depicting 
quantification of the mean number of nucleoids in the cytosol in proliferating and senescent 
cells, the blue represents the proportion of cytosolic nucleoids which colocalise with TFAM, 
and the green represents the proportion which is positive for DNA staining only. (C) Bar graph 
represents the percentage of cytosolic DNA which colocalises with TFAM in proliferating and 
senescent cells. Bar graph data is shown as mean, error bars represent the standard error of the 
mean, statistical significance was determined using a two-tailed unpaired t test., n=4 
independent experiments.  
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Collectively, my data demonstrates that mtDNA/TFAM complexes relocalise beyond the 
mitochondrial outer membrane. It has been reported that in certain instances cytosolic mtDNA 
can be attached to fragments of the inner mitochondrial membrane (Riley et al., 2018). Thus 
far the inner membrane integrity has not been explored in this study. For example, it is possible 
that during senescence the outer membrane could be damaged or broken down whereby mtDNA 
complexes in the cytosol could still be localised with the inner membrane. As such, I wanted to 
understand whether mtDNA was crossing the inner and outer membrane of the mitochondria, 
or whether it was still localised with the inner membrane. To investigate this a triple 
immunofluorescence staining was used to label the mtDNA nucleoids, the inner membrane 
protein AIF (apoptosis inducing factor) and the outer membrane by labelling TOM20. Analysis 
revealed that compared to proliferating cells, senescent cells had an increased mean number of 
mtDNA nucleoids in the cytosol which were not associated with AIF or TOM20 (p=0.0021) 
(Figures 3.4A and B). Furthermore, senescent cells also displayed an increased percentage of 
cells displaying free mtDNA which did not colocalise with AIF or TOM20 (p<0.0001) (Figures 
3.4A and C). 
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Figure 3.4 – Cytosolic mtDNA does not colocalise with mitochondrial inner membrane 
protein AIF. 
(A) Representative immunofluorescence images of DAPI (blue) DNA (green), TOM20 
(yellow) and AIF (red) acquired by confocal microscopy using a 63x objective in both 
proliferating and senescent cells. (B) Bar graph depicting quantification of the mean number of 
DNA nucleoids outside of the mitochondrial network (i.e. did not colocalise with TOM20 or 
AIF) in proliferating (white bar) and senescent (red bar) cells, n=4 independent experiments. 
(C) Bar graph depicting the percentage of cells displaying DNA outside of the mitochondrial 
network (i.e. did not colocalise with TOM20 or AIF) in proliferating (white bar) and senescent 
(red bar) cells, n=4 independent experiments. Bar graph data is shown as mean, error bars 
represent the standard error of the mean, statistical significance was determined using a two-

















Chapter 3 – Mitochondrial pores BAX and BAK release mtDNA during senescence and 





3.3. mtDNA provokes an inflammatory response in fibroblasts 
It has been reported by a number of groups that free mtDNA is recognised as a DAMP by the 
immune system and can promote the secretion of inflammatory factors. This can occur either 
through TLR9, the NLRP3 inflammasome or the cGAS-STING axis (Shimada et al., 2012; 
West et al., 2015; Bao et al., 2016). Therefore, I questioned whether mtDNA provokes an 
inflammatory response in MRC5 fibroblasts where I previously observed mtDNA to be visible 
in the cytosol upon induction of senescence. To address this question, mitochondria were 
isolated and the mtDNA was then extracted and purified. This extracted DNA was then ran on 
a DNA gel to confirm that it corresponded to the 16,569bp size of circular mtDNA (Figure 
3.5A). The extracted mtDNA was then transfected into proliferating MRC5 cells, following 
transfection, DNA was visible in the cytosol of the cells (Figures 3.5B and C). Post mtDNA 
transfection, the secretion of the cytokine IL-6 and the chemokine IL-8 was measured. IL-6 and 
IL-8 are key factors secreted as part of the SASP and in response to mtDNA (Campisi and 
d'Adda di Fagagna, 2007; Little et al., 2014). It was found that transfection of whole mtDNA 
led to an increased secretion of both IL-6 and IL-8 (p<0.0001 for IL-6 and IL-8), furthermore, 
mtDNA which had been sonicated to apply shear stress and subsequently form fragments also 
led to an increase in both IL-6 and IL-8 (p<0.0001 for IL-6 and IL-8) (Figures 3.5D and E). 
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Figure 3.5 - Transfection of mtDNA into the cytosol provokes the secretion of IL-6 and 
IL-8. 
(A) Mitochondria from MRC5 cells were isolated by centrifugation to remove any nuclear DNA 
and mtDNA was subsequently extracted. The extracted mtDNA was ran on a 0.5% agarose gel 
to confirm that it conformed to the 16,569bp size of whole circular mtDNA. (B) Schematic 
overview of experimental introduction of mtDNA into MRC5 human fibroblasts. (C) 
Proliferating MRC5 cells were transfected with mtDNA for 48 hours, following transfection, 
cells were labelled with DAPI (blue), DNA (green) and TOM20 (red) to confirm that mtDNA 
was visible in the cytosol of the transfected cells. Representative image taken on a 63x objective 
by confocal microscopy. (D and E) Bar graph depicts the levels of IL-6 (D) and IL-8 (E) 
secreted into the media 48 hours post transfection as measured by ELISA, n=6 independent 
experiments. Bar graph data is shown as mean, error bars represent the standard error of the 






Chapter 3 – Mitochondrial pores BAX and BAK release mtDNA during senescence and 





In order to further investigate the impact of mtDNA in the induction of the SASP I used cells 
which were completely devoid of mtDNA (Rho (0) cells) and induced them to become 
senescent, then I measured the secretion of the key SASP cytokines IL-6 and IL-8 and compared 
them to their mtDNA proficient counterparts (Figures 3.6A and B).  
Following the induction of senescence, I observed a significant increase in the secretion of IL-
6 and IL-8 in the mtDNA proficient parental cells compared to the proliferating parental cells 
(p<0.0001 for both IL-6 and IL-8). However, Rho (0) cells displayed a significantly ameliorated 




Figure 3.6 – Rho (0) cells display reduced secretion of the SASP factors IL-6 and IL-8. 
The concentration (pg/ml) of secreted IL-6 and IL-8 was measured via ELISA in parental 
(mtDNA proficient) and Rho (0) (mtDNA deficient) osteosarcoma 143B cells were either 
maintained in a proliferating state or induced to become senescent via irradiation (10Gy 
irradiation 5 days post). (A and B) Bar graph depicts the levels of IL-6 (A) and IL-8 (B) secreted 
into the media in proliferating and senescent parental and Rho (0) cells as measured by ELISA, 
n=6 independent experiments. Bar graph data is shown as mean, error bars represent the 
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3.4. Characterisation of BAX and BAK in senescent cells 
Following my earlier observations that mtDNA was present in the cytosol of senescent cells 
and that mtDNA can provoke a pro-inflammatory response similar to that of the SASP I 
investigated the mechanism by which mtDNA can escape to the cytosol. It has recently been 
published that the presence of cytosolic mtDNA occurs due to the formation of BAX and BAK 
macropores, which allows the inner membrane to herniate and mtDNA release (McArthur et 
al., 2018; Riley et al., 2018). Therefore I wanted to characterise the pore forming proteins BAX 
and BAK in senescent cells. 
Firstly, the total protein levels of BAX and BAK were assessed in whole cell extracts (Figure 
3.7A). It was found that the total level of BAX was not statistically different in senescent cells 
compared to proliferating cells when normalised to the mitochondrial protein VDAC or β-Actin 
(p=0.7608 and 0.8898 respectively, Figures 3.7B and C). However, BAK expression was 
increased in senescent cells both when normalised to both mitochondrial and total protein levels 
(p=0.0456 and 0.0201 respectively, Figures 3.7 D and E) 
 
Figure 3.7 – Total levels of BAK but not BAX are increased in senescent cells. 
The total protein levels of BAX and BAK were analysed in proliferating and stress-induced 
senescent cells (10 days post irradiation) (A) Representative western blot of the total levels of 
BAX, BAK, VDAC and β-Actin. Bar graphs demonstrating quantification of BAX normalised 
to VDAC (B) and β-actin (C) in proliferating (white bars) and senescent (red bars). 
Quantification of BAK normalised to VDAC and β-Actin is shown in bar graphs (D) and (E). 
Bar graph data is shown as mean + SEM and represents 6 independent experiments, statistical 
significance was determined using a two-tailed unpaired t test. 
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Next, I wanted to characterise further the cellular location of both BAX and BAK. It has been 
reported that BAK is maintained in the mitochondria where it is anchored in an inactive state 
(Ferrer et al., 2012). BAX on the other hand is continuously retro-translocated from the 
mitochondria to the cytosol in non-apoptotic cells, however, when it accumulates on the outer 
membrane of the mitochondria this has been observed to enhance the sensitivity to apoptotic 
stimuli (Schellenberg et al., 2013). As such I wanted to understand whether there was any 
changes in the cellular location of BAX and BAK in proliferating and senescent cells. 
Therefore, I separated proliferating and senescent cells into mitochondrial and cytosolic 
fractions which were subsequently probed for BAX and BAK.  
I found that BAK was localised to the mitochondrial fraction of senescent cells (95% of BAK) 
and proliferating cells (85%) to a similar extent (, Figures 3.8A and B). A similar level was 
observed in replicatively senescent cells (85%), this however needs to be confirmed 
independently to establish whether it is statistically significant  
When the percentage of mitochondrially localised BAX was assessed it was found that there 
was a significant decrease in senescent cells (30% of BAX) compared to proliferating cells 
(70%) (p<0.0001, Figures 3.8A and C), a similar trend was observed in replicatively senescent 
cells (20%) although statistical significance was not tested due to the inadequate sample size.  
It is known that the dynamic nature of BAX shuttling from the mitochondria to the cytosol is 
facilitated by the pro-survival proteins BCL-2 and BCL-XL, specifically, BCL-2 can prevent 
shuttling of BAX to the mitochondria (Edlich et al., 2011; Schellenberg et al., 2013). The total 
protein level of BCL-2 was measured in proliferating and senescent cells to understand whether 
it may be contributing to the increased amount of cytosolic BAX observed in senescent cells. 
Consistently, I found that BCL-2 was increased approximately 1.5 fold in senescent cells 
compared to proliferating cells when normalised to mitochondrial and total protein levels 
(p=0.0283 and 0.0049 respectively, Figures 3.8D, E and F). 
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Figure 3.8 - Characterisation of the sub-cellular location of BAX and BAK. 
Proliferating and senescent cells (stress-induced by irradiation and replicatively exhausted 
cells) were separated into mitochondrial and cytosolic fractions prior to characterisation via 
Western Blotting. (A) Representative Western Blot image of UQCRC2, BAX, BAK and β-
Actin. (B) Bar graph representing the percentage of BAK localised to mitochondria in 
proliferating (white bar) and senescent (red bars) cells. (C) Bar graph depicting quantification 
of the percentage of BAX localised to mitochondria in proliferating (white bars) and senescent 
(red bars) cells. (D) Representative Western Blot image of the total levels of BCL-2, VDAC 
and β-Actin. Bar graphs demonstrating quantification of BCL-2 normalised to VDAC (E) and 
β-actin (F) in proliferating (white bars) and senescent (red bars). Bar graph data is shown as 
mean + SEM and represents 6 independent experiments for (B and C, note replicative 
senescent quantification n=1), and 3 independent experiments for (E and F), statistical 
significance was determined using a two-tailed unpaired t test. 
 
The characterisation of BAX and BAK in the previous figures highlights that following the 
development of senescence the total levels of BAK are increased, whereas the total levels of 
BAX are not changed. However the assessment of overall protein levels does not provide 
information on whether BAX or BAK are existing in an inactive or an active state. It is 
particularly difficult to determine whether these proteins are active, however, it has been 
demonstrated that when BAX is in an active state it undergoes a conformational change which 
exposes the 6A7 epitope (Gavathiotis et al., 2010). Therefore an antibody against the BAX 6A7 
epitope was used to characterise proliferating and senescent cells via Western Blotting and 
Immunofluorescence. First, the total levels of BAX (6A7) were assessed. It was found that there 
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was no difference between proliferating and senescent cell when normalised to either the 
mitochondrial protein VDAC or overall protein level (p=0.1574 and 0.4958, Figures 3.9A, B 
and C). Next the levels of BAX (6A7) were assessed in mitochondrial and cytoplasmic fractions 
derived from proliferating and senescent cells. It was found that in the mitochondrial fraction, 
the level of BAX (6A7) was decreased in senescent cells compared to proliferating cells 
(p<0.0001, Figures 3.9D and E). Furthermore, it was found that the ratio of mitochondrial to 
cytoplasmic BAX (6A7) was decreased in senescent cells compared to proliferating cells, 
indicating that there is more cytoplasmic BAX (6A7) in senescent cells (p=0.0110, Figures 
3.9D and F). Finally, proliferating and senescent cells were labelled with the 6A7 antibody as 
shown in the representative images in Figure 3.9G and the mean fluorescence intensity of the 
staining was measured. Conversely, it was found that the mean fluorescence intensity was 
significantly increased in senescent cells compared to proliferating cells indicating that BAX 
(6A7) is more abundant in senescent cells (p=0.0286, Figures 3.9G and H).   
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Figure 3.9 – Characterisation of BAX (6A7) in proliferating and senescent cells. 
The total protein levels of BAX and BAK were analysed in proliferating and stress-induced 
senescent cells (10 days post irradiation). (A) Representative western blot of the total levels of 
BAX (6A7), VDAC and β-Actin. Bar graphs demonstrating quantification of BAX (6A7) 
normalised to VDAC (B) and β-actin (C) in proliferating (white bars) and senescent (red bars), 
n=6 independent experiments. (D) Representative Western Blot image of UQCRC2, BAX 
(6A7) and β-Actin. (E) Bar graph demonstrating the fold change of BAX (6A7) normalised to 
the mitochondrial protein UQCRC2 in the mitochondrial fraction of proliferating (white bar) 
and senescent (red bars) cells. (F) Bar graph depicting quantification of the ratio of 
mitochondrial/cytosolic BAX (6A7) in proliferating (white bars) and senescent (red bars) cells, 
n=3 independent experiments. (G) Representative image of proliferating and senescent cells 
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labelled with DAPI (blue), TOM20 (red) and BAX (6A7) (cyan) imaged by confocal 
microscopy using a 63x objective. (H) Bar graph represents quantification of the mean 
fluorescence intensity of BAX (6A7) as measured by the mean integrated density in 
proliferating (white bar) and senescent cells (red bar), n=4 independent experiments. Bar graph 
data is shown as mean + SEM, statistical significance was determined using a two-tailed 
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3.5. The presence of cytosolic mtDNA is dependent on BAX and BAK pores 
It has recently been reported that the escape of mtDNA from within the mitochondrial matrix 
occurs due to the formation of BAX and BAK macropores (McArthur et al., 2018; Riley et al., 
2018). Therefore I wanted to address whether the formation of BAX and BAK pores can 
facilitate the release of mtDNA observed during senescence. In order to do this, I utilised the 
CRISPR-Cas9 gene editing tool to generate cells that were deficient for both BAX and BAK 
alongside an empty vector control cell line (Figure 3.10B). Then, to test whether BAX and BAK 
pores impact on the release of mtDNA, I induced both the empty vector control and BAX/BAK 
deficient cells to become senescent alongside proliferating controls. As expected, the senescent 
empty vector control cells displayed mtDNA nucleoids in the cytoplasmic region (Figure 
3.10A), however, in BAX/BAK deficient cells the mean number of cytoplasmic mtDNA was 
significantly reduced (p<0.0001, Figure 3.10C), similarly, the percentage of BAX/BAK 
deficient cells displaying cytoplasmic mtDNA was significantly reduced compared to senescent 
empty vector control cells (p<0.0001) (Figure 3.10D). 
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Figure 3.10 – Release of mtDNA during senescence is dependent on BAX and BAK pores. 
(A) Representative images of empty vector and BAX/BAK deficient MRC5 fibroblasts labelled 
with DAPI (blue), DNA (green) and TOM20 (red), shown are proliferating and stress-induced 
senescent cells which have been imaged by confocal microscopy on a 63x objective. (B) 
Representative western blot showing protein levels of BAX and BAK in empty vectorCRISPR and 
BAX/BAKCRISPR cells. (C) Bar graph depicting the mean number of nucleoids in proliferating 
(white bars) and senescent (red bars) empty vector and BAX/BAK deficient cells. n=4 
independent experiments. (D) Bar graph depicting the percentage of cells displaying mtDNA 
nucleoids outside of the mitochondrial network in proliferating (white bars) and senescent (red 
bars) empty vector and BAX/BAK deficient cells. n=4 independent experiments. Bar graph 
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data is shown as mean, error bars represent the standard error of the mean, statistical 
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3.6. The SASP is dependent on mtDNA release by BAX and BAK pores 
Following the observation that cells deficient for BAX and BAK no longer display cytosolic 
mtDNA I wanted to assess what the wider implications of this were on the senescence 
phenotype. As the transfection of mtDNA into MRC5 fibroblasts provoked a pronounced 
inflammatory response (Figure 3.5), it was of particular interest to understand whether 
BAX/BAK cells which no longer display mtDNA had any observable changes in there pro-
inflammatory secretome. It has been previously been published that following the induction of 
stress-induced senescence it typically takes between 7 and 10 days for the senescence 
phenotype and SASP to be established (Coppe et al., 2008; Passos et al., 2010). Therefore, once 
the senescent phenotype had established 10 days post exposure to X-ray irradiation, the levels 
of IL-6 and IL-8 being secreted by senescent empty vector and BAX/BAK deficient cells were 
measured by ELISA (Figures 3.11A and B). It was observed that senescent empty vector control 
cells had a marked increase in the secretion of IL-6, and IL-8 compared to their proliferating 
counterparts (p<0.0001 for both cytokines). BAX/BAK deficient senescent cells on the other 
hand were not significantly increased compared to BAX/BAK deficient proliferating cells for 
any of the cytokines. Interestingly, the secretion of IL-6 and IL-8 was dramatically attenuated 
in senescent BAX/BAK deficient cells compared to senescent empty vector cells (p<0.0001 in 
both instances, Figures 3.11A and B). Following these observations, I wanted to assess the 
secretome profile more widely and comprehensively. In order to do this media was taken from 
proliferating and senescent empty vector and BAX/BAK deficient cells at 10 days post 
senescence induction and then analysed by cytokine array (Figure 3.11C). Consistently, IL-6 
and IL-8 were both upregulated in empty vector senescent cells compared to their proliferating 
counterparts. Notably, IP-10, FGF-2 (fibroblast growth factor 2), GM-CSF (granulocyte-
macrophage colony-stimulating factor), Gro-α, MCP-3 (monocyte chemoattractant protein 3), 
IL-15 and VEGF-A (vascular endothelial growth factor A) were all also upregulated. 
Comparing between the senescent empty vector and BAX/BAK deficient cells, each of these 
noted cytokines were downregulated. Although reduced compared to senescent empty vector 
cells, in senescent BAX/BAK deficient cells the cytokines Gro-α, G-CSF (granulocyte-colony 
stimulating factor) and IL-6 were still upregulated to a small extent compared to this 
proliferating counterparts (Figure 3.11C).   
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Figure 3.11 – The SASP is dependent on BAX and BAK pores. 
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Empty vector and BAX/BAK deficient cells were induced to undergo stress-induced 
senescence using irradiation, 20Gy. Serum-free media was collected 10 days post irradiation 
following 24 hours of serum starvation. Samples were then analysed either by ELISA or 
cytokine array. (A and B) Bar graphs depict the levels of IL-6 and IL-8 (pg/ml) secreted into 
the media as measured by ELISA for proliferating (white bars) and senescent (red bars) empty 
vector and BAX/BAK deficient cells, n=6 independent experiments normalised to the number 
of cells per sample. (C) Tabular summary of secreted cytokine array represented as fold change 
compared to the proliferating empty vector control samples, where green equals no fold  change 
and red equates to up to a 50-fold change in accordance with the scale on the right hand side, 
n=6 independent experiments. Bar graph data is shown as mean, error bars represent the 
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3.7. BAX and BAK do not regulate the cell cycle arrest 
After it was observed that senescent cells deficient for BAX and BAK no longer displayed the 
pro-inflammatory senescence signature, it was of further interest to characterise whether there 
was an impact on the cell cycle arrest. Therefore, I assessed the expression of two key cyclin-
dependent kinase inhibitors which have been associated with enforcing the cell cycle arrest, 
p16 and p21 (Campisi and d'Adda di Fagagna, 2007). As cellular senescence is characterised 
by a stable cell cycle arrest, the proliferation marker Ki67 was also analysed. Furthermore, SA-
β-Gal is considered a classical marker of senescent cells and was therefore also measured 
(Dimri et al., 1995). First, SA-β-Gal was assessed by histochemical staining for beta-
galactosidase activity at pH 6.0 (Figure 3.12A). Following the induction of senescence it was 
found that empty vector senescent cells compared to proliferating cells displayed a vast increase 
in the percentage of cells positive for SA-β-Gal (p<0.0001), similarly, BAX/BAK deficient 
cells displayed a large increase in the percentage of cells positive for SA-β-Gal compared to 
their proliferating controls (p<0.0001). Furthermore, there was no statistical difference in the 
number of positive cells between senescent empty vector and BAX/BAK deficient cells 
(Figures 3.12A and B). To assess levels of p16 and p21, immunofluorescence was utilised. It 
has been demonstrated that activation of both p16 and p21 results in translocation of these 
proteins to the nuclear region (Stein et al., 1999; Rodriguez-Vilarrupla et al., 2002). Therefore, 
the percentage of proliferating and senescent empty vector and BAX/BAK deficient cells with 
positive staining for each of these markers was assessed (Figure 3.12C). For p16, it was 
demonstrated that the percentage of positive cells was significantly increased in empty vector 
senescent cells compared to proliferating empty vector cells (p<0.0001). Similarly, BAX/BAK 
deficient cells had significantly increased p16 levels compared to proliferating BAX/BAK 
deficient cells (p<0.0001). There was no statistically significant difference between p16 
positive senescent empty vector and BAX/BAK deficient cells (Figures 3.12C and D). Nuclear 
p21 was detected by using an antibody against the p21cip1/WAF1 antigen (Figure 3.12C). It was 
demonstrated that the percentage of positive cells was significantly enhanced in empty vector 
senescent cells compared to proliferating empty vector cells (p<0.0001). Furthermore, 
BAX/BAK deficient cells had significantly increased p21 levels when compared to their 
proliferating counterparts (p<0.0001). Comparison of empty vector and BAX/BAK deficient 
cells revealed no statistically significant difference (Figures 3.12C and E). Finally, in order to 
assess whether cells were undergoing replication the proliferation marker Ki67 was assessed 
by immunofluorescence (Figure 3.12F). As such, the proliferating empty vector and BAX/BAK 
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deficient cells displayed approximately 35% of cells stained positively for this marker. In the 
senescent groups, both the empty vector and BAX/BAK deficient cells displayed very few Ki67 
positive cells indicating that these cells were no longer dividing, there was no significant 
difference between the two. Both senescent groups displayed significantly reduced levels of 
Ki67 compared to their proliferating controls (p<0.0001 for both empty vector and BAX/BAK 
deficient cells) (Figure 3.12F and G).   
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Figure 3.12 – BAX and BAK do not affect the expression of cyclin dependent kinase 
inhibitors p16, p21 and SA-β-Gal activity. 
Empty vector and BAX/BAK deficient cells were induced to become senescent by X-ray 
irradiation, 20Gy. Markers of senescence were subsequently analysed 10 days post irradiation 
when the senescent phenotype has developed. (A) SA-β-Gal activity was detected by 
histochemical staining for beta-galactosidase activity at pH 6.0. Representative images of SA-
β-Gal staining (histochemical light blue) and DAPI (immunofluorescence dark blue nuclear 
stain), acquired using a 20x objective on a wide-field microscope. (B) Bar graph depicts the 
percentage of cells positive for SA-β-Gal staining in proliferating (white bars) and senescent 
(red bars) empty vector and BAX/BAK deficient cells, n=4 independent experiments.  (C) 
Representative images following staining of cells for DAPI (blue), p16 (green) and p21 (red) 
acquired using a 40x objective on a wide-field microscope. Cells were considered positive for 
p16 or p21 when they displayed nuclear staining. (D) Bar graph depicts the percentage of cells 
positive for p16 staining in proliferating (white bars) and senescent (red bars) empty vector and 
BAX/BAK deficient cells, n=7 independent experiments.  (E) Bar graph depicts the percentage 
of cells positive for p21 staining in proliferating (white bars) and senescent (red bars) empty 
vector and BAX/BAK deficient cells, n=7 independent experiments.  (F) Representative images 
following staining of cells for DAPI (blue) and Ki67 (red), acquired using a 40x objective on a 
wide-field microscope. Cells were considered positive for Ki67 when they displayed nuclear 
staining. (G) Bar graph depicts the percentage of cells positive for Ki67 staining in proliferating 
(white bars) and senescent (red bars) empty vector and BAX/BAK deficient cells, n=4 
independent experiments. Bar graph data is shown as mean, error bars represent the standard 
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3.8. BAX and BAK do not mediate DNA damage or ROS production. 
Previous work has implicated that the cell cycle arrest occurs in response to a DDR. 
Furthermore, it has been demonstrated that ROS provide a positive feedback loop by driving 
DNA damage which reinforces the cell cycle arrest (Alcorta et al., 1996; Passos et al., 2010; 
Correia-Melo et al., 2016). Phosphorylation of histone H2AX, referred to as γH2AX, occurs in 
response to DNA damage as a signal to mediate DNA damage repair, therefore, it provides a 
reliable marker of DNA damage. As there was BAX/BAK deficient cells displayed no change 
in p16 and p21 which induce and maintain the cell cycle arrest, it was therefore of interest to 
assess whether DNA damage was affected (Figure 3.13A). Analysis of γH2AX 10 days post-
induction of senescence revealed that senescent empty vector cells had a significant 2-fold 
increase in the mean number of γH2AX foci compared to proliferating empty vector cells 
(p<0.0001), similarly, BAX/BAK deficient senescent cells displayed a 2-fold increase in the 
mean number of γH2AX foci (p<0.0001). There was no significant difference in the number of 
foci between senescent empty vector and BAX/BAK deficient cells (Figure 3.13B). As it is 
known that mitochondrial derived ROS are responsible for inducing short-term foci which 
maintain the DDR, I wanted to assess whether cells lacking BAX/BAK had any changes in 
ROS generation. Therefore, ROS was measured using MitoSOX. It was found that ROS was 
vastly increased in senescent empty vector cells compared to their proliferating controls 
(p<0.0001), the same increase was observed in BAX/BAK deficient senescent cells and their 
proliferating controls (p<0.0001). However, no significant difference was observed between 
BAX/BAK deficient senescent cells and senescent empty vector cells (Figure 3.13C).     
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Figure 3.13 – BAX and BAK do not mediate DNA damage or ROS production. 
Empty vector and BAX/BAK deficient cells were induced to become senescent by X-ray 
irradiation, 20Gy. Markers of senescence were subsequently analysed 10 days post irradiation 
when the senescent phenotype has developed. (A) Representative images of proliferating and 
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senescent empty vector and BAX/BAK deficient cells labelled for γH2AX (green) and DAPI 
(blue). Imaged using a 40x objective using a wide-field microscope, individual γH2AX foci 
were counted in each nucleus. (B) Bar graph depicting the mean number of γH2AX foci per 
cell in proliferating (white bars) and senescent (red bars) empty vector and BAX/BAK deficient 
cells, n=4 independent experiments. (C) Bar graph depicting MitoSOX integrated intensity 
measured following imaging using a 63x objective on a confocal microscope in proliferating 
(white bars) and senescent (red bars) empty vector and BAX/BAK deficient cells, n=4 
independent experiments. Bar graph data is shown as mean, error bars represent the standard 
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3.9. BAX/BAK deficient cells do not undergo metabolic reprogramming 
Following the observation that BAX/BAK deficient cells display a diminished SASP, I wanted 
to assess whether this could be associated with metabolic changes. It has been reported that 
cells deficient for BAX are less able to produce ATP via oxidative phosphorylation and shift to 
energy production via glycolysis (Boohaker et al., 2011). Moreover, in the study where it was 
demonstrated that senescent cells which were depleted of mitochondria lacked a SASP, these 
cells were also entirely dependent on glycolysis for their energy requirements (Correia-Melo et 
al., 2016). Therefore, it is plausible that the SASP reducing effects may be due to metabolic 
reprogramming to glycolysis following genetic deletion of BAX and BAK. As such, I wanted 
to investigate how BAX/BAK deficient cells produce there ATP. 
First, using the Seahorse XF analyser which measures overall ATP production it was discovered 
that both senescent Empty Vector and BAX/BAK deficient cells had a significantly increased 
overall ATP production compared to their proliferating counterparts (Figure 3.14A).  When the 
overall ATP production was normalised to represent the percentage that was acquired from 
glycolysis and oxidative phosphorylation it was found that there was no difference in the source 
of ATP between proliferating and senescent Empty Vector and BAX/BAK deficient cells 
(Figure 3.14B).  
 
 
Figure 3.14 - BAX/BAK deficient cells do not undergo metabolic reprogramming 
Proliferating and senescent Empty Vector and BAX/BAK deficient MRC5 human fibroblasts 
were assessed for ATP production using the Seahorse XF24 analyser. (A) The bar graph 
represents overall ATP production for proliferating and senescent Empty Vector and 
BAX/BAK deficient MRC5 human fibroblasts. Green represents the amount of energy derived 
from glycolysis and red by oxidative phosphorylation. (B) The bar graph represents the energy 
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production by glycolysis or oxidative phosphorylation normalised to total ATP production and 
expressed as a percentage.  Green represents the percentage of energy derived from glycolysis 
and red by oxidative phosphorylation. In both cases n=5 independent experiments. Bar graph 
data is shown as mean, error bars represent the standard error of the mean, statistical 
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3.10. The MPTP pore does not contribute to mtDNA release 
Whilst characterising the function of mitochondria in senescent cells I observed that they exist 
in a depolarised state (Figure 3.1G). Mitochondria are maintained in this state of depolarisation 
by the mitochondrial permeability transition pore (MPTP). The MPTP allows the influx/efflux 
of molecules up to 1500 Da from the mitochondrial matrix, its opening is associated with 
mitochondrial depolarisation and has been demonstrated to result in an impairment of energetic 
function, promote Ca2+ release. Collectively, these changes are associated with matrix swelling 
which leads to release of pro-apoptotic proteins such as cytochrome C (Halestrap, 2009; Rasola 
and Bernardi, 2011). Therefore I investigated whether the MPTP contributes to the release of 
mtDNA during senescence. It has been demonstrated that Cyclosporin A can block the MPTP 
by its binding to the mitochondrial cyclophilin D (Halestrap et al., 1997). To address the role 
of the MPTP, I treated senescent cells with Cyclosporin A and then measured mtDNA release 
and the SASP factors; IL-6, IL-8 and IP10. In proliferating cells, treatment with Cyclosporin A 
had no effect on the mean number of free mtDNA nucleoids or the percentage of cells with 
mitochondrial-free DNA. Following the induction of senescence, as expected, there was an 
increase in the mean number of nucleoids present outside of the mitochondria, as well as an 
increase in the percentage of cells exhibiting mitochondrial-free DNA compared to proliferating 
cells (p<0.0001). However, treatment with Cyclosporin A did not affect the percentage of cells 
with cytoplasmic DNA, however, there was a small but non-significant decrease in the mean 
number of nucleoids outside of the mitochondria compared to control senescent cells (Figures 
3.15A, B and C). Furthermore, treatment of senescent cells with Cyclosporin A provoked an 
enhancement in the levels of IL-6, IL-8 and IP10. This was significant for all of the measured 
cytokines (p<0.0001). Cyclosporin A had no effect on the secretion of these cytokines in 
proliferating cells. (Figures 3.15D, E and F).           
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Figure 3.15 – The MPTP pore does not contribute to mtDNA release. 
MRC5 fibroblasts were induced to undergo stress-induced senescence (20Gy irradiation). 
Following the induction of senescence, cells were maintained with Cyclosporin A. Leakage of 
mtDNA and secretion of SASP factors was assessed 10 days later (A) Representative images 
of proliferating and senescent cells labelled with DAPI (blue), TOM20 (red) and DNA (green) 
which have been treated with either Cyclosporin A (1µM) or DMSO only as a control. Images 
acquired using a 63x objective by confocal microscopy. (B) Bar graph depicts quantification of 
the mean number of mtDNA nucleoids outside of the mitochondrial network in proliferating 
and senescent cells treated with Cyclosporin A (1µM) or DMSO only as a control, n=4 
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independent experiments. (C) Bar graph depicts the percentage of cells exhibiting mtDNA 
nucleoids outside of the mitochondrial network in proliferating and senescent cells treated with 
Cyclosporin A (1µM) or DMSO only as a control, n=4 independent experiments. (D, E and F) 
Bar graphs depict the levels of IL-6, IL-8 and IP10 (pg/ml) secreted into the media as measured 
by ELISA for proliferating and senescent cells treated with Cyclosporin A (1µM) or DMSO 
only as a control, n=4 independent experiments. Bar graph data is shown as mean, error bars 
represent the standard error of the mean, statistical significance was determined using a one-
way ANOVA. 
 
Although not fully understood at this stage, it is recognised that the MPTP pore is composed of 
a number of subunits, such as cyclophilin D, the adenine nucleotide translocase (ANT) and the 
voltage dependent anion channel (VDAC) (Briston et al., 2017). Following the observation that 
inhibition of the cyclophilin D by Cyclosporin A had no effect on mtDNA release and did not 
suppress the SASP, it was therefore of interest to assess whether the drugs Olesoxime (which 
inhibits VDAC) and Bongkrekic acid (which inhibits ANT) have any effect on the SASP 
(Bordet et al., 2010; Anwar et al., 2017). To address the effect of these inhibitors on the SASP, 
senescent cells were treated with either Olesoxime or Bongkrekic acid, then IL-6 or IL-8 were 
measured. Treatment of senescent cells with Olesoxime (1µM) promoted a small but non-
significant increase in the secretion of both IL-6 and IL-8 (Figures 3.16A and B). Furthermore, 
blockage of ANT using Bongkrekic acid (0.1 - 25µM) had no effect on the secretion of IL-8 in 
senescent cells (Figure 3.16C). 
   
Figure 3.16 – Pharmacological inhibition of VDAC or ANT does not suppress the SASP 
MRC5 fibroblasts were induced to undergo stress-induced senescence (20Gy irradiation). 
Following the induction of senescence, cells were maintained with either Olesoxime or 
Bongkrekic acid. Secretion of SASP factors was assessed 10 days later. (A and B) Bar graphs 
depict the levels of IL-6 and IL-8 (pg/ml) secreted into the media as measured by ELISA for 
senescent (red bars) and senescent cells treated with Olesoxime (1µM) (white bars), n=3 
technical replicates. (C) Bar graph depicts the levels of IL-8 (pg/ml) secreted into the media as 
measured by ELISA for senescent (red bars) and senescent cells treated with Bongkrekic acid 
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(0.1 - 25µM) (white bars), n=1. Bar graph data is shown as mean, error bars represent the 
standard error of the mean, for A and B statistical significance was determined using a two-
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3.11. Pharmacological inhibition of BAX prevents mtDNA release and the SASP 
Next, I wanted to assess whether I could suppress mtDNA release and subsequently, the SASP, 
using pharmacological inhibitors of BAX and BAK. The formation of pores can be prevented 
using the pharmacological agent BAX-inhibiting peptide v5 (BIP v5) which suppresses 
translocation of BAX to the mitochondria by inhibiting the Ku70 binding domain found on the 
BAX protein (Sawada et al., 2003). As such to test whether pharmacological blockage of BAX 
and BAK pores could prevent mtDNA release, cells were treated with BIP v5 following the 
induction of senescence. As previously observed, the induction of senescence provokes an 
increase in the mean number of cytosolic mitochondrial nucleoids, interestingly, the inhibition 
of pore formation using BIP v5 significantly decreases the release of mtDNA to a level 
comparable with that of proliferating cells (p<0.001) (Figures 3.17A and B). Similarly, the 
percentage of cells displaying cytosolic mtDNA is significantly reduced in senescent cells 
treated with BIP v5 compared to those which have not (p<0.001) (Figures 3.17A and C). In 
proliferating cells, BIP v5 has no effect on the mean number of mtDNA nucleoids outside of 
the mitochondrial network or the percentage of cells displaying mitochondrial free DNA 
(Figures 3.17A, B and C). Following the finding that BIP v5 could prevent mtDNA release, I 
next wanted to understand whether this could potentially suppress the SASP.  
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Figure 3.17 – Pharmacological inhibition of BAX prevents mtDNA release. 
MRC5 fibroblasts were induced to undergo stress-induced senescence (20Gy irradiation). 
Following the induction of senescence, cells were maintained with BIP v5. Leakage of mtDNA 
was assessed 10 days later. (A) Representative images of proliferating and senescent cells 
labelled with DAPI (blue), TOM20 (red) and DNA (green) which have been treated with either 
BIP v5 (100µM dissolved in water) or untreated as a control. Images acquired using a 63x 
objective by confocal microscopy. (B) Bar graph depicts quantification of the mean number of 
mtDNA nucleoids outside of the mitochondrial network in proliferating and senescent cells 
treated with BIP v5 (100µM dissolved in water) or untreated as a control, n=4 independent 
experiments. (C) Bar graph depicts the percentage of cells exhibiting mtDNA nucleoids outside 
of the mitochondrial network in proliferating and senescent cells treated with BIP v5 (100µM 
dissolved in water) or untreated as a control, n=4 independent experiments. Bar graph data is 
shown as mean, error bars represent the standard error of the mean, statistical significance was 
determined using a one-way ANOVA. 
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In order to assess whether pharmacological inhibition of BAX and BAK pores could prevent 
the SASP, MRC5 fibroblasts were induced to become senescent and subsequently maintained 
with BIP v5. The senescent cells displayed a large increase in the secretion of the SASP factors 
IL-6, IL-8 and IP10 (p<0.0001 in each case). Treatment of senescent cells with low doses of 
BIP v5 (1-10µM) does not have any significant effect on the secretion of IL-6, IL-8 or IP10. 
However, treatment of senescent cells with high doses of BIP v5 (50 and 100µM) significantly 
decreases the secretion of IL-6, IL-8 and IP10 in untreated senescent cells. Furthermore, 
treatment of proliferating cells with BIP v5 had no effect on cytokine secretion at any of the 
tested concentrations (Figures 3.18A, B and C).   
Another drug which blocks pores is the BAX channel blocker (BCB), however the mechanism 
of action of this drug is slightly different. This does not prevent BAX undergoing its 
conformational change during activation, but blocks pores that have formed. BCB has been 
demonstrated to prevent apoptosis and the release of inner membrane proteins such as 
cytochrome C following pore blockage (Bombrun et al., 2003). As such, MRC5 fibroblasts 
were induced to become senescent and then maintained in the presence of the BCB. The 
induction of senescence lead to a significant increase in each of the measured cytokines (IL-6, 
IL-8 and IP10). Treatment of senescent cells with BCB lead to a significant decrease in IL-6 
and IP10 at each of the tested concentrations, 0.1, 1 and 2.5µM. Interestingly, for IL-8, only the 
2.5µM concentration was effective at suppressing the SASP, where an approximate 40% 
decrease was observed. Treatment with BCB had no effect on any of the cytokines in 
proliferating cells (Figures 3.18D, E and F).    
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Figure 3.18 - Pharmacological inhibition of BAX suppresses the SASP. 
MRC5 fibroblasts were induced to undergo stress-induced senescence (20Gy irradiation). 
Following the induction of senescence, cells were maintained with either BIP v5 or BCB at a 
range of concentrations. Secretion of SASP factors was assessed 10 days later. (A, B and C) 
Bar graphs depict the levels of IL-6, IL-8 and IP10 (pg/ml) secreted into the media as measured 
by ELISA for proliferating and senescent cells treated with BIP v5 (1-100µM) or untreated as 
a control, n=4 independent experiments. (D, E and F) Bar graphs depict the levels of IL-6, IL-
8 and IP10 (pg/ml) secreted into the media as measured by ELISA for proliferating and 
senescent cells treated with BCB (01-2.5µM) or treated with DMSO only as a control, n=4 
independent experiments. Bar graph data is shown as mean, error bars represent the standard 
error of the mean, statistical significance was determined using a one-way ANOVA. 
 
Following my observations in vitro that genetic removal and pharmacological inhibition of 
BAX and BAK alleviate the SASP I wanted to test whether these findings can be translated in 
vivo. It has been recently demonstrated that liver tissue obtained from irradiated mice display 
upregulation of the SASP genes IL-1α, IL-1β, IFN-α, IL-6, CXCL1 and MMP3 (Dou et al., 
2017). Furthermore, another study demonstrated that a number of interferon related genes are 
upregulated in adipose tissue 3 months following irradiation; IFN1α, OAS1 and inhibin A (De 
Cecco et al., 2019). To dissect the role of BAX and BAK in the SASP, mice with BAX and 
BAK deleted (BAXfl/BAK-/-) specifically from the liver were irradiated and the SASP genes 
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listed above were assessed alongside p16 and p21 7 days later, BAK-/- mice were used as a 
control.  
In the BAK-/- control mice following irradiation there was a trend for an increase in the 
following inflammatory genes; CXCL1 (15.5 fold), IFNα (1.6 fold), IL-1α (2.4 fold), IL-1β (2.2 
fold), IL-6 (1.5 fold), Inhibin A (1.7 fold), MMP3 (2.2 fold), OAS1 (2.4 fold). Following 
irradiation in the BAXfl/BAK-/- mice there was no increase in any of the inflammatory genes. 
The following genes were significantly decreased in irradiated BAXfl/BAK-/- mice compared 
to irradiated BAK-/- mice; IL-1α (p<0.05), IL-1β (p<0.001) and OAS1 (p<0.05). There was a 
tendency although not significant for the other inflammatory genes to be decreased in 
BAXfl/BAK-/- irradiated mice compared to BAK-/- irradiated mice; CXCL1, IFNα, IL-6, 
Inhibin A and MMP3 (Figures 3.19A-H).  
Next, the cell cycle kinase inhibitors p16 and p21 were assessed. Following irradiation in BAK-
/- mice, there was a non-significant increase in both p16 (1.5 fold) and p21 (2.0 fold).  For the 
BAXfl/BAK-/- mice there was no observable increase in p16 or p21 expression following 
irradiation. Irradiated BAXfl/BAK-/- mice had lower expression of p16 (p<0.05) and p21 
compared to irradiated BAK-/- mice (Figures 3.19I and J).  
The heat map in Figure 3.19K summarises the fold change for each of the 10 genes assessed in 
Figures 3.19A-J. 
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Figure 3.19 – BAX and BAK deletion reduces the SASP in vivo. 
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Mice harbouring BAK-/- and BAXfl/BAK-/- deleted livers were either irradiated (4Gy) or sham 
irradiated. Livers were collected and analysed 7 days post-irradiation for inflammation and 
senescence associated genes by RT-PCR. Fold change in CXCL1(A), IFNα (B), IL-1α (C), IL-
1β (D), IL-6 (E), Inhibin A (F), MMP3 (G), OAS1 (H), p16 (I) and p21 (J) mRNA levels from 
wild type and BAX BAK -/- mice as determined by RT-PCR. Data are normalised to the 18s 
house keeping gene for each sample, and then normalised to the median wild type non-
irradiated mice to determine fold-change in gene expression (n=5 per group). (K) Heat map 
summarising the fold change of target genes analysed in A-J. The animal work was performed 
by Stephen Tait and Joel Riley from the Beatson Institute for Cancer Research. Dot plots shown 
as mean with each dot representing an individual animal, statistical significance was determined 
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Our lab recently established for the first time an essential role of mitochondria in senescence. 
It was shown that during the development of senescence the DDR drives mitochondrial 
biogenesis through MTORC1, moreover, the removal of mitochondria from human fibroblasts 
led to senescent cells which were devoid of the pro-inflammatory features of senescence. 
Similarly, a reduction of mitochondrial content in vivo by either MTORC1 inhibition or 
silencing of PGC1-β ameliorated aspects of the senescence phenotype (Correia-Melo et al., 
2016). Therefore the first aim of this study was to decipher a potential mechanism by which 
mitochondria contribute to the SASP. Collectively, our data has pinpointed the role of mtDNA 
as an immunostimulatory molecule which is found in the cytoplasmic region of senescent cells. 
This leakage is attributed to pro-apoptotic BAX and BAK pores which occur during senescence.  
Research over a number of years has established that the state of mitochondria are 
fundamentally altered in senescent cells with regards to dynamics, metabolic function and the 
production of ROS (Passos et al., 2007; Wiley et al., 2016; Correia-Melo et al., 2017; Chapman 
et al., 2019). First, I wanted to validate that following the induction of senescence in MRC5 
human fibroblasts there was detectable changes in line with the existing literature. The initial 
characterisation of the mitochondrial network size revealed that its size was exacerbated in 
senescent cells compared to proliferating cells. Although, it is not entirely understood why 
senescent cells accumulate more mitochondria it has been established in the literature that this 
increase in network size has been associated with the expression of mTOR dependent activation 
of PGC1-β (Correia-Melo et al., 2016). Consistently, I found PGC1β to be increased in 
senescent cells. Moreover, the protein VDAC which is a highly conserved mitochondrial outer 
membrane protein was also increased in senescent cells indicating that overall mitochondrial 
content is increased in senescent cells. Interestingly, both with age and the onset of senescence 
there is evidence that mitochondria have a reduced mitochondrial membrane potential, indeed 
our data in both stress-induced and replicative senescence corroborate these published findings 
(Nicholls, 2004; Passos et al., 2007).  
Furthermore, one of the ways in which mitochondria have been demonstrated to drive the 
senescence phenotype is through the production of ROS. ROS instigates cellular damage which 
in turn promotes the activation of p53 and p21 which has been shown to stabilise the growth 
arrest (Passos et al., 2010; Luo et al., 2011). Furthermore, the excessive production of 
endogenous ROS has been associated with a number of models of senescence: replicative, OIS 
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and stress-induced senescence (Saretzki et al., 2003; Moiseeva et al., 2006; Ramsey and 
Sharpless, 2006; Passos et al., 2007; Passos et al., 2010). Consistently, I found that stress-
induced senescent cells displayed a clear increase in the production of mitochondrial superoxide 
as measured by the mitochondrial ROS specific dye MitoSOX.     
Together, these data corroborate published findings that mitochondria are dysfunctional during 
senescence. A recent proof of principle study demonstrated mitochondria are essential for the 
SASP. It was shown that the complete removal of mitochondria prior to the induction of 
senescence lead to the development of a senescence phenotype which was completely lacking 
the pro-inflammatory element of senescence (Correia-Melo et al., 2016). Furthermore, the 
inhibition of mTOR which drives mitochondrial biogenesis in senescence through PGC1-β has 
been demonstrated to attenuate the SASP (Herranz et al., 2015; Correia-Melo et al., 2016). 
Similarly, knockout of PGC1-β both in vitro and in vivo has been shown to ameliorate aspects 
of senescence (Correia-Melo et al., 2016). However, the mechanism linking mitochondria and 
the SASP is not understood.  
A study investigating the links between mitochondrial function and regulation of the SASP 
observed that senescent Rho (0) IMR90 cells (which have a diminished ability to undergo 
oxidative phosphorylation) no longer displayed an increase in IL-6 mRNA levels or its secretion 
when compared to their proficient counterparts (Correia-Melo et al., 2016; Wiley et al., 2016). 
However, Rho (0) cells are also completely devoid of mtDNA, therefore I speculated that 
mtDNA could in fact be responsible for the pro-inflammatory response observed during 
senescence. From an ageing perspective mtDNA is particularly interesting as it has been 
observed that circulating mtDNA which is free from mitochondria increases with age in 
humans. This increase also correlates with the expression of a number of pro-inflammatory 
cytokines (Pinti et al., 2014). In addition, increased levels of circulating mtDNA have been 
observed in a number of diseases where senescent cells have been implicated, for example; 
idiopathic pulmonary fibrosis, type-2 diabetes, acute myocardial infarctions and Alzheimer’s 
disease amongst others (Ryu et al., 2017; Schafer et al., 2017; Wu et al., 2017; Anderson et al., 
2019; Palmer et al., 2019; Silzer et al., 2019; Walaszczyk et al., 2019; Zhang et al., 2019). It 
has also been observed that mtDNA copy number is increased in senescent cells (Passos et al., 
2007; Correia-Melo et al., 2016; Hubackova et al., 2019). Furthermore, there is evidence that 
mtDNA can activate a number of inflammatory pathways through its action as a DAMP, 
primarily the NLRP3 inflammasome, cGAS-STING axis and TLRs (Nakahira et al., 2011; 
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West et al., 2015; Bao et al., 2016).  These pathways have also been previously implicated in 
senescence and regulation of the SASP (Dou et al., 2017; Gluck et al., 2017; Yin et al., 2017; 
Hari et al., 2018). 
Therefore I wanted to begin by assessing whether there was mitochondria-free mtDNA present 
in senescent cells. Using confocal, electron and super-resolution microscopy it was revealed 
that there was DNA visible in the cytosol of cytosol. Although these methods are widely used 
in the field to determine the sub-cellular location of mtDNA, the anti-DNA antibody labels both 
nuclear and mitochondrial double stranded DNA. Therefore, to ensure what I were observing 
was specifically of mitochondrial origin I used a triple-immunofluorescent assay to label 
mitochondria, DNA and TFAM. Using this assay it was observed that the DNA staining outside 
of the mitochondrial network also colocalised with TFAM, this was further supported by 
analysis of TFAM protein levels and mRNA levels in cytosolic fractions acquired from 
proliferating and senescent cells. Furthermore, the quantification of the number of mtDNA 
nucleoids in the cytosol via microscopy does not allow us to dissect whether this may in fact be 
occurring due to the overall increase in mitochondrial mass and content that is associated with 
senescence (Correia-Melo et al., 2016). Whereas Western Blot and PCR allowed us to 
normalise the cytosolic fraction of mtDNA relative to overall mitochondrial content in 
proliferating and senescent cells. Collectively, these data indicate that mtDNA is escaping from 
the mitochondria to the cytosol where it is available for detection via DNA sensors which can 
mediate an inflammatory response. However, it would be expected that cytosolic mtDNA (or 
nuclear DNA) would be rapidly degraded by DNases to prevent an inflammatory response. It 
was recently published that senescent cells exhibit downregulation of the cytoplasmic DNases 
TREX1 and DNase2, which could explain why mtDNA persists in senescent cells (Takahashi 
et al., 2018). This therefore is likely the explanation as to why mtDNA is detectable in the 
cytosolic fraction of senescent cells.  
Next, mtDNA was isolated and transfected into human fibroblasts to confirm that mtDNA had 
the capacity to induce an inflammatory response in human fibroblasts. I found a clear increase 
in both IL-6 and IL-8 which are key constituents of the SASP. This fits with data demonstrating 
that mtDNA promotes an inflammatory response and production of IL-6 and IL-8 via cGAS 
mediated upregulation of IFN-1 genes (Little et al., 2014; West et al., 2015; Chen et al., 2016; 
Yang et al., 2017). Furthermore, it has been shown that when the release of mtDNA is induced 
pharmacologically using BH3 mimetics, the upregulation of IFN-B1 genes does not occur in 
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cells which do not express STING (Riley et al., 2018). I also observed that Rho (0) cells lacking 
mtDNA displayed an impaired secretion of both IL-6 and IL-8 when compared to their mtDNA 
proficient counterparts, this supports published observations that Rho (0) cells display an 
impaired SASP (Correia-Melo et al., 2016; Wiley et al., 2016). However, it is important to note 
that this experiment was conducted in human osteosarcoma 143B cells which are not routinely 
used for the study of senescence due to being an immortalised cancer cell line. As such, it would 
be preferable to generate Rho (0) cells in primary fibroblasts using either ethidium bromide 
(inhibits mtDNA synthesis) or 2’,3’-dideoxycytidine (blocks mtDNA replication) to deplete 
mtDNA. The two aforementioned studies demonstrated that these cells exhibited a diminished 
SASP as a consequence of these cells being unable to undertake oxidative phosphorylation, 
however they did not investigate the potential for mtDNA to be contributing to the SASP 
(Correia-Melo et al., 2016; Wiley et al., 2016). 
As part of the study, I wanted to investigate how mtDNA escapes to the cytosol. I hypothesised 
that non-specific mitochondrial rupture could contribute to mtDNA release. I also hypothesised 
that either the MPTP or BAX and BAK pores could facilitate its release. I found that the release 
of mtDNA during senescence is dependent on the ability for fibroblasts to form BAX and BAK 
pores as when I removed these proteins using the CRISPR CAS9 system the amount of mtDNA 
present in the cytosol was reduced. Conversely, inhibition of the MPTP using Cyclosporin A 
did not prevent mtDNA release. In agreement with our data two published studies have 
demonstrated that BAX and BAK form macropores which can facilitate this release in the 
context of apoptosis. Furthermore, they also found that cells which were deficient for 
cyclophilin D (a key component of the MPTP and target of Cyclosporin A) still released 
mtDNA (McArthur et al., 2018; Riley et al., 2018). In our study I did not assess the individual 
contribution of BAX and BAK to the release of mtDNA, however, the study by Riley et al 
indicates that individual knockout of BAX or BAK did not block mtDNA release, only when 
they were both removed was mtDNA release prevented (Riley et al., 2018). In the context of 
senescence it would be interesting to understand the individual contribution of BAX and BAK 
to mtDNA release, therefore, this is currently being investigated.  
With regards to senescence, it is widely acknowledged that senescent cells are resistant to a 
number of apoptotic stimuli (Wang, 1995; Chaturvedi et al., 1999; Chen et al., 2000; Yeo et 
al., 2000). This is in part due to the overexpression of pro-survival BCL-2 family proteins which 
are a senolytic target (Wang, 1995; Chen et al., 2000; Sanders et al., 2013; Chang et al., 2016). 
Chapter 3 – Mitochondrial pores BAX and BAK release mtDNA during senescence and 





Conventionally, pro-survival BCL-2 proteins maintain the pro-apoptotic proteins BAX and 
BAK in an inactive state by occupying their active sites (Tait and Green, 2010). Indeed, I 
observed upregulation of the anti-apoptotic protein BCL-2. As such it would be expected that 
BAX and BAK would exist in an inactive state and therefore it is a paradox that they are 
enabling the release of mtDNA. Characterisation of BAK and BAX. Revealed that total levels 
of BAK but not BAX were increased in senescence cells relative to overall mitochondrial 
content. When I assessed the cellular location of BAK I found as expected that it was solely 
located in the mitochondrial fraction as published work indicates that it remains anchored 
within the mitochondrial outer membrane both in both its active and inactive form (Ferrer et 
al., 2012). Although I observed increased levels of BAK in senescent cells, this only gives us 
information on the total amount of protein and does not allow us to determine whether it is in 
an active state or not.  
Interestingly, the distribution of BAX was different between proliferating and senescent cells. 
In proliferating cells BAX was found to exist almost entirely in the mitochondrial fraction, 
whereas in senescent cells BAX was evenly dispersed between the mitochondrial and cytosolic 
fraction. This finding was puzzling as these cells were in a healthy proliferating state and there 
was no evidence of apoptosis. The dynamic nature of BAX is still an area of intense research 
and not well understood. There is evidence that where BAX accumulates predominantly on the 
mitochondria it is generally in an inactive state (6A7 negative), however, whilst localised at the 
mitochondria it is primed ready for activation. This accumulation has been associated with low 
levels of pro-survival proteins, it was shown that the accumulation of mitochondrial BAX was 
reversed when pro-survival protein levels were increased (Schellenberg et al., 2013). This 
matches our observations of proliferating cells where the expression of BCL-2 was low and the 
proportion of mitochondrial BAX was vastly increased compared to cytosolic BAX. Where 
survival signals are higher, i.e. increased expression of BCL-2 as observed in senescent cells 
BAX is generally shuttled from the mitochondria to the cytosol. This process of retro-
translocation occurs continuously and matches our findings in senescent cells. Interestingly, a 
cells ability to alter the distribution of BAX has been associated with being able to alter the 
sensitivity to apoptosis and is referred to as apoptotic priming (Certo et al., 2006; Schellenberg 
et al., 2013). Cells where BAX is predominantly located on the mitochondria are more sensitive 
to apoptotic stimuli and readily undergo MOMP (Schellenberg et al., 2013). These findings 
suggest that senescent cells are more resistant to apoptotic stimuli than proliferating cells which 
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agrees with existing findings regarding senescent cells (Wang, 1995; Chaturvedi et al., 1999; 
Chen et al., 2000; Yeo et al., 2000; Chang et al., 2016).  
Furthermore, there is evidence that there are two distinct populations of mitochondrial BAX 
within cells; one population which is stably bound to mitochondria and maintained by BCL-
XL and a second population which is in a dynamic state between the cytosol and mitochondria 
(Llambi et al., 2011; Schellenberg et al., 2013). Furthermore, only a few hundred molecules of 
BAX per mitochondria are required to form a functional pore (Dussmann et al., 2010). 
Therefore it is possible that although senescent cells display a reduced proportion of 
mitochondrial BAX, these may in fact be active and contributing to mtDNA release. 
Corroborating with this notion, it has been identified that a sub-population of mitochondria can 
become permeabilised via BAX and BAK in the absence of cell death (Ichim et al., 2015).  
To address the idea that senescent cells may harbour an increased proportion of active 
mitochondrial BAX compared to proliferating cells I assessed the active BAX epitope 6A7 
which is exposed following its conformational change during its activation (Gavathiotis et al., 
2010). First, the total protein levels of BAX (6A7) were assessed via Western Blot in whole 
cell, mitochondrial and cytosolic extracts. Interestingly, the findings matched exactly those 
found for BAX when it was assessed earlier in the study. This was particularly unusual as it 
would not be expected that proliferating cells would display the 6A7 epitope which is indicative 
of BAX activation and initiation of the apoptotic process. Therefore it seems plausible to 
suggest that during sample preparation the protein denaturation step may lead to exposure of 
this epitope. As such, BAX (6A7) was also analysed via confocal microscopy using 
immunofluorescence. Here, it was found that the intensity of the staining was increased in 
senescent cells indicating that BAX (6A7) is more prevalent in senescent cells than proliferating 
cells. This conflicts with the Western Blot data, therefore it is difficult to draw direct 
conclusions on the state of BAX in senescent cells. However, taken together with the 
observations that both genetic removal and pharmacological inhibition of BAX and BAK 
prevent the release of mtDNA it seems clear that at least a small proportion of BAX and BAK 
must be constitutively active to enable the release of mtDNA. Further confidence could be 
gained in this finding by assessing the size of BAX (6A7) pores labelled by 
immunofluorescence. It is known that an individual mtDNA nucleoids is approximately 100nm 
in size, therefore using super-resolution microscopy to determine the number of BAX (6A7) 
pores over 100nm in proliferating and senescent cells may shed light on the presence of BAX 
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and BAK macropores which could facilitate its release. Furthermore, it is unknown at what 
stage following the induction of senescence that mtDNA is released. Live-cell imaging 
experiments in cells expressing fluorescent proteins on the mitochondria, TFAM and BAX 
(6A7) would provide a useful insight to determine the point at which mtDNA is released during 
senescence. 
Interestingly, both the genetic knockout and pharmacological inhibition of BAX and BAK lead 
to a reduction in the presence of cytosolic mtDNA, furthermore this was associated with a 
reduced secretion of SASP factors. I assessed the SASP by ELISA and cytokine array in BAX 
and BAK deficient cells, I found that a number of the key SASP constituents (IL-6, IL-8, IP-
10, MCP-3, Gro-α and VEGF-A) were downregulated when cells were unable to form BAX 
and BAK pores. These findings suggest that mtDNA is associated with regulation of the SASP.  
I also explored the role of other mitochondrial pores in the regulation of the SASP. The MPTP 
is crucial for maintaining mitochondrial homeostasis allowing the release of calcium and ROS 
following transient opening. When it is permanently open it facilitates the apoptotic process 
(Panel et al., 2018). Interestingly, the sensitivity of this pore to opening has been shown to 
increase with age (Hepple, 2016). I and others have found that mitochondria are depolarised 
during senescence indicating that this pore is open to an extent, furthermore, it has been shown 
that calcium accumulates in the mitochondria of senescent cells as a consequence of alterations 
in the opening of the MPTP (Nicholls, 2004; Passos et al., 2007; Wiel et al., 2014). In the 
literature, studies investigating the pro-inflammatory effects of mtDNA have demonstrated that 
mtDNA fragments can escape via the MPTP and the associated inflammation can be prevented 
by blocking the MPTP using Cyclosporin A (Patrushev et al., 2004; Nakahira et al., 2011). 
Together, these observations warrant investigating the role of the MPTP in contributing to 
mtDNA release during senescence. 
I found that inhibition of the MPTP using Cyclosporin A did not prevent the release of the 
mtDNA and subsequently I did not observe a decrease in the SASP. In fact, Cyclosporin A lead 
to an increase in the secretion of IL-6, IL-8 and IP-10 during senescence. This seems conflicting 
as Cyclosporin A is used routinely in the clinic as an immunosuppressive agent for the 
recipients of organ transplants (Faulds et al., 1993). However, it is recognised that sustained 
exposure to Cyclosporin A promotes nephrotoxicity. Furthermore, it has been demonstrated in 
renal tubular epithelial cells that Cyclosporin A promotes exacerbated production of H2O2. This 
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induced DNA damage which led to an upregulation of the p53-p21 axis and consequently 
induction of stress-induced senescence (Jennings et al., 2007). Therefore, it is plausible that in 
our scenario Cyclosporin A is elevating the SASP by exacerbating the DDR through increased 
production of ROS. This leads to the activation of ATM and ATR as part of the DDR, it is 
known that during senescence they are responsible for the stabilisation of the transcription 
factor GATA binding protein 4 (GATA4). GATA4 is an upstream regulator of NF-κB, a master 
regulator of the SASP (Chien et al., 2011; Kang et al., 2015). Alternatively, blockage of the 
MPTP could be leading to intracellular calcium accumulation. This could in turn promote 
activation of the protease calpain, which leads to proteolytic cleavage of IL-1α and the 
subsequent upregulation of cytokines associated with the SASP such as IL-6 and IL-8 
(McCarthy et al., 2013; Wiel et al., 2014).    
Although not entirely clear, it is known that the MPTP is made up of a number of subunits, 
specifically; cyclophilin D, ANT and VDAC. (Briston et al., 2017). Following the inhibition of 
cyclophilin D by Cyclosporin A, I further tested the inhibition of the MPTP by targeting ANT 
using Bongkrekic acid and VDAC using Olesoxime. Similarly, I found that neither inhibition 
of ANT or VDAC promoted a reduction in secretion of the SASP. Although I found that 
inhibition of cyclophilin D did not prevent mtDNA release, I did not test whether inhibition of 
ANT and VDAC impacted on the release of mtDNA. 
Together, these data implicate that the MPTP is not responsible for mtDNA release during 
senescence, furthermore, blockade of the MPTP using pharmacological inhibitors does not lead 
to a reduction in the secretion of pro-inflammatory factors. Earlier I observed that senescent 
cells display cytosolic mtDNA, in addition, the transfection of mtDNA into fibroblasts 
promoted a profound pro-inflammatory response, as measured by the secretion of IL-6 and IL-
8. Supporting these findings I established that when mtDNA release was prevented either by 
genetic knockout or pharmacological inhibition of BAX and BAK, there was a substantial 
decrease in secretion of the SASP. Collectively, these observations provide strong evidence that 
mtDNA is mediating the link between mitochondria and regulation of the SASP in senescence. 
The mechanistic basis concerning how mtDNA promotes this inflammatory response is 
explored and discussed later in this study.   
It is important to consider that mtDNA is not the sole candidate that can act as a mitochondrial 
DAMP. In fact, it is recognised that cytochrome C, N-formyl peptide, succinate, cardiolipin and 
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ATP are all of mitochondrial origin and can induce a pro-inflammatory response if they escape 
from the confines of the mitochondria to the cytosol (Grazioli and Pugin, 2018). I investigate 
and discuss the role of cytochrome C later in this study. N-formyl peptide and succinate have 
not been extensively investigated in the context of senescence. Previously, cardiolipin (a 
glycerophospholipid located in the inner mitochondrial membrane) has been shown to 
accumulate in senescent cells, in addition to this, it has been shown that exposure of fibroblasts 
to cardiolipin leads to the induction of senescence (Arivazhagan et al., 2004; Wan et al., 2014). 
In this study the authors demonstrated that cardiolipin accumulates during senescence, however 
they did not investigate its sub-cellular location and measured only total protein. It is likely that 
their observation of cardiolipin accumulating in senescent cells occurs as a consequence of the 
increase in mitochondrial mass that is observed during senescence (Arivazhagan et al., 2004). 
Indeed, another study demonstrated that mitochondrial mass increases during senescence using 
nonyl acridine orange staining, it is known that nonyl acridine orange binds to cardiolipin, this 
therefore supports the idea that cardiolipin accumulates in senescence as a consequence of 
increased mitochondrial content (Passos et al., 2010). With regards to ATP, there is evidence 
that ATP levels are reduced during senescence as cells display a high AMP:ATP ratio, 
consistently, inhibition of ATP synthase or depletion of ATP induces senescence via a p53-
AMPK mediated mechanism (Wang et al., 2003; Zwerschke et al., 2003; Stockl et al., 2006; 
Jiang et al., 2013). It has recently been shown that the mitochondrial peptides MOTS-c 
(mitochondrial open reading frame of the 12S rRNA-c, which acts on AMPK) and humanin 
(activates the JAK/STAT pathway) are elevated in senescent cells, furthermore, exposure of 
senescent cells to these peptides enhances mitochondrial energetics and leads to an increase in 
the SASP (Kim et al., 2018). These observations warrant the investigation of further 
understanding of other mitochondrial DAMPS which could influence the SASP.  
I found that genetic removal of BAX and BAK could alleviate the SASP, but this did not prevent 
the cell cycle arrest from occurring following the induction of stress-induced senescence. I 
found that SA-β-Gal, p16, p21 and Ki67 were unchanged compared to senescent Empty Vector 
control cells. This suggests that the release of mtDNA via BAX and BAK pores regulate the 
SASP but not progression of the cell cycle. This complements the recent study which 
demonstrates that mitochondrial depletion removes the pro-inflammatory features of 
senescence (both at the protein and mRNA level) but does not prevent the growth arrest 
(Correia-Melo et al., 2016). The SASP (specifically IL-8) has been implicated in stabilising and 
Chapter 3 – Mitochondrial pores BAX and BAK release mtDNA during senescence and 





reinforcing the senescence phenotype via its autocrine effects (Acosta et al., 2008; Passos et 
al., 2010). It was therefore postulated that BAX and BAK deficient cells which display a 
dramatically ameliorated SASP may not completely undergo the cell cycle arrest. However, the 
growth arrest that occurs in senescence is also associated with the DDR. It has been 
demonstrated that mitochondria can drive the DDR by producing ROS which induce short-lived 
foci and maintain it until a stable growth arrest occurs through p21 and p53 (Passos et al., 2010; 
Luo et al., 2011). In BAX and BAK deficient cells I found that the production of mitochondrial 
derived ROS (MitoSOX) and induction of DNA damage (measured by γH2AX) were 
unaffected compared to senescent Empty Vector control cells. These findings suggest that the 
DDR is still being maintained by a mitochondrial ROS mediated feedback loop and as such the 
stable growth arrest is unaffected, therefore potentially explaining the growth arrest still 
occurring despite the SASP being reduced.  
Following our in vitro observations, I wanted to experimentally dissect the role of BAX and 
BAK in regulation of the SASP in vivo. It has been previously reported that following the 
induction of senescence using sub-lethal irradiation there is an upregulation  of the SASP related 
genes; IL-1α, IL-1β, IFN-α, IL-6, CXCL1, MMP3, IFN1α, OAS1 and inhibin A (Dou et al., 
2017; De Cecco et al., 2019). Therefore, we assessed whether mice harbouring BAX and BAK 
deleted livers displayed an altered SASP in liver tissue following irradiation compared to BAK-
/- mice. Following irradiation, we observed an enrichment for each of the target genes compared 
to non-irradiated BAK-/- mice, however, none of these were significant. Of further interest, 
following irradiation we did not observe an increase for any of the target genes in mice with 
BAXfl/BAK-/- deleted livers. For the genes IL-1α, IL-1β, OAS1 and p16 there was a significant 
decrease in irradiated BAXfl/BAK-/- mice compared to irradiated BAK-/- mice. Within this 
experiment the n numbers were relatively small with only 5 mice per group. Collectively, there 
is evidence for a clear trend of SASP genes being upregulated in BAK-/- but not BAXfl/BAK-
/- mice following irradiation, this corroborates our in vitro data where removal of BAX and 
BAK impairs the SASP. To confidently clarify this relationship an increase in the n numbers 
per group are required to increase the statistical power. Also, it is interesting that neither p16 
nor p21 were upregulated in BAXfl/BAK-/- mice following irradiation as in vitro I demonstrated 
that BAX/BAK deficient cells still underwent the cell cycle arrest and had observable 
upregulation of both p16 and p21. This highlights the need for further investigation using a 
larger sample size and the analysis of other genes associated with regulation of the cell cycle. 
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A further limitation to the in vivo data is the use of a BAK-/- mouse as the control rather than a 
wild-type control. This study has not dissected the relative role of BAX and BAK individually 
in vitro. However, published data suggests that the deletion of both BAX and BAK together is 
required to prevent mtDNA release as individual knockout of BAX or BAK still leads to 
mtDNA release (McArthur et al., 2018; Riley et al., 2018). This agrees with the in vivo data 
which has shown that BAK-/- mice have an increase in SASP-related genes following sub-
lethal irradiation but BAXfl/BAK-/- mice do not. However, in contrast to this it has been shown 
in this study that the BAX inhibitors BCB and BIPv5 can diminish the SASP in vitro. This 
therefore questions whether BAX may be more important than BAK in facilitating mtDNA 
release. Alternatively, it may be that these inhibitors are not specific to BAX and may also 
inhibit BAK. This therefore needs to be tested comprehensively. In addition, further work is 
required to elucidate the exact contribution of BAX and BAK individually to mtDNA release.  
Together these observations highlight the potential of targeting mitochondrial BAX and BAK 
as a senostatic therapy. Senostatic therapies are beneficial as they maintain the beneficial 
tumour suppressive role of senescent cells and potentially do not disrupt tissue architecture by 
preserving senescent cells. The SASP has also been associated with the induction of senescence 
in neighbouring cells; this process is referred to as paracrine senescence (Nelson et al., 2012; 
Acosta et al., 2013). It is postulated that the induction of paracrine senescence could be a 
potential mechanism which explains the accumulation of senescent cells and inflammation with 
age. With that in mind, there is significant clinical interest in finding strategies to remove the 
chronic inflammation that is associated with the presence of senescent cells that occur with age 
and for the first time this study demonstrates that pharmacological targeting of BAX and BAK 
can alleviate the SASP (Birch and Passos, 2017). However, it is important to consider that the 
SASP also plays a role in signalling to the immune system for senescent cell clearance (Kang 
et al., 2011b; Munoz-Espin et al., 2013; Brighton et al., 2017; Egashira et al., 2017). If this 
signal is supressed by senostatic therapies then this may further contribute to the accumulation 
of senescent cells. To address this caveat, there is evidence that immune system function 
declines with age, furthermore, it has recently been reported that the accumulation of senescent 
cells occurs due to a compromised immune capacity associated with advancing age (Montecino-
Rodriguez et al., 2013; Ovadya et al., 2018).  
The role of BAX and BAK has not been previously investigated in senescence and regulation 
of the SASP. The observation that both of the pharmacological inhibitors BIPv5 and BCB 
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promote an alleviation of the SASP without impacting upon the cell cycle arrests is of clear 
clinical interest. At this stage it remains to be seen whether these findings will translate and 
have beneficial effects within aged organism. However, there is some evidence within the field 
that BAX and BAK inhibitors may be clinically useful. It has been established that senescent 
cells are present in idiopathic pulmonary fibrosis disease and correlate with disease severity. 
Furthermore, the removal of senescent cells either genetically (INK-ATTAC mouse) or 
pharmacologically (dasatanib and quercetin) improves pulmonary function and physical health 
in a bleomycin-injury idiopathic pulmonary fibrosis model (Schafer et al., 2017). Not only do 
senescent cells alleviate aspects of idiopathic pulmonary fibrosis but there is also evidence that 
extracellular mtDNA is increased in both plasma and bronchoalveolar lavage acquired from 
patients with idiopathic pulmonary fibrosis. Additionally, the authors demonstrated that the 
concentration of mtDNA correlated with disease mortality (Ryu et al., 2017). Interestingly, in 
pulmonary fibrosis BAX has been implicated with driving inflammation through TGF-β and 
matrix metalloproteinases (Kang et al., 2007). TGF-β has been implicated as an inducer of 
senescence and the secretion of matrix metalloproteinases are upregulated as part of the SASP 
(Coppe et al., 2010; Senturk et al., 2010; Wu et al., 2014). It was demonstrated that BAX 
knockout mice and mice treated with the BIPv5 inhibitor display attenuation of bleomycin-
induced lung injury as measured by degree of injury and overall survival (Kang et al., 2007; 
Suzuki et al., 2017). Considering that both the removal of senescent cells and the inhibition of 
BAX have beneficial effects, it seems plausible to hypothesise that in this scenario senescent 
cells are aggravating pulmonary fibrosis as a consequence of BAX and BAK mediated release 
of mtDNA driving inflammation.   
Despite these potential benefits, caution would certainly be required as BAX and BAK are 
crucial for engagement of the apoptosis process. Naturally, if apoptosis is inhibited then the 
chances of tumorigenic transformation occurring are exacerbated.   
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4. Chapter 4: Limited mitochondrial permeabilisation contributes to 
mtDNA release and the DDR via sub-lethal caspase activity 
 
Recent work has unveiled a previously unknown phenomenon referred to as limited 
mitochondrial permeabilisation or miMOMP. Specifically, miMOMP is a process whereby a 
small sub-set of mitochondria experience outer membrane permeabilisation which facilitates 
the release of cytochrome C via BAX and BAK pores. This release is insufficient to induce cell 
death, however it promotes DNA damage through sub-lethal activation of caspases 3 and 7 
(Ichim et al., 2015).  
Senescent cells have been shown to have dysfunctional mitochondria (Passos et al. 2007, 2010) 
and a persistent DDR (Rodier 2009; Passos et al. 2010; Hewitt et al. 2012). Additionally, 
mitochondria have been proposed to contribute to the DDR mostly via the generation of ROS 
(Passos et al. 2010).  However, the relationship between the DDR and miMOMP during 
senescence is not understood. 
Furthermore, I have observed that mitochondria release mtDNA to the cytosol, a process which 
is dependent on the presence of BAX and BAK pores (see chapter 3). Therefore it is of 
significant interest to investigate whether these phenotypes may in fact be occurring as a 
consequence of miMOMP.  
Firstly, I investigated whether mitochondria in senescent cells displayed miMOMP. Secondly, 
I aimed to investigate whether miMOMP could be a driver of senescence and the mechanisms 
involved. Finally, as miMOMP promotes the sub-lethal activation of caspases I dissected the 
role of caspases in the induction of the senescence phenotype.  
 
4.1. Senescent cells display reduced colocalisation of Cytochrome C and TOM20 
In order to investigate mitochondrial outer membrane permeabilisation in senescent cells 
immunostained fixed cells with antibodies against cytochrome C (a small protein loosely 
associated with the mitochondrial inner membrane) and TOM20 (an outer mitochondrial 
membrane protein). Then, I performed confocal 3D imaging of the cells, followed by rendering 
and processing of the images to statistically measure the extent of cytochrome C and TOM20 
colocalisation. A reduced colocalisation was indicative of mitochondrial permeabilisation. 
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Using this methodology, I first determined the co-localisation between cytochrome C and 
TOM20 in proliferating, stress-induced senescent cells and replicatively senescent cells. I noted 
that while in proliferating cells most TOM20 co-localized with cytochrome C, in senescent cells 
I observed some discrete areas which were positive for TOM20 but negative for cytochrome c. 
Representative images of rendered 3D images are shown in Figure 4.1A where mitochondria 
are represented in red and cytochrome C in green, where the two colocalise the overlap is 
displayed in orange.  
In order to quantitatively evaluate the level of co-localisation between TOM20 and cytochrome 
C I performed the Pearson Correlation Coefficient statistical test. I found that both stress-
induced senescent cells and replicatively senescent cells displayed a reduced level of co-
localisation between TOM20 and cytochrome C compared to proliferating cells (p<0.0001 for 
both, Figures 4.1A and B). I found that stress-induced senescent cells displayed a 37% decrease 
in co-localisation and replicatively senescent cells displayed a 15% reduction in co-localisation 
compared to proliferating cells (p<0.0001 and <0.05 respectively, Figures 4.1A and C). 
Interestingly, cytochrome C was visible in the cytosol of senescent cells (see Figure 4.1A). To 
further explore if cytochrome C is present in the cytosol of senescent cells, I conducted 
fractionation of the cytosol and mitochondria followed by Western blotting to detect 
cytochrome C. Western Blotting revealed that compared to proliferating cells there was a 4-
fold increase in the levels of cytosolic cytochrome C in stress-induced senescent cells 
(p=0.0238, Figures 4.1D and E), and a 3-fold increase in replicatively senescent cells 
(p=0.0441, Figure 4.1E).  
Finally, it has been published that miMOMP promotes genomic DNA damage through sub-
lethal caspase activity (Ichim et al., 2015). In order to assess this, I used Western Blotting to 
characterise the levels of cleaved caspase 3 by measuring the presence of its cleaved 
counterparts detectable at 17 and 19kDa (Figure 4.1F). In senescent cells there was a significant 
enrichment in the presence of both bands compared to proliferating cells (p=0.0104 and 0.0240 
for 17 and 19kDa respectively, Figures 4.1G and H). 
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Figure 4.1 – Senescent cells display reduced colocalisation of cytochrome C and TOM20. 
Proliferating, stress-induced senescent (analysed 10 day’s post 20Gy x-ray irradiation) and 
replicatively senescent MRC5 cells were analysed for colocalisation of cytochrome C and 
Tom20 using confocal microscopy and the presence of cytosolic cytochrome C by Western 
Blotting. (A) Representative images of a proliferating and replicatively senescent cells labelled 
using DAPI (blue), TOM20 (red) and cytochrome C (green). Colocalisation of TOM20 and 
cytochrome C is displayed in orange. Images acquired in z-stacks by confocal microscopy using 
a 63x objective, following acquisition, the images were rendered using Huygens Deconvolution 
Software and colocalisation was measured using the Pearson Correlation Coefficient. White 
arrows in the enlarged image highlight cytosolic cytochrome C (B) Dot plot represents the 
statistical analysis of colocalisation of cytochrome C and TOM20 using the Pearson Correlation 
Coefficient where 1.0 is perfect colocalisation between the two channels. Each dot represents 
an individual cell. (C) Bar graph represents the Pearson Correlation Coefficient for proliferating 
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(white bar) and senescent cells (red bars) expressed as a percentage of the control. n=3 
independent experiments. (D) Representative Western Blot image of UQCRC2, Cytochrome C 
and β-Actin in mitochondrial and cytosolic extracts taken from proliferating and stress-induced 
senescent cells. (E) Bar graph represents quantification of cytosolic cytochrome C expressed 
as fold-change compared to the control for proliferating (white bar) and senescent cells (red 
bars). For stress induced senescent cells n=6 and for replicatively induced senescent cells n=3 
independent experiments. (F) Representative Western Blot image of Cleaved Caspase 3 and β-
Actin in proliferating and stress-induced senescent cells. (G and H) Bar graph shows the fold 
change in protein levels of cleaved caspase 3 19kDa (G) and 17kDa (H) in proliferating (white 
bars) and senescent cells (red bars), n=4 independent experiments. Bar graphs represent mean 
+SEM, statistical analysis performed using a One-way ANOVA for (B, C and E). For (G and 
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4.2. Pharmacological induction of miMOMP promotes a senescence-like response 
miMOMP can be promoted by low doses of the BH3 mimetic ABT737 (Ichim et al., 2015). 
ABT737 inhibits the pro-survival proteins BCL-2 and BCL-XL which are normally bound to 
BAX and BAK proteins which prevents them from forming pores. Furthermore, it was 
demonstrated that treatment with ABT737 induced miMOMP, which was associated with 
cytochrome C release and subsequent caspase-mediated DNA damage. Specifically, caspase 3, 
7 and 9 were found to be active at sub-lethal levels during miMOMP, which was associated 
with activation of CAD (caspase-activated DNase) which is responsible for DNA fragmentation 
during the apoptotic process (Ichim et al., 2015). The mechanism of action of ABT737 is 
highlighted in Figure 4.2A.  
First, it was important to verify that ABT737 was inducing miMOMP. To test this, I measured 
co-localization between cytochrome C and TOM20. It was found that treatment with ABT737 
(2.5µM) for 48 hours promoted a significantly reduced level of co-localisation between 
cytochrome C and TOM20 in individual cells as measured using the Pearson Correlation 
Coefficient (p<0.0001, Figure 4.2B). Furthermore, when colocalisation was expressed as a 
percentage of control it was observed that there was a 12% decrease in the level of 
colocalisation (p=0.0128, Figure 4.2C).  
Following the confirmation that ABT737 was inducing permeabilisation of mitochondria in the 
absence of cell death, I investigated whether this was associated with caspase 3 activity and 
subsequent DNA damage. The Western Blot image in Figure 4.2D indicates that control cells 
display no cleavage of caspase 3, however when treated with ABT737 for 48 hours there is 
visible cleavage of caspase 3. As such, I questioned whether this caspase 3 activity was 
associated with the induction of DNA damage. To dissect this relationship, cells were treated 
with ABT737 alone, and another cohort were treated with ABT737 in the presence of the broad 
spectrum caspase inhibitor QVD to determine whether caspase activity was contributing to the 
DDR.  
Following treatment with ABT737 there was a significant increase in the mean number of 
γH2AX foci (p<0.001) which was suppressed by QVD (p<0.001, Figure 4.2E). It is well 
established that in the context of senescence that mitochondrial ROS can promote a DDR 
(Passos et al., 2010). Furthermore, caspase dependent disruption of mitochondrial function 
through cleavage of the respiratory complex I protein, NDUFS1, has been shown to generate 
ROS following MOMP (Ricci et al., 2004). Therefore, it is possible that miMOMP may 
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contribute to mitochondrial ROS and the DDR. In order to test the involvement of ROS in 
miMOMP induced DDR, I measured mitochondrial-derived ROS using the ROS-indicator dye 
MitoSOX by flow cytometry. I found that both treatment with ABT737 or ABT7373+ QVD 
had no effect on MitoSOX fluorescence levels, supporting the concept that ROS is not involved 
in the process (Figure 4.2F).   
 
Figure 4.2 – ABT737 induces miMOMP. 
Proliferating MRC5 cells were treated with either DMSO (control), ABT737 (2.5µM) or 
ABT737 (2.5 µM) + QVD (1µM) for 48 hours. (A) Schematic outlining the mechanism of 
action by which ABT737 induces miMOMP. (B) Dot plot represents the statistical analysis of 
colocalisation of cytochrome C and TOM20 using the Pearson Correlation Coefficient where 
1.0 is perfect colocalisation between the two channels. Each dot represents an individual cell. 
(C) Bar graph represents the Pearson Correlation Coefficient for proliferating (white bar) and 
ABT737 treated cells (pink bars) expressed as a percentage of the control. n=3 independent 
experiments. (D) Representative Western Blot image of Cleaved Caspase 3 and β-Actin in 
control proliferating cells and ABT737 treated cells.  (E) Bar graph represents the quantification 
of the mean number of γH2AX foci in control, ABT737 and ABT737 + QVD treated cells. (F) 
Bar graph represents the fold change in MitoSOX fluorescence as measured by flow cytometry 
in control, ABT737 and ABT737 + QVD treated cells, n=3 independent experiments. Bar 
graphs represent mean +SEM, statistical analysis performed using an unpaired two tailed t-test 
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Following the observation that ABT737 can induce miMOMP and a subsequent DNA damage 
response I aimed to test whether prolonged treatment with ABT737 would result in a senescent 
arrest. It has previously been published that ABT737 can induce senescence in apoptosis-
resistant cancer cell lines (Song et al., 2011). Conversely, it has also been demonstrated that 
ABT737 is a senolytic agent and can in fact promote apoptosis in senescent cells which 
overexpress pro-survival BCL-2 proteins (Yosef et al., 2016b). Following the continued 
exposure of MRC5 human fibroblasts to ABT737 for 9 days I observed that that there was a 
detectable increase in the number of SA-β-Gal positive cells (approximately 10%) compared to 
the control group (3% positive) (p<0.0001, Figures 4.3A, B). As it is known that ABT737 
induces miMOMP and subsequent caspase-mediated DNA damage it was of interest to assess 
whether the increase in SA-β-Gal was dependent on caspase-mediated DNA damage. 
Interestingly, I found that cells co-treated with ABT737 and QVD for 9 days displayed a 
reduction in the number of SA-β-Gal positive cells compared to those treated with ABT737 
alone (p<0.001, Figures 4.3A, B). Cells were continually cultured in the presence of ABT737 
for 23 days and it was found that there was an increase to approximately 10% of cells positive 
for SA-β-Gal (p<0.0001), however there was no further increase compared to the 9 day time 
point. Similarly, co-treatment with ABT737 and QVD prevented the increase in the number of 
SA-β-Gal induced by ABT737 alone (p<0.05, Figure 4.3B). 
As it was hypothesised that ABT737 drives its effects through caspase-mediated DNA damage 
I wanted to verify that levels of DNA damage were increased at each time point by ABT737. 
Following 9 days of culture with ABT737 I observed a significant increase in the mean number 
of γ-H2AX foci (1.8 to 3.2 per cell on average, p<0.05) which was reversed following co-
treatment with QVD (p<0.05, Figure 4.3C). At 23 days, again there was a detectable increase 
following treatment with ABT737 compared to the controls (p<0001) which was dependent on 
caspase activity as it was prevented following co-treatment with QVD (p<0.001, Figure 4C). 
At 23 days the baseline level of γH2AX foci was slightly higher in the control group compared 
to the 9 day controls (3.2 compared to 1.9), however this was non-significant. Similarly, 
treatment with ABT737 was slightly higher following 23 days of treatment compared to 9 days 
(4.4 compared to 3.2), however this was non-significant (Figure 4.3C). 
Next I wanted to assess whether sustained exposure to ABT737 would provoke a SASP. 
Therefore IL-6 and IL-8 were measured following treatment for 9 and 23 days. At the 9 day 
time point ABT737 there was no increase in the secretion of IL-6, there was a small increase in 
IL-8 although this was no significant. At the 23 day time point there was a highly significant 
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increase in the secretion of both IL-6 and IL-8 (p<0.0001 in both cases), the increase in both 
IL-6 and IL-8 was dependent on caspase activity as co-treatment with QVD lead to a 
significantly decreased secretion of IL-6 and IL-8 (p<0.0001 in both cases, Figures 4.3D and 
E).  
As senescence is associated with an up-regulation of cell cycle inhibitors, expression of the key 
senescence mediators p16 and p21 were assessed following treatment with ABT737 alone and 
in conjunction with QVD. At 9 days, there was a small increase in the percentage of p16 positive 
cells following treatment with ABT737 (16% to 21% of cells p16 positive), however this was 
not significant. Similarly co-treatment with QVD had no effect on the percentage of cells 
positive for p16 (Figure 4.3F). Next p21 was assessed, it was found that there was a significant 
increase in the percentage of p21 positive cells following ABT737 treatment (p<0.05, 31% to 
40%), which was prevented following co-treatment with QVD (p<0.05, 40% to 32%, Figure 
4.3G).  
Our data shows that induction of miMOMP can induce various senescent markers such as a 
DDR, increased expression of p21, SA-b-GAL and secretion of SASP components IL-6 and 
IL-8 in a caspase-dependent manner. However, the effects of ABT-737 on markers of the 
senescence arrest are considerably milder than its effects on the secretion of SASP components 
which are comparable to the ones found in stress-induced and replicatively senescent cells. 
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Figure 4.3 – Sustained exposure to ABT737 induces a pro-inflammatory response and a 
low level of induction of the growth arrest pathways. 
MRC5 fibroblasts were maintained with either DMSO (control group), ABT737 (2.5µM 
dissolved in DMSO) or ABT737 + QVD (2.5µM and 1µM dissolved in DMSO) for 9 days or 
23 days and then analysed for markers of senescence. (A) Representative images of SA-β-Gal 
for the control group, ABT737 alone and ABT737 + QVD after 9 days of treatment. White 
arrows denote positive SA-β-Gal staining. (B) Bar graph shows quantification of the percentage 
of SA-β-Gal positive cells following treatment with either DMSO, ABT737 or ABT737 + QVD 
for 9 days (white bars) and 23 days (blue bars), n=4 independent experiments. (C) Bar graph 
shows quantification of the mean number of γH2AX foci per cell following treatment with 
either DMSO, ABT737 or ABT737 + QVD for 9 days (white bars) and 23 days (blue bars), 
n=4 independent experiments. (D and E) Bar graphs show the secretion of IL-6 (D) and IL-8 
(E) following treatment with either DMSO, ABT737 or ABT737 + QVD for 9 days (white bars) 
and 23 days (blue bars), n=3 independent experiments. (F and G) Bar graphs show the 
quantification of the percentage of p16 (F) and p21 (G) positive cells following treatment with 
either DMSO, ABT737 or ABT737 + QVD for 9 days, n=5 independent experiments. Bar 
graphs represent mean +SEM, statistical analysis performed using a One-way ANOVA. 
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4.3. miMOMP promotes mtDNA release 
Earlier it was observed that treatment of cells with ABT737 could promote a senescent-like 
phenotype which was associated with the secretion of IL-6 and IL-8. Whilst investigating 
caspase-independent apoptosis it has been reported that treatment of cells with high doses of 
ABT737 promotes mtDNA release and associated inflammation (McArthur et al., 2018; Riley 
et al., 2018). It was therefore questioned whether low doses of ABT737 which promote 
miMOMP could be associated with contributing to the release of mtDNA. To investigate this 
cells were maintained with ABT737 and assessed at the following time points for mtDNA 
release; 0, 2, 9 and 23 days. 
At 0 days the mean number of nucleoids visible outside of the mitochondrial network was low 
(0.04 per cell), this was non-significantly increased to 0.15 following 2 days of 2.5µM ABT737 
exposure, after 9 days there was 0.42 nucleoids visible per cell (p<0.0001 compared to the 0 
day time point), and after 23 days of treatment there was 0.60 nucleoids per cell (p<0.0001 
compared to the 0 day time point, Figures 4.4A and B).  
When assessed as the percentage of cells displaying cytosolic DNA, there were 2.8% of cells 
displaying nucleoids outside of the mitochondrial network at the 0 day time point. This was 
non-significantly increased to 12.1% of cells following 2 days of 2.5µM ABT737 exposure, 
after 9 days there was 28.5% of cells displaying cytosolic nucleoids (p<0.0001 compared to the 
0 day time point), and after 23 days of treatment there was 45.5% of cells with cytosolic 
nucleoids (p<0.0001 compared to the 0 day time point, Figures 4.4A and C).  
As it has been reported that high doses of ABT737 can promote mtDNA release via herniation 
of the inner membrane through BAX and BAK macropores, I assessed the effect of 20µM 
ABT737 on mtDNA release. Using immuno-gold labelling of DNA in conjunction with 
electron microscopy I observed that in untreated cells (0 hours) mtDNA was conserved within 
the inner mitochondrial membrane. Following ABT737 treatment, there were mitochondria 
which displayed evidence of mitochondrial blebbing, extrusion of the inner mitochondrial 
membrane and cytosolic mtDNA labelling (Figure 4.4D).  
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Figure 4.4 – miMOMP promotes mtDNA release. 
Proliferating MRC5 human fibroblasts were maintained with either ABT737 (2.5µM) for 0 
days, 2 days, 9 days and 23 days and then assessed for leakage of mtDNA. (A) Representative 
images of ABT737 treated cells at 0 days and 23 days labelled for DAPI (blue), DNA (green) 
and TOM20 (red) taken using confocal microscopy on a 63x objective, white arrows in the 
enlarged images highlight mtDNA nucleoids located outside of the mitochondrial network. (B) 
Bar graph depicting quantification of the mean number of DNA nucleoids outside of the 
mitochondrial network in U20S cells treated with ABT737 for 0, 2, 9 and 23 days, n=3-4 
independent experiments. (C) Bar graph depicting the percentage of cells displaying DNA 
outside of the mitochondrial network in in cells treated with ABT737 for 0, 2, 9 and 23 days, 
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n=3-4 independent experiments. (D) Representative electron microscopy images of untreated 
and 20µM ABT737 treated (90mins) U20S cells labelled for DNA using a 10µm gold-
conjugated secondary antibody. Bar graphs represent mean +SEM, statistical analysis 
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4.4. miMOMP is dependent on BAX and BAK 
It has been reported by Ichim et al that damage associated with miMOMP is dependent on the 
presence of BAX and BAK pores to facilitate cytochrome c release (Ichim et al., 2015). As 
such, it was of interest to determine whether BAX and BAK deficient cells displayed a reduced 
colocalisation of cytochrome C and TOM20 following the development of senescence. 
Therefore the assay developed in Figure 4.1 was employed to assess miMOMP in proliferating 
and stress-induced senescent cells following CRISPR/CAS9 mediated deletion of BAX and 
BAK as shown in Figure 4.5A.  
The level of colocalisation for individual cells was measured using the Pearson Correlation 
Coefficient statistical test, there was no statistical difference between proliferating Empty 
Vector and BAX/BAK deficient cells (0.81 vs 0.85). It was found that stress-induced senescent 
Empty Vector cells displayed a reduced level of colocalisation compared to proliferating Empty 
Vector cells (0.67 vs 0.81 respectively, p<0.001 in both cases). Senescent BAX/BAK deficient 
cells did not display a reduced level of colocalisation compared to proliferating BAX/BAK 
deficient cells (0.85 vs 0.81, Figures 4.5A and B). Similarly, when expressed as a percentage 
of the control, it was found that Empty Vector senescent cells were significantly reduced 
compared to their proliferating counterparts (87% vs 100%, p<0.001), whereas, senescent 
BAX/BAK deficient cells did not display a reduced level of co-localisation (95%, Figure 4.5C).  
Earlier it was observed that treatment of MRC5 fibroblasts with ABT737 (2.5µM) for 9 and 23 
days promoted the secretion of IL-6 and IL-8. Therefore, I wanted to assess whether BAX/BAK 
deficient cells would secrete IL-6 and IL-8 in response to ABT737 treatment (Figure 4.5D and 
E). Treatment of Empty Vector cells led to a significant increase in both IL-6 and IL-8 (p<0.001 
in both cases). Treatment of BAX/BAK deficient cells led to a significant increase in both IL-
6 and IL-8 (p<0.01 in both cases). Empty Vector cells treated with ABT737 had an increased 
secretion of IL-6 compared to BAX and BAK deficient cells treated with ABT737 (160 vs 95 
pg/ml, p<0.01, Figure 4.5D). Similarly, Empty Vector cells treated with ABT737 had an 
increased secretion of IL-8 compared to BAX and BAK deficient cells treated with ABT737 
(486 vs 329 pg/ml, p<0.05, Figure 4.5E). 
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Figure 4.5 – miMOMP is dependent on BAX and BAK. 
Proliferating and stress-induced senescent cells (Empty Vector and BAX/BAK deficient cells) 
were analysed for colocalisation of cytochrome C and Tom20 using confocal microscopy. (A) 
Chapter 4 – Limited mitochondrial permeabilisation contributes to mtDNA release and the 




Representative images of a proliferating and stress-induced senescent cells labelled using DAPI 
(blue), TOM20 (red) and cytochrome C (green). Images acquired in z-stacks by confocal 
microscopy using a 63x objective, following acquisition, the images were rendered using 
Huygens Deconvolution Software and colocalisation was measured using the Pearson 
Correlation Coefficient. White arrows in the enlarged image highlight cytosolic cytochrome C 
(B) Dot plot represents the statistical analysis of colocalisation of cytochrome C and TOM20 
using the Pearson Correlation Coefficient where 1.0 is perfect colocalisation between the two 
channels. Each dot represents an individual cell from 3 independent experiments. (C and D) 
Bar graphs show the secretion of IL-6 (C) and IL-8 (D) following treatment with either DMSO 
or ABT737 for 9 days, n=3 independent experiments. Bar graphs represent mean +SEM, 
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4.5. Caspases have a role in regulating the SASP and DDR 
It was observed that ABT737 can induce a senescence-like phenotype which could in part be 
ameliorated by caspase inhibitors. This observation therefore led me to question whether 
caspases have a role in regulating different aspects of the senescent phenotype. Published work 
on the role of caspases in senescence has mostly focused on the role of caspase 1 activating the 
NLRP3 inflammasome as part of the SASP in OIS (Acosta et al., 2013). Recent work has also 
highlighted the requirement of caspase 5 for activation of the IL-1α arm of the SASP following 
inflammasome activation, furthermore, caspase 11 was demonstrated to be a requirement for 
SASP-driven immune surveillance of senescent cells in vivo (Wiggins et al., 2019). 
As such I used the broad scale caspase inhibitor QVD in human senescent fibroblasts induced 
by both X-ray irradiation and replicative exhaustion. Consistently with previous observation, I 
found that following the development of the senescence phenotype in both models there was a 
robust increase in the secretion of IL-6 and IL-8 compared to the proliferating controls (<0.0001 
in each case, Figures 4.6A and B). Following the induction of stress-induced senescence, cells 
were maintained with QVD to inhibit caspase activity whilst the senescence phenotype 
developed (10 days). I observed that both IL-6 and IL-8 were decreased following treatment 
with QVD compared to the untreated stress-induced senescent cells (p<0.05 for IL-6 and <0.001 
for IL-8, Figures 4.6A and B). Replicatively senescent cells were maintained with the caspase 
inhibitor for 10 days following replicative exhaustion. It was found that when treated with QVD 
there was a significant decrease in the secretion of both IL-6 and IL-8 (p<0.001 for IL-6 and 
<0.0001 for IL-8, Figures 4.6A and B).  
Earlier it was observed that ABT737 provokes sub-lethal caspase activity which drives a DDR. 
Senescent cells are characterized by a persistent DDR which is thought to contribute to the 
stabilization of the senescent phenotype (Rodier et al., 2009; Passos et al., 2010). However, the 
role of caspases in this process is not known. To test this I inhibited caspase activity in both 
stress-induced senescent cells and replicative cells using QVD and then assessed γH2AX. I 
found that both models of senescence displayed an enhanced mean number of γH2AX foci 
compared to the proliferating control cells (p<0.001 for stress induced senescence and p<0.0001 
for replicative senescence) which was significantly decreased by treatment with QVD (p<0.05 
for stress induced and p<0.0001 for replicatively senescence cells, Figure 4.6C).    
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Figure 4.6 – Caspases mediate the SASP and DDR during senescence. 
Proliferating and senescent cells (stress-induced and replicatively exhausted cells) were treated 
with the caspase inhibitor QVD (1µM) for 10 days or a DMSO control and then assessed for 
secretion of IL-6, IL-8 and the formation of DNA damage foci via γH2AX. (A and B) The bar 
graphs show the secretion of IL-6 (A) and IL-8 (B) in proliferating, stress-induced (red bars) 
and replicatively senescent cells (blue bars) treated with either QVD or the DMSO control. (C) 
The bar graph shows the mean number of γH2AX foci per cell in proliferating, stress-induced 
(red bars) and replicatively senescent cells (blue bars) treated with either QVD or the DMSO 
control. Bar graphs represent mean +SEM for 5 independent experiments, statistical analysis 
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4.6. Caspase inhibition does not rescue the cell-cycle arrest characteristic of senescent 
cells 
In order to comprehensively characterise the role of caspases in the senescence phenotype I 
analysed markers associated with senescence and the cell cycle arrest. First, I assessed whether 
caspase inhibition had an impact on the number of cells which displayed SA-β-Gal positive 
staining. Compared to proliferating cells, both stress-induced and replicatively senescence cells 
displayed an increased percentage of cells positive for SA-β-Gal (p<0.0001 in both cases). 
However, when stress-induced and replicatively senescent cells were treated with QVD there 
was no effect on the number of cells that displayed SA-β-Gal positive staining (Figure 4.7A).  
As senescence is associated with a termination of the cell cycle, Ki67, a marker of proliferation, 
was analysed. I found that treatment with QVD did not impact on the frequency of KI67 positive 
cells in senescent cells. 
Proliferating cells were approximately 60% positive for Ki67, following the induction of 
senescence, this was significantly reduced to 15% in stress-induced senescence cells (p<0.0001) 
and 3% in replicatively senescent cells (p<0.0001). When senescent cells which had been 
treated with the caspase inhibitor QVD were analysed there was no restoration of the decrease 
in Ki67 positivity for either stress-induced or replicatively senescent cells. (Figure 4.7B).  
Next, the cyclin-dependent kinase inhibitors p16 and p21 were assessed. In proliferating cells, 
its expression was low with 15% of cells on average being positive for p16 and 23% for p21, 
following the induction of senescence, 56% and 94% of stress-induced senescent cells were 
positive for p16 and p21 respectively (p<0.0001 in both cases), replicatively senescent cells 
were 60% and 95% positive for p16 and p21 respectively (p<0.0001 in both cases). Treatment 
with QVD had no effect on the number of p16 or p21 positive cells in any of the groups; 
proliferating, stress-induced senescence and replicatively senescent cells (Figures 4.7C and D).  
Finally, I assessed for the presence of Lamin B1. Lamin B1 is a protein responsible for 
maintaining nuclear integrity and has been reported to be decreased following the onset of 
senescence (Freund et al., 2012). Therefore I wanted to assess whether caspase inhibition could 
prevent this loss. Using Western Blotting it was found that the protein Lamin B1 was present 
in proliferating cells and proliferating cells treated with QVD. It was not present in both stress-
induced senescence and replicative senescence. Treatment of senescent cells with QVD did not 
prevent the decrease in Lamin B1 (Figure 4.7E).   
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Figure 4.7 – Caspases do not have a role in regulation of the cell cycle arrest features of 
senescence or SA-β-Gal activity. 
Proliferating and senescent cells (stress-induced and replicatively exhausted cells) were treated 
with the caspase inhibitor QVD (1µM) for 10 days or a DMSO control and then assessed for 
markers of senescence. (A) The bar graph shows the percentage of cells positive for SA-β-Gal 
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in proliferating, stress-induced (red bars) and replicatively senescent cells (blue bars) treated 
with either QVD or the DMSO control. (B) The bar graph shows the percentage of cells positive 
for Ki67 in proliferating, stress-induced (red bars) and replicatively senescent cells (blue bars) 
treated with either QVD or the DMSO control. (C) The bar graph shows the percentage of cells 
positive for p16 in proliferating, stress-induced (red bars) and replicatively senescent cells (blue 
bars) treated with either QVD or the DMSO control. (D) The bar graph shows the percentage 
of cells positive for p21 in proliferating, stress-induced (red bars) and replicatively senescent 
cells (blue bars) treated with either QVD or the DMSO control. (E) Representative Western 
Blot image of total protein levels of Lamin B1 and β-Actin in proliferating, stress-induced and 
replicatively senescent cells treated with either QVD or the DMSO control. Bar graphs 
represent mean +SEM for 5 independent experiments, statistical analysis performed using a 
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4.7. Caspase 3 contributes to DNA damage and has a small role in the SASP during 
senescence 
Earlier it was demonstrated that there was evidence of caspase 3 cleavage in senescent cells, 
furthermore, both the SASP and DDR that occurs during senescence are reduced by QVD 
treatment which is a known irreversible broad spectrum inhibitor of caspases. It has been 
reported that QVD has potent efficacy against caspases 1, 3, 8 and 9, as well as a lower level of 
activity against caspase 2, 5, 6, 7, 10 and 12 (Kuzelova et al., 2011).  The caspases 1 and 4 have 
been associated with the inflammasome and processing of IL-1β which can modulate 
inflammation (Martinon and Tschopp, 2004). Caspase 5 has also been reported to regulate the 
IL-1α arm of the SASP during senescence (Wiggins et al., 2019). Caspase 3 is classically an 
executor caspase which is activated by caspase 8 and 9, once activated it fulfils the apoptosis 
process by inducing cleavage of DNA and degradation of cytoskeletal proteins (Elmore, 2007). 
In addition it has been reported that caspase 3 can promote sub-lethal DNA damage in the 
absence of cell death (Ichim et al., 2015). Caspase 2 has been associated with promoting 
formation of BAX and BAK pores during the apoptotic process (Gao et al., 2005). As such I 
decided to test the effect of inhibiting Caspases 1-4 individually on the SASP. Proliferating and 
stress-induced senescence cells were maintained in caspase inhibited conditions for 10 days 
prior to cytokine measurement. Initiation of senescence provoked a pronounced secretion of 
IL-6, IL-8 and IP-10 (p<0.0001 in each case). In senescent cells, individual inhibition of 
caspases 1, 2, 3 and 4 had no effect on the secretion of IL-6 (Figure 4.8A). With regards to IL-
8, inhibition of caspases 1, 2 and 4 did not significantly alter the secretion of this cytokine, 
although caspase 1 and 2 did provoke a small decrease. Inhibition of caspase 3 on the other 
hand promoted a significant decrease of IL-8 (p<0.001, Figure 4.8B). Inhibition of caspases 1, 
2, 3 and 4 provoked a small decrease in the secretion of IP-10 compared to senescent cells 
alone, however, none of these were significant.  
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Figure 4.8 – Inhibition of Caspase 3 decreases the SASP component IL-8. 
Proliferating and stress-induced senescent cells (20Gy irradiation) were maintained under 
control conditions (DMSO) or with one of the following caspase inhibitors; caspase 1, 2, 3 and 
4 at 10µM for 10 days. (A, B and C) Bar graphs show the secretion of IL-6 (A), IL-8 (B) and 
IP-10 (C) following treatment with either DMSO or the caspase 1, 2 3 and 4 inhibitors, n=4 
independent experiments. Bar graphs represent mean +SEM, statistical analysis performed 
using a One-way ANOVA.   
 
As part of investigating which caspases were contributing to the SASP and DDR, I assessed the 
activity of caspases 1 and 2 in senescent cells. To do this I assessed whether there was evidence 
for cleavage of these caspases which indicates that it is functionally active.  First, I assessed 
Caspase 1. Interestingly, total protein levels of caspase 1 measured by pro-caspase 1 revealed 
that there was a significant 3-fold increase in the levels found in senescent cells (p=0.0216) 
(Figures 4.9 A and B). Indeed, there was also a 3-fold increase in the levels of cleaved-caspase 
1 in senescent cells when compared to proliferating cells (p=0.0012, Figure 4.9C). When the 
level of cleaved-caspase 1 was normalised to the total amount of caspase 1 there was not a 
significant difference (Figure 4.9D). Next, I measured caspase 2 which was significantly 
decreased in senescent cells when compared to proliferating cells (p<0.0001, Figures 4.9E and 
F), in addition, there was no detectable difference in the levels of cleaved caspase 2 (Figures 
4.9G).  
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Figure 4.9 – Caspase1 cleavage is increased  in senescent cells. 
Proliferating and stress-induced senescent cells (20Gy irradiation) were assessed for activity of 
caspase 1, 2 and 3. (A) Representative image of total protein levels of pro-caspase 1, cleaved 
caspase 1 and β-Actin. (B) Bar graph shows the fold change in protein levels of pro-caspase 1 
normalised to β-Actin  in proliferating (white bars) and senescent cells (red bars). (C) Bar graph 
shows the fold change in protein levels of cleaved caspase 1 in proliferating (white bars) and 
senescent cells (red bars) normalised to the total level of β-Actin. (D) Bar graph shows the fold 
change in protein levels of cleaved caspase 1 in proliferating (white bars) and senescent cells 
(red bars) normalised to the total level of Caspase-1.  (E) Representative image of total protein 
levels of total caspase 1, cleaved caspase 2 and β-Actin. (F) Bar graph shows the fold change 
in protein levels of caspase 2 in proliferating (white bars) and senescent cells (red bars). (G) 
Bar graph shows the fold change in protein levels of cleaved caspase 2 in proliferating (white 
bars) and senescent cells (red bars). Bar graphs represent mean +SEM, n=3-4 independent 
experiments, statistical analysis performed using a two tailed unpaired t-test.   
 
In this study, I found that there was evidence of increased caspase-1 cleavage and caspase-3 
activity in senescent cells. The treatment of senescent cells with a known inhibitor of caspase 1 
did not have an effect on the SASP, caspase 3 inhibition on the other hand was associated with 
a reduced secretion of IL-8. Therefore, I wanted to characterise further whether it contributes 
to the DDR in senescence. Therefore proliferating and senescent cells were cultured alone and 
in the presence of the caspase 3 inhibitor. Then the senescence marker Lamin B1 and 
constituents of the DDR γH2AX and 53BP1 were assessed by Western Blot. It was found that 
senescent cells lost the expression of Lamin B1 (p<0.0001) compared to proliferating cells. 
Treatment with the caspase 3 inhibitor had no effect on its expression in the proliferating cells, 
in addition, its inhibition did not prevent the loss of Lamin B1 in senescent cells (Figures 4.10A 
and B). Next, 53BP1 levels were measured. 53BP1 is part of the DNA damage repair signalling 
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network, particularly in response to DSBs. It was found that senescent cells had a significantly 
increased total level of 53BP1 compared to proliferating cells (p=0.0391). Senescent cells 
treated with the caspase 3 inhibitor displayed a 50% reduction in the fold change of 53BP1 
compared to untreated senescent cells, although this was not significant (p=0.1835). The 
caspase 3 inhibitor had no effect on the levels of 53BP1 in proliferating cells (Figures 4.10A 
and C). Finally, γH2AX was assessed. Senescent cells displayed a 2.5 fold increase in total 
levels of γH2AX compared to proliferating cells (p=0.0765). This increase was not observed in 
senescent cells treated with the caspase 3 inhibitor (1.2 fold higher than proliferating cells), 
these treated cells had a 50% decreased level of γH2AX compared to untreated senescent cells 
(p=0.2142). The caspase 3 inhibitor had no effect on the proliferating cells (Figures 4.10A and 
D).       
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Figure 4.10 – Caspase 3 inhibition leads to a small reduction in the DDR. 
Proliferating and stress-induced senescent cells (10 days post 20Gy irradiation) treated with the 
caspase 3 inhibitor (10µM) or a DMSO control were analysed for Lamin B1, γH2AX and 
53BP1 by Western Blotting. (A) Representative Western Blot image of total protein levels of 
Lamin B1, γH2AX, 53BP1 and β-Actin. (B) Bar graph shows the fold change in protein levels 
of Lamin B1 in proliferating (white bars) and senescent cells (red bars). (C) Bar graph shows 
the fold change in protein levels of 53BP1 in proliferating (white bars) and senescent cells (red 
bars). (D) Bar graph shows the fold change in protein levels of γH2AX in proliferating (white 
bars) and senescent cells (red bars). Bar graphs represent mean +SEM, n=3 independent 
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4.8.  Discussion 
Following our observation that senescent cells harbour cytosolic mtDNA as a consequence of 
BAX and BAK pores I wanted to further investigate the underlying process which could 
facilitate this. Recent work has unveiled a phenomenon called limited mitochondrial outer 
membrane permeabilisation (Ichim et al., 2015). I set out to investigate this in the context of 
senescence. Collectively, we demonstrate that senescent cells display evidence of miMOMP. 
Moreover, the pharmacological induction of miMOMP promotes mtDNA release and a 
senescence phenotype. Finally, I provide evidence that miMOMP leads to cytochrome C release 
and subsequent sub-lethal caspase 3 activity which can instigate DNA damage in senescent 
cells.   
Classically the process of mitochondrial outer membrane permeabilisation was considered an 
all or nothing process; either mitochondria were completely permeabilised and apoptosis was 
engaged or not at all (Tait and Green, 2010). As I observed that mtDNA leakage during 
senescence is dependent on BAX and BAK pores, I wanted to understand how mitochondrial 
permeabilisation could facilitate this. In the cancer field, it was recently discovered that cells 
can have a subset of mitochondria permeabilised which are releasing inner mitochondrial 
proteins such as cytochrome C in the absence of cell death (Ichim et al., 2015). As mitochondria 
are widely associated with being dysfunctional during senescence I speculated that this process 
could be contributing to mtDNA release during senescence (Passos et al., 2007; Passos et al., 
2010; Correia-Melo et al., 2016; Wiley et al., 2016; Chapman et al., 2019). As such our first 
step was to characterise senescent cells for miMOMP. It has been reported that cytochrome C 
is detectable by confocal microscopy in the cytosol of cells undergoing miMOMP (Ichim et al., 
2015). By Western Blotting I discovered that cytochrome C was detectable in the cytosolic 
fraction of stress-induced and replicatively senescent cells but not proliferating cells. As 
cytochrome C is distributed completely through the mitochondrial network rather than 
individual nucleoids like mtDNA it is difficult to quantify the extent to which cytochrome C is 
present in the cytosol. In the Ichim et al., 2015 paper cells were used which expressed a 
fluorescent tag on their mitochondria (mCherry) and a fluorescent tag in the cytoplasm 
(cytoGFP), when the mitochondria become permeabilised the cytosolic tag can pass into the 
mitochondria where it dimerises with the mitochondrial mCherry tag and provides a fluorescent 
signal to indicate mitochondrial permeabilisation. In this study I utilised confocal microscopy 
to acquire 3D images of cells labelled with TOM20 and cytochrome C. Following acquisition 
the Huygens Deconvolution Software was used to process these images and statistically analyse 
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them to determine how well the two channels co-localised. Using a Pearson’s Correlation 
Coefficient test both stress-induced and replicatively senescent cells had a reduced level of 
colocalisation compared to proliferating cells. In normal proliferating cells, cytochrome C and 
TOM20 colocalise completely. In senescent cells there was cytochrome C staining visible 
which did not colocalise with TOM20. Indeed, I also observed areas of TOM20 which no longer 
colocalised with cytochrome C. These data indicate that in senescent cells there is an overall 
reduction of colocalisation between cytochrome C and TOM20 suggesting that these cells are 
undergoing miMOMP. However, there are some limitations to our analysis. First, as part of the 
processing to improve the reliability of the statistical analysis it is necessary to remove the 
background signal from images by deconvolution. Background signal needs to be removed as 
this is different between channels and will interfere with the colocalisation measurement 
between the two channels as it will be registered as signal by the software. All images are 
acquired and deconvolution is performed using identical parameters to avoid introducing any 
bias. However, the background does vary very slightly between individual coverslips and areas 
of coverslips. As such there is naturally a slight element of variation between images. This can 
be seen in the proliferating cells where it would be expected that there would be perfect 
colocalisation between cytochrome C and TOM20, however, looking at the dot plot for 
individual proliferating cells there is a degree of cell to cell variability in the level of 
colocalisation. Therefore, the data has been expressed both on an individual cell basis using the 
raw colocalisation value and in the bar graph as a percentage of the control cells where perfect 
colocalisation would be expected.  
Following the development of our assay for measuring colocalisation of cytochrome C and 
TOM20 as a measure of miMOMP I wanted to validate that it could detect miMOMP in 
conditions known to induce miMOMP. In the literature it has been reported that mild stress 
using BH3 mimetic drugs such as ABT737 can induce miMOMP (Ichim et al., 2015). Therefore 
I treated fibroblasts with ABT737 and then assessed our cells for miMOMP using our assay. 
Indeed, I found that cells treated with ABT737 displayed a reduced level of cytochrome C and 
TOM20 colocalisation compared to control fibroblasts. In the literature, ABT737 treatment was 
associated with approximately 5% of cells displaying miMOMP with approximately 3% of 
mitochondria being permeabilised (as measured by volume permeabilised) (Ichim et al., 2015). 
For our data, I have not stratified it into an assessment of whether an individual cell displays 
permeabilisation or not. However, when expressed as a percentage of the control I observed a 
12% decrease in the level of colocalisation, this therefore suggests that 12% of mitochondria 
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display miMOMP. With that in mind, it is possible that our assay is not quite as stringent as the 
one used by Ichim et al, although the experiments were performed in different cell lines (U20S 
cancer cells and MRC5 human fibroblasts) which may explain the slight differences seen (Ichim 
et al., 2015). Alternatively, as the Ichim et al method measures the dimerization signal rather 
than the overall colocalisation between the two channels it may be that our method introduces 
more variability due to the removal of background during image processing.      
The downstream effects of miMOMP induced by ABT737 include the release of cytochrome 
C and subsequent sub-lethal caspase 3 activity which drives DNA damage (Ichim et al., 2015). 
Consistent with this notion, I observed cleavage of caspase 3 in cells treated with ABT737. 
Moreover, I found that treatment with ABT737 lead to an increase in DNA damage (measured 
by γH2AX). I found that this DNA damage was dependent on caspase activity as the co-
treatment of cells with ABT737 and the caspase inhibitor QVD lead to a decrease in the level 
of DNA damage compared to ABT737 alone. Corroborating the finding that this DNA damage 
is driven by caspases I also found that ABT737 did not have an effect on the production of 
mitochondrial ROS. Collectively, these findings demonstrate that I can induce miMOMP using 
ABT737 and our assay is reliable enough to detect miMOMP.  
In the context of senescence, I also observed downstream effects of cytochrome C release. In 
senescent cells I observed by Western Blot that there is increased caspase 3 activity compared 
to proliferating cells. In line with this finding, I found that in both stress-induced and 
replicatively senescent cells the inhibition of caspase activity using QVD led to a reduction in 
the number of γH2AX foci. These data in conjunction with the reduced colocalisation of 
cytochrome C and TOM20 in senescent cells provides good evidence that senescent cells have 
permeabilised mitochondria which are driving DNA damage through caspase 3 activity. The 
link between mitochondria and caspases has not been explored in senescence, therefore these 
observations raised two pivotal questions; first, can miMOMP be a driver of senescence? 
Second, to what extent do caspases regulate the senescence phenotype?  
Our work has discovered that mitochondria in senescent cells display evidence of 
permeabilisation. However, at this stage it is difficult to determine whether miMOMP is a driver 
of senescence or a feature that occurs in response to the dysfunctional nature of mitochondria 
found in senescent cells. To address whether miMOMP can drive senescence I cultured cells 
continually in the presence of ABT737 (at 2.5µM which I demonstrated to induce miMOMP) 
and then assessed markers that are characteristic of senescence. After 9 days of continuous 
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culture, compared to control cells ABT737 led to an increase in SA-β-Gal, γH2AX and p21, 
there was also a tendency for increases in p16 and the secretion of IL-6 and IL-8. After 23 days 
of culture, the number of SA-β-Gal positive cells remained the same but there was a further 
increase in γH2AX and the secretion of IL-6 and IL-8. However, at this time point p16 and p21 
have not been measured. The levels of p16 and p21 were relatively low at the 9 day time point, 
it may be that a longer period of exposure such as 23 days is required to observe upregulation 
of the growth arrest pathways. Therefore future work should seek to address this caveat. 
Together, these results highlight that sustained culture with ABT737 is promoting markers of 
senescence. As ABT737 induces caspase-mediated DNA damage I speculated that this could 
be responsible for driving the induction of senescence. As such, I also co-cultured cells with 
both ABT737 and QVD. Interestingly, at both the 9 and 23 day time point markers of 
senescence such as SA-β-Gal, γH2AX and the secretion of IL-6 and IL-8 were diminished in 
cells co-treated with QVD. These data support the idea that ABT737 is inducing miMOMP, 
which in turn is driving DNA damage through sub-lethal caspase activity. This damage is 
instigating the DDR which leads to an upregulation of p21 and increased expression of SA-β-
Gal. As the senescence phenotype develops the secretion of IL-6 and IL-8 increases. This 
mechanisms supports a previous study where it was observed that ABT737 could induce 
senescence (p21, SA-β-Gal, IL-6 and IL-8 increased) in an apoptosis-resistant breast cancer cell 
line through caspase mediated DNA damage (Song et al., 2011). Interestingly, they 
demonstrated that the DNA damage was generated by an increase in ROS production which 
was responsible for caspase 3 activation, however, in our study there was no observed increased 
production of ROS following treatment with ABT737. It is possible that cell line differences 
account for differences in ROS production, it is also plausible that as ABT737 can promote 
mitochondrial permeabilisation this could be associated with stress which results in an 
increased production of ROS. However, Ichim et al demonstrated that AB737 promotes 
activation of caspase 3 as a consequence of cytochrome C release by miMOMP (Ichim et al., 
2015). This fits with our observations as we observed both miMOMP and no increase in ROS 
production.  
Interestingly, in the study by Song et al, they observed (depending on the cell line used) between 
60 and 75% of cells being positive for SA-β-Gal following treatment with ABT737 whereas in 
our study we only observed approximately 10% of cells being positive for SA-β-Gal at both 
time points (Song et al., 2011). It has recently been established that ABT737 belongs to a class 
of BH3 mimetic drugs which can induce apoptosis in senescent cells (Chang et al., 2016; Yosef 
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et al., 2016b). ABT737 has been demonstrated to be effective at killing senescent human 
fibroblasts (IMR90s), MEFs and senescent cells in vivo due to their dependence on the 
upregulation of pro-survival proteins BCL-2 and BCL-XL (Yosef et al., 2016b). Therefore it is 
likely that cells which become senescent following ABT737 driven miMOMP will undergo 
apoptosis due to exposure to ABT737. Furthermore, the study by Song et al was performed in 
cancer cell lines which were found to be resistant to apoptosis. It has been shown that the 
senolytic ABT-263 which is structurally similar to ABT737 is not effective in all cell types 
(Zhu et al., 2016; Zhu et al., 2017). Therefore it is plausible that when senescent these cancer 
cells may be less reliant on BCL-2 and BCL-XL mediated survival and therefore not undergo 
apoptosis when exposed to ABT737. This is likely the explanation as to why our study has 
observed a low number of SA-β-Gal and p21 positive cells compared to Song et al (Song et al., 
2011). 
The observation that miMOMP can promote DNA damage and an increase in markers of 
senescence is particularly interesting as ABT737 and its related family members are currently 
being proposed as promising senolytic drugs. Naturally, this therefore raises the question of 
what the effects of ABT737 will be on healthy cells and tissue. Our data indicates that it can 
induce substantial amounts of DNA damage which can drive a senescence-like phenotype. 
Furthermore, there is evidence in the literature that ABT737 can be pro-tumourigenic (Ichim et 
al., 2015). These data suggest that using ABT737 as a senolytic agent may in fact be a double 
edged sword as it can remove the detrimental senescent cells, but it may provoke senescence in 
healthy cells. Pharmacological clearance of senescent cells generally seems to be performed 
using intermittent dosing rather than continual treatment (Chang et al., 2016; Ovadya et al., 
2018; Walaszczyk et al., 2019). This is therefore likely to mitigate the effects on healthy tissue. 
However, our data indicates that 48 hours of exposure was sufficient to induce DNA damage. 
In addition, the literature demonstrates that within three hours of ABT737 treatment there is 
detectable DNA damage measured by γH2AX in vitro. Moreover, the authors also demonstrated 
increased γH2AX following 1 day of ABT737 treatment in vivo which was not associated with 
an increase in TUNEL staining (a measure of DNA fragmentation that occurs during apoptosis) 
(Ichim et al., 2015). These data indicate that caution should be employed when administering 
BH3 mimetics as senolytics to ensure that the benefit of senescent cell clearance outweighs the 
detriment of DNA damage. As such, this supports the idea of senescent cell clearance 
intermittently during the later stages of life rather than throughout the life course of an 
organism.   
Chapter 4 – Limited mitochondrial permeabilisation contributes to mtDNA release and the 




It has been reported by Ichim et al that damage associated with miMOMP is dependent on the 
presence of BAX and BAK pores to facilitate cytochrome c release (Ichim et al., 2015). 
Consistent with this observation, I found that in the context of senescence, cells deficient for 
BAX and BAK did not display reduced colocalisation of cytochrome C and TOM20 to the same 
extent as senescent Empty Vector cells. This indicates that miMOMP in senescence is 
dependent on BAX and BAK. Future experiments should seek to understand whether treatment 
of cells with BIPv5 or BCB also prevent miMOMP from occurring. Moreover, it was 
demonstrated earlier in this study that the SASP is dependent on BAX and BAK as a 
consequence of mtDNA release. It has been published that the release of mtDNA can occur in 
response to mitochondrial permeabilisation following treatment of fibroblasts with ABT737, 
similarly this has been shown to be dependent on BAX and BAK (McArthur et al., 2018; Riley 
et al., 2018). Therefore, we reasoned that the pro-inflammatory response that occurs in response 
to treatment with ABT737 could be promoting the release of mtDNA by miMOMP. Therefore 
I assessed whether miMOMP induced by ABT737 was associated with mtDNA release.  
It has been reported that high doses of ABT737 promote mtDNA release during apoptosis 
(McArthur et al., 2018; Riley et al., 2018). However, it has not been assessed whether low 
doses which induce miMOMP lead to mtDNA release. As I observed that senescent cells 
display evidence of miMOMP and cytosolic mtDNA which were both dependent on BAX and 
BAK being present, I speculated that miMOMP could be responsible for facilitating mtDNA 
release. Indeed, I found that the pharmacological induction of miMOMP using ABT737 led to 
an increase in the level of cytosolic mtDNA. The increase was small after 48 hours, but was 
significantly increased at 9 days and further increased by 23 days of sustained exposure. These 
findings indicate that miMOMP can promote mtDNA release. Interestingly, both the percentage 
of cells and the mean number of cytosolic nucleoids per cell were lower in ABT737 treated 
cells at each time point compared to the number of nucleoids observed in senescent cells which 
were characterised in the previous chapter. In line with this observation, it was also observed 
that both stress-induced and replicatively senescent cells had a reduced level of cytochrome 
C/TOM20 colocalisation compared to the level of colocalisation observed in cells treated with 
ABT737. These data suggest that senescent cells have an increased proportion of permeabilised 
mitochondria compared to ABT737 treated cells which may explain the increased level of 
cytosolic DNA in senescent cells. Alternatively, this observation could be explained by activity 
of cytosolic DNases responsible for degrading cytosolic DNA. As senescent cells have 
downregulated activity of the cytoplasmic DNases TREX1 and DNase2 it could be plausible 
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that DNA released by ABT737 induced miMOMP is rapidly removed from the cell, hence the 
lower observed level of cytosolic mtDNA (Takahashi et al., 2018). As both senescent markers 
and the level of cytosolic mtDNA increase at 9 days and 23 days, it is therefore possible that as 
the senescent phenotype develops following ABT737 mediated miMOMP there is reduced 
activity of DNases which could explain the accumulation of cytosolic mtDNA at the later time 
points.     
Surprisingly, treatment of BAX and BAK deficient cells with ABT737 still resulted in an 
increased secretion of IL-6 and IL-8. Although the level of secretion was not as high as control 
Empty Vector cells it would be expected that if mtDNA release in response to ABT737 was 
solely responsible for the pro-inflammatory response then this would not be detectable in BAX 
and BAK deficient cells. Interestingly, work by Riley et al demonstrated that in response to 
ABT737 mediated mtDNA release there is a 100-fold increase in Ifnb1 in control cells, in 
BAX/BAK deficient cells there is a 20-fold increase compared to the control cells (Riley et al., 
2018). As they also observed an increased pro-inflammatory response following exposure of 
BAX and BAK deficient cells to ABT737 this suggests that the effects of ABT737 are not 
completely attributed to mtDNA release. Therefore future work should seek to explore 
alternative mechanisms that ABT737 may be promoting part of its inflammatory response 
through.  
Interestingly, the secretion of IL-6 and IL-8 which occurs in response to ABT737 treatment can 
be prevented by caspase inhibition. I speculated that as miMOMP can promote mtDNA release 
co-treatment of ABT737 with QVD would not have an effect on the secretion of IL-6 and IL-8 
as mtDNA would presumably still be being released regardless of caspase activity. Indeed, it 
has been demonstrated that doses of ABT737 which are sufficient to induce apoptosis still lead 
to an inflammatory response under caspase inhibited conditions through NF-κB (Giampazolias 
et al., 2017). Moreover, it has been demonstrated that caspases are responsible for silencing the 
inflammatory response to mtDNA which is released during apoptosis, they demonstrated that 
during apoptosis under caspase inhibited conditions an inflammatory response was observed 
(White et al., 2014). Contrastingly, in this study I observed that caspase inhibition completely 
prevented the inflammatory response to ABT737. Interestingly, in senescent cells caspase 
inhibition reduced IL-6 and IL-8 secretion by approximately 25-30% rather than completely as 
observed in response to ABT737. These observations indicates that in the context of ABT737 
exposure the inflammatory response is potentially associated with caspase-mediated DNA 
damage rather than solely attributed to mtDNA release. As such, it is plausible that cytosolic 
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DNA which is released in response to ABT737 may be rapidly degraded before an 
inflammatory response is mounted. Alternatively, caspases may contribute mechanistically to 
the release of mtDNA. There is evidence that caspases 3, 6, 7 and 8 can promote cytochrome c 
release (Bossy-Wetzel and Green, 1999; Garrido et al., 2006). It is known that cytochrome C 
release occurs via BAX and BAK pores, therefore, hypothetically these caspases could enable 
mtDNA release which would not occur in cells co-treated with both ABT737 and QVD (Tait 
and Green, 2010). It would therefore be of interest in the future to experimentally test this by 
assessing mtDNA leakage in cells which have been co-treated with ABT737 and QVD. At this 
stage the data demonstrates a caspase-mediated reduction in SA-β-Gal, γH2AX and p21 
therefore lending weight to the idea that the reduction in IL-6 and IL-8 secretion is attributed to 
a reduced number of cells becoming senescent due to reduced DNA damage induction through 
sub-lethal caspase activity. This highlights the requirement for further work to dissect the 
relationship between mtDNA, caspases and the secretion of IL-6 and IL-8.         
As it has been established that senescent cells display evidence of miMOMP and the effects of 
pharmacologically inducing miMOMP can be mitigated by caspase inhibition, we questioned 
whether inhibition of caspases could be beneficial in the context of senescence. To address this 
I used the broad spectrum caspase inhibitor QVD for 10 days during the development of stress-
induced senescence and following the development of replicative senescence and then 
characterised markers of the SASP and the cell cycle arrest. I found that DNA damage was 
reduced in both models of senescence when the caspases were inhibited, in addition, I also 
found that the SASP was reduced by approximately 50% in stress-induced senescent cells and 
30% in replicatively senescent cells. These two findings highlight that caspases have a multi-
faceted role during senescence, first, they are in part responsible for inducing DNA damage in 
senescent cells, and secondly, they have a role in SASP regulation which will be discussed in 
detail later. However, it seems that the role of caspases in senescence are restricted to the SASP 
and DNA damage as there were no observable effects on other markers of senescence/cell cycle 
arrest such p16, p21, Ki67, SA-β-Gal or the loss of Lamin B1 in both models of senescence. At 
this stage it is important to consider that although QVD and the individual caspase inhibitors 
are known to inhibit the relevant caspases, I have not verified mechanistically that caspase 
activity has been inhibited. Therefore, future work should seek to confirm that their activity has 
been blocked in MRC5 human fibroblasts. 
Following these observations I wanted to investigate further the role of caspases instigating 
DNA damage. Previous studies have largely linked the induction of DNA damage during 
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senescence with the production of ROS (Saretzki et al., 2003; Ramsey and Sharpless, 2006; 
Passos et al., 2007). However, as it was established that damage associated with miMOMP was 
linked with caspase 3 activity, I assessed the cleavage of caspase 3 in senescent cells (Ichim et 
al., 2015). Western blotting revealed that compared to their proliferating counterparts there was 
an increased level of cleaved caspase 3 in senescent cells indicating its activation. Both γH2AX 
and 53BP1 are reliable markers of DNA damage which have been demonstrated to be 
upregulated as part of the DDR (d'Adda di Fagagna, 2008). Western blotting revealed that the 
selective inhibition of caspase 3 in stress-induced senescent cells led to a non-significant 
reduction of both γH2AX and 53BP1. Although it is possible that the number of samples in this 
experiment was not sufficient to determine statistical significance, an important point of 
consideration in this experiment is that western blotting may not be sufficiently sensitive to 
determine physiologically relevant differences in small numbers of γH2AX foci. Therefore, 
these data should be treated as preliminary until the individual number of γH2AX foci have 
been characterised using confocal microscopy.  
In senescent cells it was found that neither broad-scale inhibition of caspases using QVD nor 
the selective inhibition of caspase 3 reduced DNA damage levels back to the levels found in 
proliferating cells. This indicates that caspase 3 is not solely responsible for the DNA damage 
in senescence. This fits with the literature which has pinpointed a key role of ROS in 
maintaining DNA damage during the development of senescence to ensure the robust 
upregulation of p21 (Passos et al., 2010; Nelson et al., 2018). A recent study demonstrated that 
p21 was important for preventing apoptosis in stress-induced senescent cells by restraining the 
activity of caspase 3 in senescent cells as the silencing of p21 led to apoptosis in senescent cells 
by JNK-caspase 3 activity. Interestingly, in their study p21 proficient stress-induced senescent 
cells still display an increase in the protein levels of cleaved caspase 3 compared to growing 
cells (although substantially lower than the p21 silenced cells which were undergoing 
apoptosis) (Yosef et al., 2017). Although their study was not investigating sub-lethal caspase 3 
activity, their observation matches ours of sub-lethal caspase activity in senescent cells. As 
caspase inhibition only partly ameliorated DNA damage levels with no effect on the cell cycle 
arrest, it is likely that ROS is still being produced which is important for maintaining the DDR 
positive feedback loop during the development of senescence. It would be interesting to test 
whether the DDR can be further reduced by inhibiting both caspase 3 and ROS using an 
antioxidant and subsequently assess whether this has prevents the cell cycle arrest.  
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Another interesting aspect of our observation is that the broad scale inhibition of caspase 
activity in replicative senescent cells also reduced the level of DNA damage. As caspase 
inhibition was performed in cells where the senescent phenotype was already established it 
suggests that caspase activity is not restricted to the development of senescence but also occurs 
once the cell cycle is averted and the senescent phenotype is fully developed. As such, it seems 
likely that the effects of caspase 3 on DNA damage occur in response to mitochondrial 
dysfunction which is promoting miMOMP. A way to dissect the link between caspase 3 activity 
and miMOMP would be to measure caspase 3 activity in BAX/BAK deficient cells which do 
not undergo miMOMP during senescence. It would be expected that BAX/BAK deficient cells 
would have a reduced level of DNA damage and caspase 3 activity as cytochrome C is not 
being released. Indeed, it has been published that treatment of BAX/BAK deficient cells with 
ABT737 does not lead to an increase in γH2AX as miMOMP cannot occur (Ichim et al., 2015). 
However, in the previous chapter I found that senescent BAX/BAK deficient cells do not have 
a reduced level of DNA damage. It may be speculated that their metabolic function may be 
altered as a consequence of BAX and BAK being genetically removed which could influence 
the amount of DNA damage. Although non-significant, it was observed that there was a small 
increase in ROS production in senescent BAX/BAK deficient cells. Therefore it is plausible 
that this increased production of ROS could explain why BAX/BAK deficient cells do not have 
a decreased amount of DNA damage despite not having evidence of miMOMP. In line with 
this, I found that treatment with ABT737 does not promote ROS production which explains 
why Ichim et al observed a complete reduction in γH2AX following the treatment of BAX/BAK 
deficient cells with ABT737 (Ichim et al., 2015). 
To further dissect the relationship between mitochondria and caspase regulation, it would be of 
significant interest to test for sub-lethal caspase 3 activity in senescent fibroblasts which have 
no mitochondria such as those generated by Correia-Melo et al (Correia-Melo et al., 2016; 
Correia-Melo et al., 2017).   
The observation that broad scale caspase inhibition could partially decrease the SASP is a 
relationship that has not been previously explored. Therefore it was of interest to understand 
specifically which caspases had a regulatory role in the production of the SASP. As such, 
caspases 1-4 were individually inhibited. It has previously been published that in OIS, caspase 
1 levels are elevated, here, it functions as part of the NLRP3 inflammasome where it cleaves 
IL-1β to promote cytokine production. Furthermore, inhibition of caspase 1 reduced the SASP, 
as well as partially preventing the induction of p21-mediated cell cycle arrest (Acosta et al., 
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2013). However, the findings of this study suggest that caspase 1 does not have a SASP 
regulatory role in stress-induced senescence as its inhibition did not have an effect on the 
secretion of IL-6 or IL-8. Although, in stress-induced senescence I found evidence of caspase 
1 cleavage, this cleavage was not associated with activation of the inflammasome (characterised 
thoroughly in the subsequent chapter). Furthermore, when the level of cleavage was normalised 
to the total amount of caspase 1 there was no difference between proliferating and senescent 
cells. This therefore suggests that there is only an increased level of cleaved caspase 1 because 
senescent cells harbour an increased total protein level of caspase 1. As such, it would be 
interesting in future studies to understand specifically why there is an increased amount of 
caspase 1in senescent cells and whether the observed increase in caspase 1 cleavage has a 
functional output in stress-induced senescence.  
Outside of the context of senescence, caspase 4 has also been associated with the inflammasome 
and processing of IL-1β which can modulate inflammation (Martinon and Tschopp, 2004). It 
was found that its inhibition did not have an effect on the secretion of IL-6 and IL-8. As both 
caspase 1 and 4 have a regulatory role in the inflammasome these data suggest that these 
caspases are not responsible for SASP regulation, similarly they also suggest that the 
inflammasome does not facilitate the SASP in stress-induced senescence.  
Caspase 2 has been associated with promoting formation of BAX and BAK pores during the 
apoptotic process by promoting cleavage of BID to tBID (Gao et al., 2005). It was therefore 
postulated that perhaps caspase 2 could be promoting BAX and BAK pore formation which is 
leading to mtDNA release and subsequently the SASP. However, it was found that the total 
protein level of caspase 2 was significantly downregulated in senescent cells. Moreover, the 
inhibition of caspase 2 during senescence was not associated with an effect on the secretion of 
IL-6 and IL-8. Together, these data highlight that caspase 2 is not active during senescence and 
indeed it is not contributing to the SASP. 
Caspase 3 is classically an executor caspase responsible for implementing the apoptosis process 
by inducing cleavage of DNA and degradation of cytoskeletal proteins (Elmore, 2007). As 
previously discussed it was found to be active and contributing towards DNA damage in 
senescence. Interestingly, the specific inhibition of caspase 3 led to a decrease in the secretion 
of IL-8. This suggests that caspase 3 can regulate the SASP. In the literature there is some 
evidence that caspase 3 is responsible for the cleavage of IL-16 indicating that it does have a 
role in the regulation of inflammation (Zhang et al., 1998; Sciaky et al., 2000). However, IL-
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16 is not observed as part of the SASP and caspase 3 has not been implicated in the regulation 
of other pro-inflammatory cytokines. This suggests that the effect of caspase 3 inhibition on IL-
8 is likely attributed to its effect on the DDR. Indeed, there is evidence in the literature that a 
reduction in the DDR can lead to a reduction in the SASP. For example, the DDR factors ATM 
and ATR stabilise GATA4 which regulates NF-κB, a key modulator of the SASP (Chien et al., 
2011; Kang et al., 2015).    
Broad scale inhibition of the caspases led to a reduction in the SASP of approximately 50 and 
30% in stress-induced and replicative senescence respectively. The specific inhibition of 
caspase 3 led to an approximate 25% reduction in IL-8 but had no effect on IL-6. It is not 
entirely clear why IL-8 was reduced but not IL-6. As suggested earlier, it seems that the most 
likely cause is due to the associated reduction in the DDR. However, there are alternative 
possibilities to consider. First, it may be that the SASP is regulated by a mechanism which 
involves the interaction between multiple caspases. Therefore, it would be interesting to explore 
this experimentally to either inhibit or genetically knockout various caspases in conjunction 
with caspase 3 to determine whether the effects are exacerbated.    
Secondly, as I only inhibited caspases 1-4 individually it is possible that other caspases are 
responsible for the effects observed by broad caspase inhibition. Other than the caspases 
discussed above it has been reported that QVD can also act against caspases 8 and 9, with a 
lower efficacy against 5, 6, 7, 10 and 12 (Kuzelova et al., 2011). In the context of senescence, 
caspase 5 has recently been demonstrated as being essential for the IL-1α arm of the SASP (IL-
6, IL-8 and MCP-1). Consistently, they demonstrated that caspase 5 (caspase 11 in mice) is 
responsible for cleavage of IL-1α, consistently, silencing of caspase 5 led to a robust reduction 
in the SASP (Wiggins et al., 2019). Therefore, this warrants investigating whether inhibition of 
caspase 5 alone could replicate the effects of broad scale caspase inhibition. Taken together, it 
indicates that caspase 3 has an effect on the SASP (likely associated with the DDR), however, 
it seems probable that alternative caspases such as caspase 5 are also important in regulating 
the SASP.




5. Chapter 5: Pharmacological inhibition of the cGAS-STING axis 
ameliorates the SASP 
 
It has been reported that the integrity of the nucleus in senescent cells becomes impaired and 
fragments of DNA termed CCFs (cytoplasmic chromatin fragments) bud off to the cytosol 
(Ivanov et al., 2013). Once located in the cytosol, they have a key role in inducing the SASP 
through the cGAS-STING pathway. Specifically, CCFs are identified by the DNA sensor 
cGAS, which leads to activation of STING. This in turn promotes phosphorylation of TBK1 
and subsequently IRF3 which leads to transcription of type 1 IFN genes. Similarly, STING can 
activate IKK which in turn acts on NF-κB, a known regulator of the SASP.  A number of groups 
have reported that activation of cGAS occurs during senescence as a consequence of CCFs, 
which lead to induction of the SASP (Dou et al., 2017; Gluck et al., 2017; Yang et al., 2017).  
As part of this study we wanted to address whether cytosolic mtDNA observed during 
senescence could also be participating in the SASP via activation of the cGAS-STING pathway. 
Studies to date have employed the use of genetic tools to indicate the role of the cGAS-STING 
axis in senescence. First and foremost this is the gold standard of indicating the role of a protein 
in a process, however, until recently there has been no pharmacological means of inhibiting 
cGAS. Therefore, one of aim of this study was to characterise the potential of pharmacological 
cGAS inhibitors as a strategy for targeting the SASP.   
 
5.1. Cytosolic mtDNA activates the cGAS-STING axis in senescence 
In Chapter 3 I have shown that mtDNA is more abundant in the cytosol of senescent cells.  
Furthermore, I have shown that genetic or pharmacological inhibition of BAX and BAK can 
suppress mtDNA release and the SASP. Following this finding, I aimed to investigate the 
pathways by which mtDNA contributes to the SASP.  
The first pathway that was assessed as a potential candidate for promoting mtDNA-mediated 
inflammation was the cGAS-STING axis. It has previously been published that cGAS-STING 
is implicated in regulation of the SASP, as well as detection of mtDNA (West et al., 2015; Dou 
et al., 2017; Gluck et al., 2017; Yang et al., 2017). To understand whether cGAS was 
responsible for detecting mtDNA I generated MRC5 fibroblasts expressing a GFP fluorescent 
tag on the cGAS protein, therefore allowing us to assess its location within the cell. First, the 




mean number of cGAS signals detectable within a cell were measured. It was observed that 
there was a significant enhancement in the number of cGAS-GFP signals in senescent cells 
compared to proliferating (p=0.0317) cells (Figures 5.1A and B). However, it is well 
acknowledged that cGAS can detect nuclear fragments of DNA as well as mtDNA in senescent 
cells (Dou et al., 2017; Gluck et al., 2017). Therefore to understand the contribution of mtDNA, 
I specifically measured the number of cGAS signals which colocalised with TFAM (located 
outside mitochondrial networks). It was discovered that the percentage of cells which displayed 
cGAS colocalising with TFAM was vastly increased in senescent cells compared to 
proliferating cells (p=0.0079) (Figures 5.1A and C). In addition, specifically addressing the 
percentage of cells which displayed cGAS colocalising with cytosolic TFAM was significantly 
increased in senescent cells compared to proliferating cells (p=0.0097) (Figures 5.1A and D).  
Following the observation that cGAS was colocalising with TFAM in senescent cells, I wanted 
to assess whether blockage of mtDNA release had any effect on the activation of this pathway. 
In response to cytosolic DNA, the activation of the cGAS-STING axis leads to the translocation 
of NF-κB and the phosphorylation of IRF3 (Tanaka and Chen, 2012; Liu et al., 2015). Together, 
NF-κB and IRF3 promote the transcription of type 1 IFNs and other cytokines (Li and Chen, 
2018).   
First, I assessed proliferating and stress-induced senescent cells by Western Blot (Figure 5.1E). 
Senescent cells displayed an increased expression of the CDKIs p16 and p21 compared to their 
proliferating counterparts. It was found that the total amount of STING was significantly 
increased by 2.5 fold in senescent cells compared to proliferating cells (p=0.0004, Figure 5.1F). 
It was also found that phosphorylated NF-κB was significantly increased by 1.4 fold in 
senescent cells when compared to proliferating cells (p=0.0013, Figure 5.1G).  
Next, I assessed the protein levels of phosphorylated IRF3 in proliferating, senescent and 
senescent cells which had been treated with the BAX inhibitor BCB to block mtDNA release. 
It was found that in senescent cells there was an increase in the phosphorylation of IRF3 
compared to proliferating cells, following the inhibition of mtDNA release using BCB the level 
of phosphorylation was reduced (Figure 5.1H).   





Figure 5.1 – cGAS colocalises with cytosolic mtDNA. 
MRC5 fibroblasts were generated which expressed cGAS with a GFP tag. Following 
transfection, cell were induced to become senescent via irradiation, 20Gy. Following 
irradiation, cells were analysed 6 days later. (A) Representative images of proliferating and 
senescent cells labelled with DAPI (blue), cGAS-GFP (cyan), TFAM (green) and TOM20 (red). 
Images acquired using a 63x objective by confocal microscopy. White arrows in the enlarged 
image indicate cGAS colocalisation with TFAM. (B) Bar graph depicts the mean number of 
cGAS-GFP signals counted in proliferating and senescent cells, n=5 independent experiments. 
(C) Bar graph depicts the percentage of cells which display cGAS-GFP signals colocalising 
with TFAM in proliferating and senescent cells, n=5 independent experiments. (D) Bar graph 
depicts the percentage of cells which display cGAS-GFP signals colocalising with free-TFAM 
(which does not colocalise with TOM20) in proliferating and senescent cells, n=5 independent 
experiments. (E) Representative western blot of STING, phospho-NF-κB (p65), total NF-κB 
(p65), p21, p16 and β-Actin in proliferating, and senescent cells. n=4 independent experiments. 
(F and G) Bar graphs represent the fold change of STING (F) normalised to β-Actin and 




phospho-NF-κB (G) normalised to total NF-κB which had been normalised to β-Actin in 
proliferating and senescent cells, n=4 independent experiments.. (H) Representative western 
blot of phosho-IRF3 and the total IRF3 in proliferating, senescent and senescent cells treated 
with BCB (2.5µM), n=2 independent experiments. Bar graph data is shown as mean, error bars 
represent the standard error of the mean, statistical significance was determined using a two-
tailed unpaired t-test. 
 
Collectively, we observed that the cytosolic DNA sensor cGAS was colocalising with cytosolic 
TFAM, in addition we have also shown indirect evidence that this pathway is activated in 
senescence via the measurement of phosphorylated IRF3. This phosphorylation was not 
observed when mtDNA release was blocked using a drug which blocks BAX channels. 
Following on from these observations I wanted to further understand the contribution of the 
cGAS-STING axis to inflammation in response to mtDNA. To test this, using the CRISPR 
CAS9 system I generated cells which were deficient for STING using three STING constructs 
(Figure 5.2A).  
Following the generation of STINGCRISPR MRC5 cell lines, mtDNA was transfected into the 
cells and known SASP components IL6 and IL-8 were measured (Schematic in Figure 5.2B). 
Following transfection, there was a clear increase in the Empty Vector control cell line for both 
IL-6 and IL-8 (p<0.0001 for both cytokines, Figures 5.2C and D). For each of the three STING 
KO cell lines there was a significant decrease in the secretion of IL-6 and IL-8 following the 
introduction of mtDNA compared to the Empty Vector cells transfected with mtDNA 
(p<0.0001 for both cytokines, Figures 5.2C and D).  
The suppression of the SASP induced by mtDNA was not complete- suggesting that other 
pathways apart from STING may be involved. 





Figure 5.2 - Genetic knockout of STING ameliorates the inflammatory response to 
mtDNA. 
(A) Representative Western Blot image of total protein levels of STING and β-Actin for Empty 
Vector control cells and the three STING deficient cell lines created (#1, #2 and #3). (B) 
Schematic representation of experimental introduction of mtDNA into Empty Vector and 
STING KO cells. (C and D) Bar graph depicts the levels of IL-6 (C) and IL-8 (D) secreted into 
the media 24 hours post transfection as measured by ELISA following 24 hours of transfection 
with mtDNA in proliferating Empty Vector and the three STING deficient cell lines, n=6 
independent experiments. Bar graph data is shown as mean, error bars represent the standard 










The presence of CCFs during senescence has been reported in both mouse embryonic 
fibroblasts and human fibroblasts in a number of models of senescence such as oxidative stress 
induced, OIS and replicatively exhausted cells (Ivanov et al., 2013; Dou et al., 2017; Gluck et 
al., 2017). Mechanistically, it has been reported that nuclear fragments occur due to the loss of 
the nuclear envelope protein Lamin B1. Downregulation of Lamin B1 leads to the loss of 
nuclear envelope integrity which promotes the budding off of nuclear fragments of DNA 
(Ivanov et al., 2013; Gluck et al., 2017). Therefore, the first aim was to assess whether CCFs 
were detectable in MRC5 human fibroblasts.     
First, the presence of Lamin B1 was assessed by Western Blot. In senescent cells there was a 
clear reduction in the overall protein level of Lamin B1 compared to proliferating cells as 
previously shown in the literature (p<0.0001, Figures 5.3A and B) (Ivanov et al., 2013; Dou et 
al., 2017). Next we wanted to assess the presence of CCFs in proliferating and senescent cells, 
in addition, we wanted to verify that these fragments were identified by cGAS. To address this, 
cells were generated which expressed cGAS-GFP and then they were subsequently labelled 
with DAPI and an anti- DNA antibody to allow for CCF identification. Quantification of the 
mean number of CCFs per cell revealed that senescent cells had more detectable CCFs than 
proliferating cells, on average, 0.4 CCFs were detectable compared to 0.05 in proliferating cells 
(p=0.0079, Figures 5.3A and D). Similarly, it was observed that the percentage of cells positive 
for harbouring CCFs was higher in senescent cells compared to proliferating cells, on average 
13% of senescent cells displayed CCFs compared to only 4% of proliferating cells (p<0.0001, 
Figures 5.3A and E). Following these observations we wanted to verify if these observable 
CCFs co-localize with cGAS. Therefore we evaluated colocalisation between cGAS-GFP. We 
found that 100% of detectable CCFs in both proliferating and senescent cells were positive for 
cGAS colocalisation consistent with previously published results (Figures 5.3A and F) (Ivanov 
et al., 2013; Dou et al., 2017).   
Published work has found that approximately 40% of IMR90scells are positive for CCFs when 
induced to become senescent by OIS or genotoxic stress, in some cell types such as BJ cells the 
CCFs are detectable in approximately 60% of cells, whereas MEFs have a lower frequency of 
CCFs; approximately 30% of cells are positive (Ivanov et al., 2013; Dou et al., 2017; Gluck et 
al., 2017). I found that only 13% of stress-induced MRC5 fibroblasts were positive for CCFs, 
but approximately 70% were positive for cytosolic mtDNA. As such, in our case I wanted to 
understand whether CCFs in our model which have largely been regarded as being only of 
nuclear origin could in fact be misidentified and in some cases be of mtDNA origin (Ivanov et 




al., 2013; Dou et al., 2017; Gluck et al., 2017). The dye DAPI which is commonly used to label 
nuclear DNA labels all double-stranded DNA, therefore it is plausible that some DAPI-positive 
CCFs could be mtDNA rather than nuclear DNA. Therefore cGAS-GFP expressing cells which 
were labelled with TOM20, TFAM and DAPI earlier in this study (Figure 5.1A) were assessed. 
Of these CCFs which colocalised with cGAS we found in proliferating cells that 12% were 
positive for TFAM and DAPI, with the remaining 88% colocalising with DAPI only. In 
senescent cells 50% of CCFs were positive for both TFAM and DAPI (p<0.01 compared to 
proliferating cells), with the remaining 50% being positive for DAPI only, (Figure 5.3G). 









Figure 5.3 – Senescent cells lack Lamin B1 and have CCFs which are recognised by cGAS.   
 (A) Representative Western Blot image of total protein levels of Lamin B1 and β-Actin. (B) 
Bar graph represents the fold change of Lamin B1 in proliferating and stress-induced senescent 
cells (10 days post 20Gy irradiation) normalised to β-Actin, n=4 independent experiments. (C) 
Representative images of proliferating cells and stress-induced senescent cells (48 hours and 5 
days post induction of senescence by irradiation 20Gy) expressing cGAS-GFP and labelled 
with DAPI and DNA acquired by fluorescent microscopy using a 63x objective. White arrows 
denote cGAS positive CCFs (characterised by being a separate entity from the nucleus and 
being positive for both DAPI and DNA). Scale bars are 20µm. (D) Bar graph represents the 
quantification of the number of mean number of CCFs per cell in proliferating and stress-
induced senescent cells (5 days post induction), n=5 independent experiments.  (E) Bar graph 
represents the quantification of the percentage of cell which display CCFs in proliferating and 
stress-induced senescent cells (5 days post induction), n=5 independent experiments. (F) Bar 
graph represents the quantification of the percentage of CCFs which colocalise with cGAS in 
proliferating and stress-induced senescent cells (5 days post induction), n=5 independent 
experiments. (G) Bar graph represents the percentage of cGAS positive CCFs which display 
colocalisation with TFAM and DAPI (green) or DAPI alone (blue) in proliferating and stress-
induced senescent cells (5 days post induction), n=5 independent experiments. Bar graph data 
is shown as mean, error bars represent the standard error of the mean, statistical significance 
was determined using a two-tailed unpaired t test. 
 
Following the observation that CCFs are detectable in senescent MRC5 human fibroblasts and 
display co-localisation with cGAS, we wanted to understand their relative contribution to the 
SASP compared to mtDNA. Therefore we assessed the number of CCFs detectable in 
BAX/BAK deficient cells, which we demonstrated earlier in this study to display a reduced 
amount of cytosolic mtDNA in conjunction with an attenuated SASP. 
Analysis of the mean number of CCFs per cell revealed that there was no difference in the mean 
number of CCFs in proliferating Empty Vector cells and proliferating BAX/BAK deficient 
cells. Furthermore, senescent Empty Vector cells had a significantly increased number of CCFs 
(0.05 to 0.38 mean CCFs per cell, p<0.0001). Senescent BAX and BAK cells also displayed an 
increase of 0.07 to 0.22 CCFs on average per cell, however this increase was non-significant. 
The difference between senescent Empty Vector and BAX/BAK deficient cells was also non-
significant (Figure 5.4A). 
In addition to characterising the mean number of CCFs, the percentage of cells harbouring 
CCFs was also analysed. Similarly, I found that there was no difference in the percentage of 
cells containing CCFs in the proliferating Empty Vector and BAX/BAK deficient cells. 
Senescent Empty Vector cells displayed a significant increase from 3.7% of cells to 13.5% of 
cells (p<0.001). Senescent BAX/BAK deficient cells also showed an increase from 4.4% to 




12.2% of cells (p<0.05). Analysis of the percentage of CCF positive cells revealed that there 
was no significant difference between senescent Empty Vector and BAX/BAK deficient cells 
(Figure 5.4B).  
At this stage, whilst our data supports that cGAS can bind to TFAM- alternative methods will 
need to be applied to confirm these results. For instance, ChIP-seq to determine which type of 
DNA is bound to cGAS, similarly immunoprecipitation between TFAM and cGAS would be 
crucial. 
 
Figure 5.4 – BAX/BAK deficient cells harbour as many CCFs as Empty Vector cells. 
Proliferating and stress-induced senescent (10 days post 20Gy irradiation) Empty Vector and 
BAX/BAK deficient cells were assessed for the presence of CCFs. (A) Bar graph represents the 
quantification of the number of mean number of CCFs per cell in proliferating and stress-
induced senescent cells (5 days post induction).  (B) Bar graph represents the quantification of 
the percentage of cell which display CCFs in proliferating and stress-induced senescent cells (5 
days post induction). n=5 independent experiments. Bar graph data is shown as mean, error 










5.2. Genetic ablation of STING alleviates the SASP 
It has been reported in the literature that following the detection of CCFs cGAS drives the 
SASP, this is mediated through cGAMP production which activates STING, which proceeds to 
form a complex with TBK1 which promotes phosphorylation and activation of the transcription 
factors IRF3 and NF-κB (Chen et al., 2016). This leads to production of type 1 IFNs and 
inflammatory cytokines associated with the SASP. It has been demonstrated that in both MEFs 
and human fibroblasts that the genetic removal of cGAS alleviates the SASP (Dou et al., 2017; 
Gluck et al., 2017). As such, I wanted to verify whether the genetic knockout of STING which 
would impair the cGAS-STING signalling pathway would also prevent the SASP. Therefore 
STING deficient MRC5 fibroblasts generated earlier in the study were used.  
In proliferating cells which harbour an Empty Vector or have had STING genetically ablated 
there was no difference in the secretion of IL-6 and IL-8. Following the development of 
senescence in the empty vector control cell line there was a clear significant increase in the 
production of both IL-6 and IL-8 (p<0.0001 for both cytokines). In each of the three STING 
deficient cell lines following the development of senescence there was no increase in the 
production of IL-6 or IL-8 compared to their proliferating counterparts. Furthermore, for each 
of the senescent STING deficient cell lines the secretion of IL-6 and IL-8 was significantly 
decreased compared to the senescent empty vector control cells (p<0.0001 in each case) 
(Figures 5.5A and B).  
Next, the cell cycle regulators p16 and p21 were assessed in proliferating and senescent Empty 
Vector and STING deficient cells by western blot (Figure 5.5C). Senescent Empty Vector cells 
displayed an increased expression of p16 and p21 compared to their proliferating counterparts 
(p<0.01 in both cases, Figures 5.5D and E). Similarly, STING deficient cells displayed an 
increased expression of p16 compared to their proliferating counterparts (p<0.01), although p21 
was not increased (Figure 5.5D and E).  





Figure 5.5 – Genetic removal of STING diminishes the SASP. 
The SASP was assessed by ELISA in empty vector (control) and STING deficient cells (#1, #2 
and #3) in proliferating and stress-induced cells (10 days post 20Gy irradiation). (A and B) Bar 
graph depicts the levels of IL-6 (A) and IL-8 (B) secreted into the media by proliferating and 
senescent Empty Vector and the three STING deficient cell lines, n=6 independent experiments. 
(C) Representative Western Blot image of total protein levels of STING, p21, p16 and β-Actin 
for Empty Vector control cells and STING deficient cells. (D and E) Bar graphs represent 
quantification of total p16 (D) and p21 (E) protein levels in proliferating and senescent empty 
vector (control) and STING deficient cells n=4 independent experiments. Bar graph data is 
shown as mean, error bars represent the standard error of the mean, statistical significance was 
determined using a one-way ANOVA. 
 
 




Earlier in Chapter 3 I observed that the BAX inhibitor BCB could decrease the SASP, similarly, 
I found that genetic removal of STING diminishes the SASP, as such I wanted to assess whether 
the effects of BCB in Empty Vector cells were similar to the genetic depletion of STING, 
secondly, I wanted to see whether treatment of STING deficient cells with BCB would have 
any further impact on the secretion of IL-6 and IL-8. 
 Following the development of stress-induced senescence both IL-6 and IL-8 were increased in 
senescent Empty Vector cells (p<0.0001 for both cytokines), no increase was observed in 
STING deficient cells. As observed earlier, treatment with BCB prompted a significant decrease 
of both IL-6 and IL-8 in Empty Vector senescent cells (p<0.0001 for both cytokines). In STING 
deficient cells, no further decrease was observed following treatment with BCB. For the 
secretion of IL-6 and IL-8 there was no statistically significant difference between senescent 
Empty Vector + BCB and senescent STING KO (Figures 5.6A and B).   
 
Figure 5.6 – Treatment with BCB does not further decrease the SASP in STING KO 
fibroblasts. 
Bar graph depicts the levels of IL-6 (A) and IL-8 (B) secreted into the media by proliferating 
and senescent Empty Vector and the STING deficient cell lines which have been treated with 
either DMSO (control) or BCB (2.5µM) 10 days post-X-ray irradiation, n=6 independent 
experiments. Bar graph data is shown as mean, error bars represent the standard error of the 
mean, statistical significance was determined using a one-way ANOVA. 
 




5.3. Pharmacological inhibition of cGAS using RU.521 inhibits the SASP but does not 
rescue the cell cycle arrest. 
Following our confirmation that cells lacking STING no longer exhibited a SASP we wanted 
to understand whether a recently identified small molecule (RU.521) which targets cGAS also 
impacted on the SASP. RU.521 was recently demonstrated to bind to the active site of cGAS 
where it could effectively block cGAS-STING activation following exposure to dsDNA 
(Vincent et al., 2017). In the context of senescence, we therefore wanted to test whether RU.521 
could effectively prevent the inflammatory response that occurs in response to cytosolic 
mtDNA and nuclear DNA. As expected the development of senescence promoted an increase 
in the secretion of IL-6, IL-8 and IP-10 (p<0.0001 for IL-6 and IL-8, p<0.05 for IP-10). 
Following the treatment of senescent cells with RU.521, there was a non-significant decrease 
in the secretion of IL-6, IL-8 and IP-10 with the 1µM concentration. However, Treatment with 
2.5µM promoted a significant decrease in the secretion of each of the cytokines compared to 
the untreated senescent cells (p<0.0001 for IL-6 and IL-8, p<0.001 for IP-10). Higher 
concentration (5uM) did not further decrease the SASP, suggesting that 2.5 is the optimal 
concentration (Figures 5.7A, B and C).  It should be noted that we still need to verify if RU521 
is acting on this pathway during senescence, by measuring for instance IRF3 phosphorylation 
or by using STING KO cells.      
 
 
Figure 5.7 – The small molecule cGAS inhibitor RU.521 suppresses the SASP. 
Proliferating and stress-induced senescent cells (20Gy irradiation) were maintained with 
RU.521 or a DMSO control for 10 days following the induction of senescence. The SASP was 
then assessed by ELISA.  (A, B and C) Bar graph depicts the levels of IL-6 (A), IL-8 (B) and 
IP-10 (C) secreted into the media by proliferating and senescent cells, n=4 independent 
experiments. This experiment was performed in collaboration with MRes student Sophia 
Quigley. Bar graph data is shown as mean, error bars represent the standard error of the mean, 
statistical significance was determined using a one-way ANOVA. 





In addition to the SASP we wanted to characterise further the effects of RU.521 on the 
development of the senescence phenotype. First SA-β-Gal was measured (Figures 5.8A and B). 
I found that following the induction of senescence there was an increase in the percentage of 
SA-β-Gal positive cells (p<0.0001), however, senescent cells treated with RU.521 displayed a 
trend towards a reduction in the number of SA-β-Gal positive cells (however, not statistically 
significant). In the proliferating cells, RU.521 also promoted an increase in the number of 
positive SA-β-Gal cells, however this was non-significant (Figure 5.8B). Next, the marker of 
proliferation Ki67 was assessed (Figure 5.8C and D). We found that for proliferating cells there 
was no difference when treated with RU.521 compared to the DMSO control with 
approximately 50% of control cells being positive and 40% of RU.521 treated cells being 
positive for Ki67. In the senescent cells there was a significant decrease in the expression of 
Ki67 compared to their proliferating counterparts with only 2% of cells positive for Ki67 
(p<0.0001). Similarly, senescent cells treated with RU.521 had no rescue in the loss of 
proliferation as they also displayed a very low level of Ki67 positive cells (4%).  
The effect of RU.521 on the cyclin-dependent kinase inhibitor p21 was also measured. In 
proliferating cells treated with RU.521 there was no difference between those treated with 
DMSO alone. Following the development of senescence there was a significant increase in the 
number of p21 positive cells with 90% of cells being positive (p<0.0001). Following the 
treatment of senescent cells with RU.521 there was a small decrease in the number of p21 
positive cells with 78% being positive, however this decrease is not significant (Figure 5.8E)  
The marker γH2AX is a reliable marker of the DDR associated with senescence. We found that 
treatment of proliferating cells with RU.521 did not impact on the mean number of γH2AX foci 
per cell (approximately 1 per cell). Following the development of senescence there was a 
significant increase in the mean number of γH2AX foci per cell (2.7 per cell, p<0.0001). Culture 
of senescent cells with RU.521 lead to a small decrease in the mean number of γH2AX (2.1 per 
cell), however this was not significant (Figure 5.8F).  
 





Figure 5.8 – RU.521 does not prevent the cell cycle arrest features of cellular senescence. 




Proliferating and stress-induced senescent cells (20Gy irradiation) were maintained with 
RU.521 (2.5µM) or a DMSO control for 10 days following the induction of senescence. 
Markers of senescence were then assessed. (A) Representative images of SA-β-Gal staining in 
proliferating and senescent cells treated with RU.521 or a DMSO control, images acquired 
using bright field microscopy and a 40x objective. (B) Bar graph represents the quantification 
of the percentage of SA-β-Gal positive cells for proliferating (white bars) and senescent cells 
(red bars) treated with RU.521 or a DMSO control. (C) Representative immunofluorescent 
images of Ki67 and DAPI staining in proliferating and senescent cells treated with RU.521 or 
a DMSO control, images acquired using bright field microscopy and a 40x objective. (D) Bar 
graph represents the quantification of the percentage of Ki67 positive cells for proliferating 
(white bars) and senescent cells (red bars) treated with RU.521 or a DMSO control. (E) Bar 
graph represents the quantification of the percentage of p21 positive cells for proliferating 
(white bars) and senescent cells (red bars) treated with RU.521 or a DMSO control. (F) Bar 
graph represents the quantification of the mean number of γH2AX foci per cell for proliferating 
(white bars) and senescent cells (red bars) treated with RU.521 or a DMSO control. These 
experiments were performed in collaboration with MRes student Sophia Quigley. Bar graph 
data is shown as mean, error bars represent the standard error of the mean, n=4 independent 


















5.4. Pharmacological inhibition of cGAS using anti-malarial drugs inhibits the SASP 
but does not rescue the cell cycle arrest. 
Prior to the development of RU.521 the only other compounds identified which had inhibitory 
activity against cGAS were a group of anti-malarial drugs. It was discovered that this family of 
drugs could interfere with the interaction of cGAS and double stranded DNA. Specifically, 
quinacrine dihydrochloride and 9-amino-6-chloro-2-methoxyacridine (ACMA) were 
demonstrated to have a good inhibitory efficiency and prevented IFN-β expression in response 
to double stranded DNA (An et al., 2015). Furthermore, these drugs are already used in the 
clinic and from a safety perspective they are well tolerated. Therefore, it was of interest to 
understand whether the findings of cGAS inhibition using RU.521 could be achieved using the 
anti-malarial drugs quinacrine dihydrochloride and ACMA.  
First the two compounds were assessed for their capacity to inhibit the SASP in MRC5 human 
fibroblasts. Quinacrine dihydrochloride was assessed at 1-10µM. Proliferating cells display low 
levels of secreted IL-6, IL-8 and IP-10, as such, treatment with quinacrine dihydrochloride at 
each of the concentrations did not have an effect on proliferating cells. Following the 
development of stress-induced senescence there was a statistical increase in each of the 
cytokines for the control senescent cells; IL-6, IL-8 and IP-10 (<0.0001 for each) (Figures 5.9A-
C). Treatment of senescent cells with quinacrine dihydrochloride at 1µM had no effect on the 
level of IL-6, IL-8 and IP-10 secreted by senescent cells. Treatment with Quinacrine 
dihydrochloride at 5µM provoked a significant decrease in the secretion of IL-6, IL-8 and IP-
10 (<0.01 for IL-6 and <0.001 for IL-8 and IP-10). Treatment with quinacrine dihydrochloride 
at 10µM had the most pronounced effect on reducing the SASP. There was a significant 
reduction in the secretion of IL-6, IL-8 and IP-10 (<0.001 for IL-6 and <0.0001 for IL-8 and 
IP-10 (Figures 5.9A, B and C).  
ACMA was assessed at 1µM. Proliferating cells display low levels of secreted IL-6, IL-8 and 
IP-10, as such, treatment with ACMA did not have an effect on proliferating cells. Following 
the development of stress-induced senescence there was a statistical increase in each of the 
cytokines for the control senescent cells; IL-6, IL-8 and IP-10 (<0.0001 for each). Treatment 
with ACMA at 1µM provoked a significant decrease in the secretion of IL-6, IL-8 and IP-10 
<0.001 for IL-6, IL-8 and IP-10, Figures 5.9 D, E and F). 






Figure 5.9 – The anti-malarial drugs quinacrine dihydrochloride and ACMA suppress the 
SASP. 
Proliferating and stress-induced senescent cells (20Gy irradiation) were maintained with 
quinacrine dihydrochloride (1-10µM), ACMA (1µM) or a DMSO control for 10 days following 
the induction of senescence. The SASP was then assessed by ELISA.  (A, B and C) Bar graph 
depicts the levels of IL-6 (A), IL-8 (B) and IP-10 (C) secreted into the media by proliferating 
and senescent cells treated with either a DMSO control or quinacrine dihydrochloride 1-10µM, 
n=4 independent experiments. (D, E and F) Bar graph depicts the levels of IL-6 (D), IL-8 (E) 
and IP-10 (F) secreted into the media by proliferating and senescent cells treated with either a 
DMSO control or ACMA 1µM, n=4 independent experiments. These experiments were 
performed in collaboration with the undergraduate student Tom Kidder. Bar graph data is 
shown as mean, error bars represent the standard error of the mean, statistical significance was 













Next, other markers of senescence and the cell cycle arrest were measured following treatment 
with quinacrine dihydrochloride. First, SA-β-Gal was measured. Treatment of proliferating 
cells with quinacrine dihydrochloride provoked a small non-significant increase in the number 
of SA-β-Gal positive cells. Following the induction of senescence there was a significant 
increase in the number of positive cells (p<0.0001). Treatment of senescent cells with 
quinacrine dihydrochloride lead to a small decrease in the number of positive cells, however 
this was not significant (Figure 5.10A). 
Next, γH2AX was measured. Treatment of proliferating cells with quinacrine dihydrochloride 
did not have an impact on the mean number of γH2AX per cell. Senescent cells displayed a 3.5 
fold increase in the number of foci (p<0.001), interestingly, senescent cells treated with 
quinacrine dihydrochloride had a significant decrease in the mean number of γH2AX foci (from 
3.5 to 2.2 foci per cell, Figure 5.10B).    
In addition the markers of the cell cycle Ki67 and p21 were measured. Ki67 was present in 
approximately 40% of proliferating cells, treatment of proliferating cells with quinacrine 
dihydrochloride had no effect on the number of Ki67 positive cells. Following the induction of 
senescence there was a decrease to only 1% of cells being positive for Ki67 (p<0.001). Similarly 
treatment of senescent cells with quinacrine dihydrochloride did not increase the number of 
Ki67 positive cells compared to senescent control cells (Figure 5.10C). For p21, there was no 
difference in the level of p21 cells in proliferating control and quinacrine dihydrochloride 
treated cells. In senescent cells, there was an increase to 97% of cells being positive for p21 
(p<0.0001). Treatment of senescent cells with quinacrine dihydrochloride did not reduce the 
number of p21 positive cells compared to senescent control cells (Figure 5.10D).    





Figure 5.10 – The anti-malarial drug quinacrine dihydrochloride does not rescue the cell 
cycle arrest. 
Proliferating and stress-induced senescent cells (20Gy irradiation) were maintained with 
quinacrine dihydrochloride (5µM) or a DMSO control for 10 days following the induction of 
senescence. Markers of senescence were then assessed. (A) Bar graph represents the 
quantification of the percentage of SA-β-Gal positive cells for proliferating (white bars) and 
senescent cells (red bars) treated with quinacrine dihydrochloride or a DMSO control. (B) Bar 
graph represents the quantification of the mean number of γH2AX foci per cell for proliferating 
(white bars) and senescent cells (red bars) treated with quinacrine dihydrochloride or a DMSO 
control. (C) Bar graph represents the quantification of the percentage of Ki67 positive cells for 
proliferating (white bars) and senescent cells (red bars) treated with quinacrine dihydrochloride 
or a DMSO control. (D) Bar graph represents the quantification of the percentage of p21 
positive cells for proliferating (white bars) and senescent cells (red bars) treated with quinacrine 
dihydrochloride or a DMSO control. These experiments were performed in collaboration with 
undergraduate student Tom Kidder. Bar graph data is shown as mean, error bars represent the 
standard error of the mean, n=4 independent experiments. Statistical significance was 
determined using a one-way ANOVA. 
 




The anti-malarial drug ACMA was also assessed for its effect on the cell cycle arrest features 
of the senescence phenotype. First, SA-β-Gal was assessed as a robust marker of senescence. 
Following the development of senescence there was a significant increase in the percentage of 
cells positive for SA-β-Gal from 1% of proliferating cells positive to 92% of senescent cells 
being positive (p<0.0001). Following the maintenance of senescent cells with ACMA there was 
a significant decrease in the number of positive cells to 28% (p<0.05, Figure 5.11A).  
Second, the number of γH2AX foci per cell were measured to assess the effect of ACMA on 
DNA damage. Following the development of senescence the mean number of γH2AX foci 
increases from an average of 1.6 foci per cell to 3.6 foci per cell (p<0.001). Treatment of 
senescent cells with ACAM produced a very small decrease in the mean number of γH2AX 
foci, however this was not significant (Figure 5.11B).  
To understand whether ACMA affects the cell cycle arrest, the proliferation marker Ki67 was 
assessed. It was present in 44% of the proliferating cells, this reduced to 1% of cells being 
positive in senescent cells (p<0.0001). Treatment of senescent cells with ACMA did not 
promote an increase in the number of Ki67 positive cells in comparison to untreated senescent 
cells (Figure 5.11C).  
Finally, the cyclin dependent kinase inhibitor p21 was measured. The development of 
senescence caused a significant increase in the number of p21 positive cells from 22% of 
proliferating cells to 98% in senescent cells (p<0.0001). Senescent cells cultured with ACMA 
displayed a small decrease in the number of p21 positive cells to 83%, however, this was not 
significant (Figure 5.11D).  





Figure 5.11 – The anti-malarial drug ACMA does not rescue the cell cycle arrest. 
Proliferating and stress-induced senescent cells (20Gy irradiation) were maintained with 
ACMA (1µM) or a DMSO control for 10 days following the induction of senescence. Markers 
of senescence were then assessed. (A) Bar graph represents the quantification of the percentage 
of SA-β-Gal positive cells for proliferating (white bars) and senescent cells (red bars) treated 
with ACMA or a DMSO control. (B) Bar graph represents the quantification of the mean 
number of γH2AX foci per cell for proliferating (white bars) and senescent cells (red bars) 
treated with ACMA or a DMSO control. (C) Bar graph represents the quantification of the 
percentage of Ki67 positive cells for proliferating (white bars) and senescent cells (red bars) 
treated with ACMA or a DMSO control. (D) Bar graph represents the quantification of the 
percentage of p21 positive cells for proliferating (white bars) and senescent cells (red bars) 
treated with ACMA or a DMSO control. These experiments were performed in collaboration 
with undergraduate student Tom Kidder. Bar graph data is shown as mean, error bars represent 
the standard error of the mean, n=4 independent experiments. Statistical significance was 
determined using a one-way ANOVA. 
 




Earlier in this study the pro-inflammatory response was reduced in STINGCRISPR cells following 
the transfection of mtDNA, however, it was not completely reduced. Therefore it was postulated 
that other pathways may be involved in the response to mtDNA in senescent cells.  
Therefore, I assessed the NLRP3 inflammasome, which has been previously implicated in OIS 
and recognised as having the capacity to mount an inflammatory response to mtDNA (Nakahira 
et al., 2011; Acosta et al., 2013). First, the total protein level of the NLRP3 inflammasome was 
measured by western blot, interestingly, there appeared to be a slight decrease in senescent cells 
however this was not statistically different (Figure 5.12A and B). It is possible that the NLRP3 
inflammasome is active and this is not associated with overall changes in protein level. Its 
activation is associated with cleavage of caspase 1, therefore the levels of cleaved caspase-1 
were assessed. Analysis of the total protein levels of caspase 1 measured by pro-caspase 1 
revealed that there was a significant 3-fold increase in the levels found in senescent cells 
(p=0.0216) (Figure 5.12C and D). Indeed, there was also a 3-fold increase in the levels of 
cleaved-caspase 1 in senescent cells when compared to proliferating cells (p=0.0012) (Figure 
5.12C and E). The cleavage of caspase 1 promotes an inflammatory response by promoting the 
maturation of IL-1β through cleavage to cleaved IL-1β, which then leads to secretion of IL-1β 
and IL-18 (Jo et al., 2016). Interestingly, despite cleaved-caspase 1 being present there was no 
detectable cleavage of IL-1β in senescent MRC5 fibroblasts (Figure 3.18F). Furthermore, as 
inflammasome activation is associated with secretion of IL-18, I measured the levels of secreted 
IL-18 in proliferating and senescent cells. The levels of IL-18 were very low, bordering on the 
detectable limit with no differences between proliferating and senescent cells (Figure 5.12G). 
 





Figure 5.12 – Characterisation of the NLRP3 inflammasome in senescence. 
MRC5 fibroblasts were analysed 10 days post induction of stress induced senescence (20Gy, 
irradiation). (A) Representative western blot of total level of NLRP3 in proliferating and 
senescent fibroblasts. (B) Bar graph depicting the protein level of NLRP3 normalised to β-actin 
in proliferating (white bar) and senescent cells (red bar), n=4 independent experiments. (C) 
Representative western blot of pro-caspase 1 and cleaved-caspase 1 in proliferating and 
senescent fibroblasts. (D)  Bar graph depicting the protein level of pro-caspase 1 normalised to 
β-actin in proliferating (white bar) and senescent cells (red bar), n=4 independent experiments. 
(E) Bar graph depicting the protein level of pro-caspase 1 normalised to β-actin in proliferating 
(white bar) and senescent cells (red bar), n=4 independent experiments. (F) Representative 
western blot of cleaved –IL-1β in proliferating (white bar) and senescent cells (red bar), n=4 
independent experiments. (G) Bar graph depicts the levels of IL-18 (pg/ml) secreted by 
proliferating (white bar) and senescent cells (red bar) as measured by cytokine array, n=6 
independent experiments.  Bar graph data is shown as mean, error bars represent the standard 








It has been reported that TLR9 can provoke a pro-inflammatory response to unmethylated 
double stranded DNA CpG motifs which are found within the genome of bacteria and viruses, 
as well as DNA that arises following cellular damage (Mouchess et al., 2011). In addition, it 
has been identified that TLR9 can induce an inflammatory response to mtDNA through p38 
MAPK and NF-κB (Bao et al., 2016). Therefore we hypothesised that if TLR9 was responsible 
for the inflammatory response to mtDNA its expression would be upregulated in senescent 
cells. We measured the total protein level of TLR9 by Western Blot and found that senescent 
cells displayed a non-significant 1.4-fold increase in the expression of TLR9 (Figures 5.12A 
and B).  
 
Figure 5.13 - The expression of TLR9 is unchanged in senescent cells. 
MRC5 fibroblasts were analysed 10 days post induction of stress induced senescence (20Gy, 
irradiation). (A) Representative western blot of total level of TLR9 in proliferating and 
senescent fibroblasts. (B) Bar graph depicting the protein level of TLR9 normalised to β-actin 
in proliferating (white bar) and senescent cells (red bar), n=3 independent experiments. Bar 
graph data is shown as mean, error bars represent the standard error of the mean, statistical 











Earlier in this study it has been demonstrated that mtDNA is present in the cytosol of senescent 
cells. Whilst here it becomes available to the innate immune system to launch a pro-
inflammatory response. In this part of the study we aimed to understand mechanistically how 
mtDNA mediates this response and whether pharmacological interventions can prevent the 
SASP. Specifically, our data indicates that the pro-inflammatory response which transpires in 
response to mtDNA ensues as a consequence of recognition by the DNA sensor cGAS. 
Furthermore, we show that pharmacological inhibitors of cGAS can alleviate the SASP without 
removing the cell cycle arrest aspect of senescence. 
I investigated the potential of the NLRP3 inflammasome as a candidate for the mtDNA-
associated SASP observed during senescence. It has previously been reported that the NLRP3 
inflammasome is active and contributes to the SASP in OIS and senescent endothelial vascular 
cells (Acosta et al., 2013; Yin et al., 2017; Wiggins et al., 2019). First, we assessed the total 
level of NLRP3 and found this to be unchanged between proliferating and senescent cells. 
However, it is possible that NLRP3 could be active with no observable change in overall protein 
levels. In order to further characterise the NLRP3 inflammasome, the cleavage of caspase 1 
was assessed. It is known that during activation caspase 1 undergoes autocatalytic activation to 
cleaved caspase 1. The role of cleaved caspase 1 is then to cleave pro-IL-1β to the mature form 
IL-1β, which promotes its secretion and that of IL-18 (Jo et al., 2016). We found that senescent 
cells had enhanced levels of cleaved caspase 1, however this was not associated with cleavage 
of IL-1β or secretion of IL-18 which both occur downstream of NLRP3 inflammasome 
activation. However, at this stage it is unclear what role cleaved caspase 1 is undertaking during 
senescence and therefore warrants further investigation. Although, in the previous chapter I 
found that inhibition of caspase 1 had no effect on the secretion of IL-6 or IL-8. Furthermore, 
cleaved IL-1β is a feature of other models of senescence such as OIS (Acosta et al., 2013). 
Therefore it is plausible that the inflammasome not being active may be a phenomenon that is 
unique to MRC5 human fibroblasts, as such further investigation is required.  Together, these 
data suggest that the NLRP3 inflammasome is not active in stress-induced senescence of MRC5 
fibroblasts. However, at this stage these findings should be considered preliminary as further 
work is still required to confirm this notion. Therefore, it is important to assess whether the 
genetic removal or knockdown of NLRP3 has an effect on SASP regulation. Similarly, it would 
be interesting to observe whether NLRP3 deficient cells display an altered inflammatory 
response to the transfection of mtDNA in MRC5 human fibroblasts and other cell lines.    




Next we assessed the potential of TLR9 as being an inducer of the SASP in response to cytosolic 
mtDNA. It has been reported that TLR9 can recognise mtDNA and stimulate the upregulation 
of IFN1 genes (Uematsu and Akira, 2007; Bao et al., 2016). It was found that senescent cells 
displayed a small non-significant increase in the total protein level of TLR9. Although 
interesting, this finding does not allow us to determine whether TLR9 is being activated during 
senescence. Furthermore, it is known that TLR9 activation culminates in signalling to NF-κB, 
which is activated by a number of other stimuli during senescence (Uematsu and Akira, 2007; 
Chien et al., 2011; Kang et al., 2015; Wiley et al., 2016). As such, it is challenging to dissect 
the role of TLR9 in senescence. Furthermore, a recent study investigating the role of TLRs in 
senescence found that during OIS there was no observable upregulation of the TLR9 gene (Hari 
et al., 2018). As such, the data in this study on TLR9 is not sufficient to draw any conclusions 
regarding its role in regulating the SASP in response to mtDNA. Therefore, to further clarify 
this relationship future work should examine whether the genetic removal or pharmacological 
inhibition of TLR9 in senescent cells has an effect on the SASP. In addition, it would be of 
interest to genetically or pharmacologically modulate BAX/BAK pores to prevent mtDNA 
release and assess whether this has an effect on the protein level of TLR9. Similarly, it would 
be useful to generate cells deficient for both STING and TLR9 and assess whether this leads to 
a further decrease in the SASP. Together, these experiments would give us a clearer idea of the 
role of TLR9 during senescence.   
In addition, to characterising the NLRP3 inflammasome and TLR9 we assessed the cGAS-
STING axis. It has been published previously that cGAS can recognise mtDNA and mount an 
inflammatory response through NF-κB and IFN1 genes (West et al., 2015). We observed that 
senescent cells expressing cGAS-GFP reporter system displayed co-localisation with cytosolic 
TFAM. This complements findings by West et al, who demonstrated that cGAS colocalises 
with mtDNA (West et al., 2015). In addition, we demonstrated that downstream of cGAS-
STING activation senescent cells display an increased level of phosphorylated IRF-3, this 
phosphorylation is diminished in senescent cells which have had mtDNA release blocked using 
BCB. To further address the importance of the cGAS-STING axis signalling in response to 
cytosolic mtDNA we generated STING deficient cells and transfected mtDNA into them. We 
found that STING deficient cells had a significantly diminished secretion of IL-6 and IL-8 
following transfection of mtDNA compared to their STING proficient counterparts. Finally, we 
observed that in the absence of STING senescent cells had a dramatically reduced SASP. These 
findings corroborate previous studies which have demonstrated that cGAS or STING deficient 




fibroblasts, MEFs and mice have a reduced SASP response (Dou et al., 2017; Gluck et al., 
2017; Yang et al., 2017). Earlier in this study, I found that the mtDNA release and associated 
pro-inflammatory response was dependent on BAX and BAK pores, consistently, it was shown 
that the BAX inhibitor BCB could decrease the SASP. Therefore, I questioned whether 
treatment of STING deficient cells with BCB would have an additional effect at decreasing the 
SASP. I found that BCB had no further effect at reducing the SASP in STING deficient cells. 
This suggests that the mechanism by which BCB and STING lead to SASP reduction are 
potentially interlinked, which in this model of stress-induced senescence is BAX/BAK 
mediated mtDNA release and subsequent detection by the cGAS-STING axis leading to pro-
inflammatory signalling. Collectively, these findings provide convincing evidence that the 
cGAS-STING axis is active during senescence in response to cytosolic mtDNA. However, there 
are some considerations which need to be taken into account. 
First, senescent STING deficient cells displayed an almost complete reduction in the SASP, 
whereas when mtDNA was transfected into STING deficient cells there was approximately a 
50% reduction in the secretion of IL-6 and IL-8. This suggests that during stress-induced 
senescence the SASP is predominantly being regulated by cGAS-STING, however, the 
transfection of mtDNA is likely activating another innate immune pathway and not solely 
cGAS-STING. It is likely that in our experiment of transfecting mtDNA, the level of DNA 
transfected is above physiological levels of mtDNA observed in the cytosol of senescent cells 
and may be activating the TLR9 or NLRP3 pathway alongside the cGAS-STING axis. To 
further dissect the pathways active it would be interesting experimentally to transfect mtDNA 
into cells that are deficient for both STING and TLR9 or NLRP3 and examine the resulting 
inflammatory response. Another point of consideration is that a recent study demonstrated that 
genetic manipulation of a gene can trigger compensatory upregulation of related genes to allow 
the cell to continue to function adequately (Rossi et al., 2015). In this context, it is conceivable 
that STING deficient cells could upregulate TLR9 and NLRP3 DNA sensing mechanisms. 
Conversely, as cGAS (which is responsible for DNA sensing) is still functional in these cells 
and it is the signalling network that is impaired by STING knockout, it is unlikely that this is 
the case. However, it would still be interesting to assess the activity of TLR9 and NLRP3 
activity in this setting. 
Interestingly, the amount of IL-6 and IL-8 produced by senescent cells and proliferating cells 
transfected with mtDNA is comparable. It is important to consider that work in the field has 
pinpointed the role of nuclear derived CCFs being recognised by cGAS-STING during 




senescence (Dou et al., 2017; Gluck et al., 2017). This indicates that as both CCFs and mtDNA 
are contributing to the SASP it is likely that the notion of transfecting more mtDNA into the 
cells than is observed physiologically in senescent cells is applicable. Conversely, earlier in our 
study BAX and BAK deficient cells displayed an almost complete ablation of the SASP, 
suggesting that mtDNA is the key determinant of the SASP rather than a dual contribution from 
CCFs. In further support of this notion, the percentage of cells positive for CCFs is relatively 
low in our model of stress-induced senescence (13.5%), whereas in published studies where 
CCFs have been implicated as drivers of the SASP the percentage of cells is much higher 
(approximately 30% in MEFs, 40% in IMR90s and 60% in BJs) (Dou et al., 2017). Moreover, 
the studies investigating CCFs have been predominantly performed in OIS or senescence 
induced by genotoxic agents such as palbociclib or etoposide (Dou et al., 2017; Gluck et al., 
2017). We also found that senescent BAX and BAK deficient cells with a significantly 
decreased SASP displayed the same percentage of cells containing CCFs as senescent Empty 
Vector control cells. To put our data into context these findings support the idea that in our 
model of stress-induced senescent cells mtDNA plays a more significant role in driving the 
SASP than CCFs. However, further investigation is still required to clarify this relationship as 
it is likely CCFs are more important in the SASP regulation of other cell types such as IMR90s 
where they are observed at a higher frequency.    
Following these observations we were interested in investigating the origin of CCFs more 
closely. The formation of CCFs has been associated with the loss of Lamin B1, a protein 
responsible for maintaining nuclear integrity (Ivanov et al., 2013; Dou et al., 2017; Gluck et 
al., 2017). Following the induction of stress-induced senescence we observed a complete loss 
of Lamin B1, furthermore, in cells expressing cGAS-GFP we saw clear co-localisation of cGAS 
with CCFs. This complements published findings where live-cell imaging demonstrates that 
CCFs “bud off” from the nucleus due to the loss of Lamin B1 and subsequently being detected 
by cGAS (Dou et al., 2017; Gluck et al., 2017).  
In our study, I observed that the percentage of MRC5 human fibroblasts harbouring CCFs was 
relatively low, I therefore speculated that some CCFs may in fact be of mitochondrial origin as 
earlier work in this study has implicated mtDNA as an important regulator of the SASP. 
Classically, CCFs have been identified by labelling with DAPI, γH2AX and Histone H3 
(generally considered to be specific to nuclear DNA). Often just DAPI and γH2AX are used to 
identify CCFs. It is known that DAPI labels all double stranded DNA, therefore it is possible 
that some CCFs may not be nuclear DNA but in fact be misidentified as mtDNA (Dou et al., 




2017; Gluck et al., 2017). Therefore we assessed cGAS co-localization with TFAM and DAPI 
signals in the cytoplasm of senescent cells. We found that 50% of cGAS positive cytosolic 
DNA fragments were positive for both TFAM and DAPI. This suggests that 50% of these 
cytosolic DNA fragments CCFs are potentially of mitochondrial origin rather than the nucleus. 
Furthermore, when we analysed senescent BAX/BAK deficient cells which do not release 
mtDNA to the cytoplasm we did not see any differences in the percentage of cells harbouring 
CCFs, however the mean number of CCFs per cell was reduced by 43% (though non-
significant). This fits with our earlier observation of 50% of cytosolic nuclear DNA being 
TFAM positive and potentially of mitochondrial origin as these would no longer be released in 
BAX/BAK deficient cells, and therefore we would expect to see a reduction in the mean number 
of CCFs per cell. An important consideration is that the TFAM antibody used could potentially 
inadvertently bind to double stranded nuclear DNA fragments found in the cytoplasm. Another 
key limitation, is that the size of the cytoplasmic DNA fragments has not been taken into 
account. It is likely that as mtDNA is only 16,569 base pairs it would appear particularly small 
as a punctate DNA foci (as seen in earlier staining’s in this study). Therefore, it would be 
interesting to characterise whether DNA which has been labelled positively for DAPI, DNA, 
TFAM and cGAS is largely restricted to smaller fragments of DNA rather than larger ones 
which are feasibly more likely to have budded from the nucleus. Similarly, as the cells in this 
analysis were not labelled for a mitochondrial marker, it cannot be ruled out that DNA which 
is positively labelled for DAPI, DNA, TFAM and cGAS is not still within the mitochondria. 
Therefore, hypothetically, cGAS could plausibly have access to the mtDNA labelled by TFAM 
if the mitochondria were damaged in some way. With this in mind, they would not be CCFs 
and skew the analysis that some CCFs are of mitochondrial origin. Therefore, a strategy to 
further dissect these findings would be to use ChIP-sequencing to determine the relative 
interactions between cGAS and nuclear/mtDNA. At this stage, these observations are relatively 
preliminary but they do highlight the plausibility that some cytosolic DNA may be mtDNA 
rather than nuclear DNA.  
It has also been reported that DNA damage enhances the formation of CCFs/cytosolic nuclear 
DNA (Lan et al., 2014; Hartlova et al., 2015). Characteristically, these CCFs are generally 
always positive for the DNA damage marker γH2AX (Dou et al., 2017; Gluck et al., 2017; 
Yang et al., 2017). With that in mind, although technically demanding to investigate, it would 
be important to understand whether cytosolic mtDNA is also associated with DNA damage. 
Following on from this it would be interesting to explore whether stress-induced senescence 




promotes damaged mitochondria and whether the level of damage correlates with mtDNA 
release.        
We observed that fibroblasts deficient for STING had a completely reduced SASP when 
induced to become senescent, complementing the findings of others who have genetically 
manipulated this pathway (Dou et al., 2017; Gluck et al., 2017). It is known that the activation 
of STING mediates the upregulation of NF-κB and interferon genes through TBK1 and IRF3 
(Chen et al., 2016). NF-κB is considered a master regulator of the SASP and it has been 
demonstrated that a number of senescence related pathways feed into NF-κB signalling, for 
example, the stabilisation of GATA4 and activity of p38MAPK mediated by the DDR have 
also been implicated with NF-κB activation (Chien et al., 2011; Kang et al., 2015; Wiley et al., 
2016). Furthermore, NF-κB is an integral part of the innate immune system and has a myriad 
of roles in regulating the response to infections (Hayden and Ghosh, 2008). Previous studies 
have demonstrated beneficial effects on both senescence and overall health span during ageing 
by targeting NF- κB signalling (Tilstra et al., 2012; Correia-Melo et al., 2019). However, we 
postulate that the inhibition of cGAS further upstream of NF- κB may be a more promising 
strategy as it has the potential to preserve NF- κB function in response to infections in healthy 
cells but prevent its SASP promoting effects in senescent cells. Thus, we wanted to address the 
question of whether pharmacological targeting of cGAS could suppress the SASP.  
In the context of senescence, to our knowledge no study has assessed pharmacological 
inhibitors of cGAS. The first identified inhibitors are derivatives of anti-malarial drugs, 
therefore we set out to test quinacrine dihydrochloride and ACMA (An et al., 2015). Following 
the discovery of these inhibitors a group of small molecule specific inhibitor of cGAS were 
developed, therefore we also tested one of these compounds; RU.521 (Vincent et al., 2017). 
We found that in stress-induced senescent cells RU.521 (2.5µM) could robustly decrease the 
secretion of IL-6, IL-8 and IP-10 to comparable levels with proliferating cells. Similarly, both 
quinacrine dihydrochloride and ACMA led to a substantial suppression of IL-6, IL-8 and IP-10 
secretion by senescent cells. Interestingly, the decrease was not as strong as that observed in 
senescent cells treated with RU.521 as the level of secretion for the three cytokines was higher 
than proliferating control cells. One possible explanation for this observation is that the small 
molecule RU.521 is believed to act as a non-competitive inhibitor and therefore acts very 
efficiently to completely prevent activation of cGAS (Vincent et al., 2017). The anti-malarial 
drugs on the other hand act by preventing the interaction between cGAS and double stranded 
DNA, interestingly, the mechanism of action occurs due to non-specific interactions with 




nucleic acids rather than direct association and interference of cGAS and its enzymatic activity 
(An et al., 2015). As such, it is possible that the anti-malarial drugs to not bind to all of the 
available DNA substrate and therefore do not fully prevent the inflammatory response. 
Therefore it seems plausible to speculate that cGAS is inhibited to a greater extent by RU.521 
than the two anti-malarial drugs which could explain why RU.521 is more effective at 
suppressing the SASP. Another possible explanation is that cGAS knockdown was recently 
demonstrated to lead to a reduction in caspase 5 protein levels. Caspase 5 was shown to be 
essential for the cleavage of IL-1α and subsequent interferon response during senescence 
(Wiggins et al., 2019). As such, RU.521 could hypothetically be more efficacious than the anti-
malarial drugs at diminishing the SASP as it is reducing IL-1α cleavage by reducing the 
expression of caspase 5 as well as blocking the detection of mtDNA.  
Early work indicated that anti-malarial drugs structurally are similar to the active site of cGAS, 
however, it is now been demonstrated that their effects are predominantly attributed to their 
interference with double stranded DNA which occurs by binding of the drug to DNA. This 
binding prevents the DNA from acting as a ligand to cGAS (Kuznik et al., 2011; An et al., 
2015). It has also been shown that this binding also inhibits interactions between DNA and 
TLRs, including TLR9 (Kuznik et al., 2011). Anti-malarial drugs which inhibit both cGAS and 
TLRs do not exert as complete a reduction in the SASP as RU.521 and genetic depletion of 
STING, these findings therefore support the notion that the cGAS-STING axis is responsible 
for the inflammatory response to mtDNA in senescent cells rather than TLR9. Although, as 
discussed previously it is possible that the observed effect is ascribed to the anti-malarial drugs 
incompletely acting on the available double stranded DNA substrate itself rather than inhibiting 
the cGAS/TLRs directly.   
In the literature the role of cGAS in senescence is conflicting. In the study by Dou et al it was 
demonstrated that both cGAS and STING deficient human fibroblasts induced to become 
senescent via stress or oncogene activation no longer displayed a SASP but still underwent the 
cell cycle arrest as measured by p16 expression. In vivo, they demonstrated that following the 
induction of senescence via irradiation STING KO mice displayed a diminished SASP but cells 
were still positive for p21 (Dou et al., 2017). Gluck et al found that cGAS was an important 
regulator of the SASP, however they also demonstrated that cGAS is important for the cell 
cycle arrest. Under normal culturing conditions cGAS KO MEFs were more resistant to 
premature senescence compared to cGAS proficient MEFs, in addition they did not present 
upregulation of p16, SA-β-Gal and various senescence associated genes which were observed 




in proficient MEFs following the induction of senescence. Furthermore, they demonstrated that 
following oxidative stress cGAS deficient WI-38 human fibroblasts cells displayed increased 
markers of proliferation and a reduced level of SA-β-Gal positive cells compared to cGAS 
competent controls. Moreover, following the establishment of stress-induced senescence the 
silencing of cGAS led to a reduction in the expression of p16. In vivo they found that cGAS 
and STING deficient mice did not display p16 whereas WT mice did following the induction 
of senescence via irradiation (Gluck et al., 2017). Similarly, another study found that cGAS 
deficient MEFs and human cells were resistant to the induction of senescence by DNA damage 
(etoposide and irradiation) (Yang et al., 2017). Of further interest it has been shown that in OIS 
the genetic removal of IFN1 downstream of cGAS leads to a bypass of the senescence 
phenotype, moreover, the reintroduction of IFN1 leads to the induction of senescence 
(Katlinskaya et al., 2016). Therefore we were curious to investigate whether the inhibition of 
cGAS using either RU.521 or the anti-malarial drugs would have an impact on the development 
of stress-induced senescence in human MRC5 fibroblasts.  
We found that following the induction of stress-induced senescence cells maintained in culture 
with RU.521 there was a significant increase in the number of cells positive for p21, SA-β-Gal 
and the mean number of γH2AX foci, there was also a complete loss of the proliferation marker 
Ki67. For each of these markers there was no significant difference between the control 
senescent cells and those treated with RU.521. Similarly, we found for the anti-malarial drugs 
that fibroblasts still underwent the cell cycle arrest following irradiation as evidenced by 
expression of p21 and loss of Ki67. Interestingly, senescent cells maintained with quinacrine 
dihydrochloride had a reduced level of DNA damage as measured by γH2AX. This is an 
unusual finding as it has been reported that quinacrine dihydrochloride can intercalate into DNA 
and inhibit DNA repair (Popanda and Thielmann, 1992). However, it has also been shown that 
quinacrine (of which quinacrine dihydrochloride is derived from) promotes antioxidant 
defences, furthermore, another antimalarial drug from the same family of drugs; chloroquine 
also has been shown to have antioxidant effects (Farombi et al., 2003; Turnbull et al., 2003). 
In this scenario, it may be that quinacrine dihydrochloride is boosting anti-oxidant defences and 
therefore is preventing some ROS mediated DNA damage which occurs during senescence. 
There is also some evidence that DNA damage could contribute to cGAS activation, a recent 
proteomic study discovered that following the induction of DNA damage cGAS is associated 
with a multi-subunit ribonuclear complex which contains the DNA repair proteins DNA-protein 
kinase (Morchikh et al., 2017). It is possible that the reduced levels of DNA damage associated 




with quinacrine dihydrochloride are responsible for a reduction in the activation of cGAS and 
as such reduced stimulation of NF-κB/IFN-1 genes. Of further consideration, it has also been 
shown that DNA damage is responsible for provoking the release of CCFs/micronuclei and self 
DNA from the nucleus which can trigger cGAS activation (Lan et al., 2014; Hartlova et al., 
2015). It would be of interest to investigate whether maintaining cells with quinacrine 
dihydrochloride has an impact on the number of CCFs. It is possible that this decrease in DNA 
damage is contributing in part to a reduction in the SASP by reducing the number of CCFs. 
 Another interesting observation was that of senescent cells which were maintained with 
ACMA, these cells displayed a reduced number of SA-β-Gal positive cells. The expression of 
SA-β-Gal is associated with the increased expression of the lysosomal β‐galactosidase protein 
(Lee et al., 2006). It has also been shown that SA-β-Gal staining clusters at sites of autophagy 
vacuoles which utilise lysosomes to clear and recycle cellular debris (Gerland et al., 2003). 
There is evidence that anti-malarial drugs inhibit autophagy, therefore, it could be that ACMA 
is reducing autophagic activity which is leading to a reduced amount of lysosomes and therefore 
less labelling of lysosomal β-galactosidase protein by SA-β-Gal staining (Golden et al., 2015). 
In addition, it has been demonstrated that quinacrine dihydrochloride is also inhibitor of 
autophagy (Golden et al., 2015). Furthermore, in senescent cells maintained with quinacrine 
dihydrochloride there is a small but non-significant decrease in the number of SA-β-Gal 
positive cells, although purely speculative, this could be because quinacrine dihydrochloride is 
inhibiting autophagy to a lower extent than ACMA. Taken together, it is plausible that a 
reduction in autophagy is responsible for the reduced number of SA-β-Gal positive cells in 
senescent cells cultured with ACMA. 
Our findings complement the work by Dou et al as we demonstrated that inhibition of cGAS 
using either RU.521 or the antimalarial drugs depleted the SASP but did not impair the cell 
cycle arrest (Dou et al., 2017).  This is in contrast to the studies by Gluck et al and Yang et al 
which demonstrated that cGAS has a regulatory role in implementing the cell cycle arrest and 
the SASP (Gluck et al., 2017; Yang et al., 2017). A potential explanation of the differences 
observed could be attributed to the cell lines used, both our work and that of Dou et al was 
performed in human lung fibroblasts (IMR90 and MRC5 fibroblasts) whereas the work 
performed by Gluck et al and Yang et al was predominantly performed in MEFs (Dou et al., 
2017; Gluck et al., 2017; Yang et al., 2017). As such it may be that the role of cGAS varies 
between mice and humans. In support of this idea Yang et al demonstrated that cGAS deficient 
BJ human foreskin fibroblasts lacked expression of SASP related genes and SA-β-Gal 




following irradiation but there was still evidence of p21 upregulation (Yang et al., 2017). 
However, Katlinskaya et al found that suppression of IFN1 downstream of cGAS could 
override the senescence phenotype in OIS IMR90 cells (Katlinskaya et al., 2016). This therefore 
lends strength to the idea that at least in human cells the effects of cGAS on cell cycle regulation 
are most likely attributed to paracrine effects of the SASP which can reinforce and induce 
senescence in neighbouring cells (Acosta et al., 2008; Nelson et al., 2012; Acosta et al., 2013; 
Dou et al., 2017).   
Nevertheless, if cGAS has an independent role in implementing the cell cycle arrest it would 
not be expected that the anti-malarial drugs would have an impact as these drugs bind to double 
stranded DNA and prevent cGAS from recognising it rather than directly inhibiting cGAS. As 
such it would be expected that cGAS would still be free to undertake its additional roles in the 
implementation of senescence. However, we also did not observe an impact on the cell cycle 
arrest with the small molecule inhibitor RU.521 which non-competitively inhibits the active 
DNA binding site of cGAS. This suggests that either cGAS does not have an independent role 
in implementing the cell cycle arrest or alternatively it can prevent cellular proliferation without 
requiring its DNA binding active site. Our findings with those of Dou et al, suggest that the 
predominant role of cGAS in human fibroblasts is in modulating the SASP but not the cell cycle 
arrest (Dou et al., 2017).  
This highlights particular promise of using RU.521 or anti-malarial drugs as senostatic drugs 
to alleviate the SASP without preventing the cell cycle arrest. Moreover, the anti-malarial drugs 
are already in use in the clinics with a relatively good safety profile. The data in this chapter 
supports a preliminary case for repurposing of these drugs as a potential strategy for 
ameliorating inflammation in senescence associated diseases. Although attention must be paid 
as direct inhibition of either cGAS or STING could exacerbate the susceptibility of individuals 
to infectious diseases. With that in mind, administration of these agents would need to be carried 
out in a manner which does not compromise immune function. 




6. Chapter 6: Conclusions 
Work over the past decades has demonstrated that senescent cells accumulate in a variety of 
tissues with age and at sites of chronic diseases (Dimri et al., 1995; Krishnamurthy et al., 2004; 
Herbig et al., 2006; Hewitt et al., 2012; Waaijer et al., 2012). More recently, it has been 
established that senescent cells can drive to a certain extent ageing and age-related pathologies 
(Baker et al., 2011; Baker et al., 2016). Mitochondria have been implicated in both ageing and 
the development of the senescent phenotype for some time, however, it is only recently that 
they have been identified as being an essential mediator of the SASP (Correia-Melo et al., 2016; 
Wiley et al., 2016; Chapman et al., 2019). Work in our lab recently conducted a proof of 
principle experiment to determine the extent that mitochondria are required for senescence. 
They generated mitochondrial-depleted senescent cells and discovered that they no longer 
displayed a SASP but still undergo an irreversible cell cycle arrest (Correia-Melo et al., 2016).  
This work led us to propose that mitochondria may be highly promising targets for anti-
senescence therapies and that by targeting them we may be able to suppress the detrimental 
SASP known to contribute to aging, while maintaining the tumour suppressor capabilities of 
senescent cells. However, mechanistically it is still not known how mitochondria regulate the 
SASP. For that reason, I aimed in this thesis to investigate the role of mitochondrial apoptosis 
in the regulation of the senescent phenotype, particularly the role of mtDNA release and caspase 
activation. 
In this study, corroborating the findings of others I found that mitochondria in senescent cells 
display signs of dysfunction such as exacerbated ROS production, enlarged networks and a 
reduced mitochondrial membrane potential (Yoon et al., 2006; Passos et al., 2007; Passos et 
al., 2010; Correia-Melo et al., 2016). For the first time, this thesis demonstrated that senescent 
cells can be characterised by the presence of cytosolic DNA which is of mitochondrial origin. 
Moreover, I found that the release of mtDNA is dependent on the capacity for a cell to form 
BAX and BAK pores as cells deficient for BAX and BAK no longer released mtDNA when 
they became senescent. Previous work has highlighted the role of mtDNA as a particularly 
potent immunostimulatory molecule (Nakahira et al., 2011; West et al., 2015; Bao et al., 2016). 
Indeed, I found that the transfection of mtDNA into human fibroblasts promoted a robust 
inflammatory response. In the context of senescence, a reduced level of cytosolic mtDNA as 
observed in BAX and BAK deficient cells was associated with a strong reduction in the SASP. 
Despite lacking a SASP, BAX and BAK deficient cells did not have an impaired induction of 
the cell cycle arrest as measured by the expression of p16, p21 and Ki67. This strengthens the 




findings that mitochondria are essential for the pro-ageing features of senescence (pro-
inflammatory and pro-oxidant) but not for implementation of the cell cycle arrest (Correia-Melo 
et al., 2016). 
The observation that mtDNA is the molecule responsible for the SASP highlighted a therapeutic 
window that could be exploited. As the release of mtDNA is dependent on the proteins BAX 
and BAK I decided to test whether two inhibitors (BIPv5 and BCB) which target these proteins 
can ameliorate the SASP. I found that both of these inhibitors could reduce the secretion of IL-
6 and IL-8 which are both key constituents of the SASP. Furthermore, comprehensive 
characterisation of the SASP in cells where BAX and BAK had been abrogated genetically 
revealed that an array of pro-inflammatory cytokines and chemokines were downregulated 
during senescence. These findings are of particular interest to the clinic as they highlight a 
strategy to alleviate the detrimental aspects of senescence without compromising the tumour 
suppressive effects of the cell cycle arrest. Building on these observations, it was shown in vivo 
that mice which harbour BAX and BAK deficient livers did not display an upregulation of 
SASP related genes following low grade irradiation which induces senescence. This highlights 
that the importance of BAX and BAK in SASP regulation is also evident in vivo. As such, it 
will be both interesting and important to establish whether the two inhibitors can replicate these 
beneficial effects in an in vivo context.     
Next, I investigated mechanisms which could trigger the release of mtDNA via BAX and BAK. 
Recent work has implicated a process whereby a subset of mitochondria are permeabilised in 
the absence of cell death, leading to cytochrome c release and the induction of DNA damage 
(Ichim et al., 2015). The implementation of DNA damage and absence of cell death are key 
distinguishing features of senescence, therefore I investigated the potential of miMOMP as a 
feature of senescence. Indeed, I found evidence that senescent cells display limited 
mitochondrial outer membrane permeabilisation as measured by colocalisation of cytochrome 
c and TOM20. Cytochrome c release also occurs via BAX and BAK pores (Tait and Green, 
2010). Supporting this it was observed that when BAX and BAK deficient cells become 
senescent they do not display reduced colocalisation of cytochrome c and TOM20. In addition, 
it was shown that the pharmacological induction of miMOMP using ABT737 promoted a 
senescence like-phenotype, complementing previous findings that demonstrated ABT737 
mediated induction of senescence in cancer cells (Song et al., 2011). These findings highlight 
that miMOMP is both a feature of senescence as well as an inducer. Of further interest, we 




found that the induction of miMOMP using ABT737 was associated with promoting mtDNA 
release.  
The observation that ABT737 can induce a senescent-like phenotype is of particular interest as 
drugs within this family are currently being explored as senolytic therapies (Chang et al., 2016; 
Yosef et al., 2016b; Walaszczyk et al., 2019). This study found that ABT737 treatment was 
associated with DNA damage and the secretion of IL-6 and IL-8 in vitro. These observations 
suggest that senolytics from this family may have a detrimental effect on healthy cells, this 
therefore highlights the need for further research to understand the effects of ABT737 on 
healthy tissue in vivo.  
A number of the miMOMP associated effects (increased levels of γH2AX, p21, SA-β-Gal and 
the secretion of IL-6 and IL-8) were dependent on caspase activity. Although caspase 1 and 5 
have been previously been identified as mediating the SASP, other caspases have not been 
investigated (Acosta et al., 2013; Wiggins et al., 2019). This prompted us to investigate whether 
caspases have a role in regulation of the senescence phenotype. It was discovered that 
specifically there is sub-lethal caspase 3 activity in senescent cells, preliminary work in this 
study suggests that its inhibition leads to a reduction in the DDR (γH2AX and 53BP1) as well 
as a partial reduction in the SASP. However, this work only assessed the role of caspases 1-4 
in SASP regulation, therefore future work should seek to further understand the role of caspase 
3 and elucidate the contribution of other caspases to the senescence phenotype. 
In addition, this study also set out to understand mechanistically how cytosolic mtDNA can 
promote a pro-inflammatory response during senescence. Whilst exploring the roles of caspases 
in senescence I observed that there was evidence of caspase 1 cleavage. Caspase 1 cleavage has 
been associated with activation of the inflammasome in response to mtDNA (Nakahira et al., 
2011; Shimada et al., 2012; Shalini et al., 2015). Furthermore, caspase 1 and the inflammasome 
have been implicated in modulating the SASP in OIS (Acosta et al., 2013). In this study, despite 
there being cleavage of caspase 1 there was no evidence of NLRP3 activation, as measured by 
the cleavage of IL-1β and the secretion of IL-18. It has been reported that TLR9 can also mount 
an inflammatory response to mtDNA (Bao et al., 2016). Our work found that there was not a 
difference in overall protein levels between proliferating and senescent cells. Previous work has 
also demonstrated that TLR9 is not upregulated in OIS (Hari et al., 2018). However, at this 
stage more data is required in order to confidently determine whether TLR9 is involved in the 
response to mtDNA during senescence.  




The cGAS-STING pathway has been previously implicated in senescence. Specifically, it acts 
as part of the innate immune system which recognises nuclear fragments of DNA referred to as 
CCFs, following recognition, it promotes an inflammatory response through NF-κB and IFN-1 
genes (Ivanov et al., 2013; Dou et al., 2017; Gluck et al., 2017; Yang et al., 2017). The cGAS-
STING axis can also induce inflammation in response to mtDNA (West et al., 2015). In stress-
induced senescence this study observed that the phosphorylation of IRF3 which is downstream 
of cGAS-STING signalling was increased in senescent cells. Moreover, when treated with the 
BAX channel blocker BCB to prevent mtDNA release the phosphorylation of IRF3 was 
reduced. Furthermore, senescent cells expressing a GFP reporter system on cGAS displayed 
colocalisation of cGAS with TFAM. It was also observed that STING deficient cells displayed 
a reduced SASP following the induction of senescence and also had a reduced pro-
inflammatory response following the transfection of mtDNA. Collectively these data 
demonstrate that the cGAS-STING axis is responsible for the SASP which occurs in response 
to mtDNA released during senescence. However, at this stage the contribution of TLR9 cannot 
be ruled out as silencing of STING does not completely prevent the response to mtDNA 
transfection.  
Following the identification that cGAS-STING contributes to the SASP in response to mtDNA 
I wanted to assess whether this pathway could be targeted pharmacologically. Previous studies 
investigating the cGAS-STING axis in SASP regulation have utilised genetic silencing of 
cGAS and STING to determine their role. However, a number of anti-malarial drugs and a 
specific small molecule inhibitor have been recently identified which can inhibit the activity of 
cGAS (An et al., 2015; Vincent et al., 2017). I found that each of the inhibitors RU.521, ACMA 
and quinacrine dihydrochloride which target cGAS activity could ameliorate the SASP in 
stress-induced senescence. Interestingly, these drugs did not prevent the cell cycle arrest as 
measured by p21 and Ki67. Similar, to the BAX and BAK inhibitors these drugs show promise 
as potential senostatic therapies.  
Collectively, we have shown that during senescence mtDNA escapes into the cytosol via BAX 
and BAK. Whilst here it can act as a profound inflammatory molecule where it is responsible 
for the SASP through cGAS-STING activation. The SASP has been associated with detrimental 
effects due to its role in paracrine-induced senescence as well as creating a microenvironment 
that is prone to tumour progression (Coppe et al., 2010; Nelson et al., 2012; Acosta et al., 2013). 
Utilising this knowledge we have identified two putative targets for suppression of the SASP 
without impacting on the cell cycle arrest aspects of senescence. First, through the inhibition of 




BAX and BAK to prevent mtDNA release and secondly by targeting cGAS which is responsible 
for identification of mtDNA downstream of its release. Cellular senescence has been identified 
as a driver of ageing and multiple age-related pathologies and indeed clinical trials are currently 
underway to assess the potential benefits of senolytics (Baker et al., 2011; Baker et al., 2016; 
Kirkland et al., 2017; Justice et al., 2019). It is therefore of significant interest to understand 
the biological mechanisms which underpin senescence and the associated SASP. As such, these 
findings are of particular interest to the clinic and may therefore be beneficial as a senostatic 
therapy for alleviating the detrimental effects associated with the accumulation of senescent 
cells and associated inflammation.  
 
 
Figure 6.1 – Summary of the relationship between mitochondria and the SASP during 
cellular senescence. 
During senescence it was discovered that mtDNA is being released through BAX and BAK 
pores into the cytosol where it is recognised by cGAS which provokes the SASP. Blockage of 
BAX and BAK pores using BIPv5 and BCB can prevent mtDNA release and the subsequent 
SASP. Similarly, targeting of cGAS using anti-malarial drugs or RU.521 can inhibit the SASP. 
It was also discovered that senescent cells display evidence of miMOMP where cytochrome c 
is also being released though BAX and BAK pores. The release of cytochrome C is associated 
with promoting caspase 3 activity during senescence which promotes DNA damage. This 
contributes to the DDR which can exacerbate the SASP.   
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